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Abstract
Asthma causes substantial public health burden. An enhanced understanding of asthma burden,
asthma course and identification of intervenable risk factor is warranted.
The objectives of this research were to: 1) examine the age, period and cohort effects on
asthma prevalence among Canadian adults during 1994–2011 (manuscript one); 2) identify the
trajectories of asthma exacerbation and their predictors in children with incident asthma
(manuscript two); and 3) examine the effect of maternal gestational diabetes mellitus on the risk
of asthma in offspring (manuscript three).
Longitudinal data from 13,616 individuals in the National Population Health Survey,
household component were used to address objective one using generalized estimating equations.
Data from 403 children with asthma in the National Longitudinal Survey of Children and Youth
(NLSCY) were used to address objective two using latent class growth modeling and
multinomial logistic regression. Pooled logistic regression was performed on data from 19,933
children in the NLSCY to address objective three.
By age, asthma prevalence was 12% in 20-year-olds, 6% in 50–60-year-olds, and 8% in
80-year-olds in Canadian adults. By period, asthma prevalence increased from 5% in 1994/1995
to 11% in 2010/2011. There was some evidence of cohort effect on asthma prevalence. Three
distinct trajectories of asthma exacerbation were identified in children with incident asthma: low
increasing (21.3% of children), medium decreasing (45.8% of children) and high decreasing
(32.8% of children). Number of siblings at home and age at asthma diagnosis predicted trajectory
group membership. The adjusted hazard ratio for the association between maternal gestational
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diabetes mellitus and incident asthma in the offspring was 1.25 (95% confidence interval [CI]:
1.03, 1.51).
Our findings suggest the presence of age, period and cohort effects on prevalence of
asthma in Canadian adults. Children with incident asthma apparently follow three distinct
trajectories of asthma exacerbations. Gestational diabetes mellitus appears to increase the risk of
asthma in the offspring. The findings from this research provide further insights into trends in
asthma burden in Canadian adults, asthma exacerbation trajectories in children that would aid
physicians in prognosticating its course, and potential opportunity for prevention of asthma in
children.

Keywords: Asthma Prevalence; Asthma Exacerbation; Trajectories; Gestational Diabetes
Mellitus; Canada
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Summary for Lay Audience

Asthma causes a huge health burden. A better understanding of asthma course and its risk factors
is needed. First, we studied the prevalence of asthma by age and time in adults. We then
researched the patterns of an asthma attack and their associated factors in children with asthma.
We looked if mothers' diabetes during pregnancy increased the risk of asthma in children. We
used data from two Canadian national surveys. Our study began with 13,616 adults, 403 children
with asthma and 19,933 children without asthma.
Asthma prevalence in adults was 12% at 20 years, 6% at 50–60 years and 8% at 80 years.
Asthma prevalence increased from 5% in 1994/1995 to 11% in 2010/2011. Such pattern over
time differed by age. Three different patterns of asthma attack course were found in children
with asthma. The patterns were: a) low increasing (21.3%), b) medium decreasing (45.8%) and
c) high decreasing (32.8%). Number of siblings at home and age at asthma diagnosis were
associated with both medium decreasing and high increasing patterns. Diabetes during
pregnancy increased the chance of asthma in children.
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1.

Chapter 1: Introduction and Objectives

1.1

Thesis Organization

Chapter 1 presents an overview of the thesis, including the introduction, rationale, research
objectives and data sources. Chapter 2 presents a review of the relevant literature related to
asthma and each of the objectives. Chapter 3 addresses Objective 1. A version of Chapter 3 is in
press in Annals of Epidemiology. Chapter 4 addresses Objective 2. A version of Chapter 4 has
been published in Annals of Allergy, Asthma and Immunology. Chapter 5 addresses Objective 3.
A version of Chapter 5 is under review in a peer-reviewed journal. Finally, Chapter 6 provides an
integrated discussion and conclusion. Other relevant information is provided in the appendices.
1.2

Introduction

Asthma is a chronic inflammatory disease of the airway characterized by recurrent attacks of
breathlessness or wheezing. Asthma affected an estimated 242–305 million people worldwide in
2017 and resulted in a 4.9% increase in age-standardized years lived with disability since 2007
[1]. Globally, asthma ranked 25th among the leading causes of disease burden and was the 16th
highest rank cause of years lived with disability contributing an estimated 18.9–29.7 million
disability-adjusted life years lost across all ages in 2016 [2, 3]. Despite reductions in asthmaassociated mortality between 2007 and 2017 [4], and in hospitalization rates between 2001 and
2015 [5], asthma remains a chronic disease of great public health importance. Asthma causes
substantial economic burden through direct (e.g. physician visits, emergency visits,
hospitalization, diagnostics, ambulance services, nursing services, devices and medications) and
indirect (e.g., lost productivity at work and school, travel and waiting time in outpatient care and
lost future potential income) costs [6]. Asthma also results in intangible costs related to pain or
suffering, impairment of quality of life, limitations of physical activities and study or job
1

performance, job changes and psychological effects [7, 8]. Furthermore, asthma is associated
with higher rates of attention-deficit/hyperactivity disorder, depression, behavioural disorders,
and learning disabilities in children [9].
This doctoral research sought to explore and advance the knowledge base on three
epidemiological aspects of asthma of public health importance - trends in asthma prevalence in
adults, the course of asthma in children with asthma, and the role of mother’s gestational
diabetes mellitus as a potential intervenable risk factor of asthma development in offspring. All
three themes are grounded in the ultimate goal of epidemiology –that is, prevention and control
of diseases, such as asthma.
1.3

Study Rationale

Asthma affects an estimated 3.8 million Canadians accounting for substantial medical and
economic burden [10, 11]. The prevalence of asthma in Canadians increased considerably from
1996 to 2012, and the prevalence differed by age: it peaked in adolescents and young adults,
decreased in middle-aged adults, and then increased in elderly persons [10, 12]. Studies have
generally examined and reported age-standardized or age-specific asthma prevalence estimates
using non-model-based approaches. However, there is a dearth of literature on studies formally
examining the effects of age and period on asthma prevalence and the differential effect of
period across ages using the theoretical and analytical age, period and cohort framework.
Examining the age, period and cohort effects employing the age, period and cohort framework
would provide insights into the observed trends in asthma prevalence in Canadians.
The clinical course of asthma follows periods of relapse and remission. However, it
remains unknown if there are any particular trajectories in asthma course. It is possible that there
are qualitatively distinct trajectories of asthma course, particularly of asthma exacerbations,
2

among children with asthma. Identifying these trajectories and their predictors could enhance
physicians’ ability to better prognosticate and manage the course of asthma.
A number of risk factors of asthma are known [13]. A growing body of evidence suggests
that not only factors one is exposed to after birth but also intrauterine exposure to maternal
conditions such as gestational diabetes mellitus (GDM) may lead to asthma in the offspring [1418]. However, results from previous studies are inconclusive [19]. Thus, the role of GDM in the
etiology of asthma in children remains unclear and warrants further investigation.
This proposed doctoral research will enhance our understanding of several important
aspects of asthma, particularly the observed trends in asthma occurrence in Canadians, the
trajectories of asthma course, and the role of GDM in the etiology of asthma in the offspring.
1.4

Research Objectives
1) To examine the effects of age and period on asthma prevalence among Canadian adults
during 1994/1995–2010/2011 and to assess if the period effect differed by age
2) To explore trajectories of asthma course in Canadian children with incident asthma:
a) To identify the trajectories of asthma exacerbation
b) To identify the predictors of the trajectories
3) To investigate the effect of maternal gestational diabetes mellitus on the risk of asthma in
the offspring:
a) To examine the total effect of maternal gestational diabetes mellitus on the risk of
asthma in the offspring

3

b) To estimate the controlled direct effect of gestational diabetes mellitus on the risk of
asthma in the offspring after accounting for the mediation by cesarean section
delivery
c) To assess the joint effect of maternal gestational diabetes mellitus and maternal
smoking during pregnancy on the risk of asthma in the offspring
1.5

Data Sources

This thesis employed two databases to address the research objectives. Each data source is
described briefly below. Additional details are provided in respective chapters.
1.5.1

The National Population Health Survey

The National Population Health Survey (NPHS), household component was a longitudinal
survey conducted by Statistics Canada to collect information on sociodemographic
characteristics and health of the Canadian population [20]. The NPHS was conducted every two
years starting from 1994/1995 among 17,276 individuals in 10 Canadian provinces. There were 9
cycles in total with the last cycle conducted in 2010/2011. Persons living on Indian reserves and
Crown lands, residents of health institutions, full-time members of the Canadian Forces living on
Canadian Forces Bases, and residents of some remote areas in Ontario and Quebec were
excluded. A stratified two-stage sampling design was employed using the sampling frame of the
Labour Force Survey in all provinces except Québec, where Santé Québec's design for the
1992/1993 Enquête sociale et de santé (ESS) was used. Data were collected using survey
questions administered through computer-assisted interviewing methods. The table of contents of
the survey questionnaire for cycle 9 is included in Appendix A. The questionnaire is available at:
http://www23.statcan.gc.ca/imdb/p3Instr.pl?Function=getInstrumentList&Item_Id=75087&UL=
1V&. Data from the NPHS were used to address Objective 1.
4

1.5.2

The National Longitudinal Survey of Children and Youth

The National Longitudinal Survey of Children and Youth (NLSCY) was a longitudinal survey
conducted by Statistics Canada and Human Resources and Skills Development Canada [21]. A
sample of Canadian children living in any of the 10 provinces of Canada was followed every two
years to monitor their development and well-being from infancy to adulthood. The first cycle
was conducted in 1994/1995 among 22,831 children aged 0–11 years. Out of the 22,831 children
surveyed in cycle 1, 16,903 children were followed through the final survey (cycle 8) in
2008/2009 when they were 14–25 years old. These children comprised the 1994 original cohort
(Appendix A). From cycle 2, a new cohort of children aged 0–1 year was included in each
subsequent cycle and followed for a variable time to monitor early childhood development
(ECD). These children comprised the ECD cohorts. The NLSCY used a multi-stage cluster
sampling to select households for the survey. The Labour Force Survey’s sampling frame was
used to select the sampling unit, households. The original cohort contained a maximum of two
children from each household. One person most knowledgeable (PMK) about the child was
selected from each household. For children less than 14 years of age, most of the information
were collected from the PMK. Data were collected through computer-assisted interviewing
methods and paper questionnaires. Computer-assisted interviewing method comprised of
computer-assisted personal interviewing or computer-assisted telephone interviewing. The table
of contents of the survey questionnaire for cycle 8 is included in Appendix B. The questionnaire
is available at:
http://www23.statcan.gc.ca/imdb/p3Instr.pl?Function=getInstrumentList&Item_Id=88288&UL=
1V&. The child-level response rates at different cycles are included in Appendix C. Data from
the NLSCY were used for Objectives 2 and 3.
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1.5.3

Ethical Approval and Data Access

Ethical approval was not needed as the study relied on anonymous and confidential secondary
data from Statistics Canada. However, the proposal for this study was approved by the Social
Science and Humanities Research Council (SSHRC), Canada (see Appendix D) to gain access to
the data in Statistic Canada’s Research Data Centre (RDC) at Western University. Data are only
accessible to researchers with approved projects who have been sworn in under the Statistics Act
of Canada as deemed employees.
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2.

Chapter 2: Literature review

2.1.

Asthma

2.1.1. Asthma in Children
2.1.1.1.Definition
The International Consensus on (ICON) Pediatric Asthma defines pediatric asthma as “a chronic
inflammatory disorder associated with variable airflow obstruction and bronchial
hyperresponsiveness. It presents with recurrent episodes of wheeze, cough, shortness of breath,
and chest tightness” [1]. Chronic inflammation, airway hyperresponsiveness and airway
remodeling are central to the complex pathophysiology of asthma. Expiratory wheezing and
intermittent dry cough are the most common symptoms of asthma in children; intermittent
nonfocal chest pain are reported more in younger children while shortness of breath, chest
congestion and tightness are commonly reported in older children [2].
2.1.1.2.Asthma Classification and Phenotypes
Being a heterogeneous disease with different phenotypes and clinical presentations, asthma in
children can be classified in various ways [2]. Based on the natural history, asthma is classified
into two common types: 1) Recurrent wheezing asthma: It is transient nonatopic wheezing
asthma that occurs in early preschool years, causes recurrent wheeze or cough primarily due to
common respiratory viral infections and usually resolves or improves during preschool and lower
school years and 2) Chronic asthma: It is persistent atopy-associated asthma that begins in early
preschool years, associated with allergy and has the highest risk for persistence into later
childhood and often adulthood. Asthma can also be classified according to disease severity into
two classes: intermittent or persistent; according to asthma control while being managed and
treated into three classes: well controlled, not well controlled, and very poorly controlled; and
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according to treatment response and medication requirements into four classes: easy-to-treat
(well controlled with low levels of daily controller therapy), difficult-to-treat (well-controlled
with multiple and/or high levels of controller therapies), exacerbators (continue to have severe
exacerbations despite being well controlled), and refractory (continue to have poorly controlled
asthma despite multiple and high levels of controller therapies) [2]. However, disease severity
can reflect multiple factors such as inherent severity of the disease, resistance to treatment and
treatment adherence and it can be difficult to differentiate between these factors. Classification
based on asthma control has more clinical utility in guiding treatment and is thus recommended
[1].
Having significant individual variability over time together with heterogenous nature in
disease manifestation, different asthma/wheeze phenotypes have been proposed or identified
from longitudinal studies. Three asthma phenotypes were proposed in children with asthma:
transient wheezing phenotype with symptoms limited to the first 3–5 years of life, non-atopic
wheezing of the toddler and pre-school aged children phenotype having wheezing due to
respiratory syncytial virus in the first years of life and more likely to continue wheezing up to 13
years of life, and IgE-mediated wheezing phenotype, also known as the classic asthma
phenotype, associated with allergic sensitization [3]. In the Tucson Children’s Respiratory Study,
a birth cohort study following children from birth to 6 years of age, one third of the children
developed lower respiratory tract illness with wheezing by three years of age and 40% of them
continued to wheeze at six years of age [4]. However, only 14% of the children with wheeze
during the first 2 years of life had asthma, defined as “at least four episodes of wheeze in the last
12 months or at least one episode of wheezing during the same period in combination with
occasional or regular treatment with inhaled glucocorticosteroids” in Barn/Children, Allergy and
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Milieu in Stockholm, an Epidemiological study (BAMSE), another population-based birth cohort
study [5]. Following children from the Tucson Children’s Respiratory Study through adolescence
showed that the patterns of wheezing prevalence and levels of lung function are established by 6
years of age [6]. Respiratory viruses, such as respiratory syncytial virus, parainfluenza virus and
rhinovirus have been commonly identified in children with lower respiratory tract illness with
wheeze during the first year of life [7, 8].
2.1.1.3.Diagnostic Challenges in Children
The diagnosis of asthma in children, particularly in preschool children is challenging [9, 10].
History of symptoms, physical examination and objective evidence of airway obstruction helps
in the diagnosis and determining the severity of asthma. The diagnostic challenge in children
relates to both clinical diagnosis and lung function tests to provide evidence of airway
obstruction. Many symptoms of asthma are not asthma-specific, and common symptoms such as
recurrent cough and wheeze can be present in a range of other pediatric diseases, including upper
airway diseases, congenital structural bronchial diseases, bronchial/tracheal compression,
endobronchial diseases, oesophageal/swallowing problems, diseases causing pulmonary
suppuration, bronchopulmonary dysplasia, tracheomalacia and pulmonary oedema secondary to
left-to-right shunting or cardiomyopathy [11]. Clinical diagnosis of asthma requires careful
consideration of symptoms and their frequency, severity, and pattern together with age of the
child and presence of known risk factors. Furthermore, lung function assessment in children aged
2–6 years remains challenging. Different lung function tests such as spirometry, multiple inert
gas washout, plethysmography, interrupter resistance and impulse oscillometry have been
assessed in preschool children, with varying results [12]. Resistance and spirometry are feasible
in young children aged 3–6 years with success increasing with age but require time, patience and
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technical skills [13, 14]. Asthma diagnosis in children aged less than two years is particularly
difficult due to absence of objective lung function measurements and specific biomarkers.
Spirometry is not often feasible in children less than 4 or 5 years of age. Even when feasible,
spirometry can not provide definitive diagnosis of asthma. Indeed, small airway dysfunction
associated with asthma was found in children with mild asthma symptoms and normal
spirometry [15]. Normal forced expiratory volume at 1 min (FEV1) has also been reported in
children with severe persistent childhood asthma [16]. But even in older children (7–12 years),
objective measurements for bronchial hyperresponsiveness only “marginally increased the
diagnostic accuracy after symptom history had been taken into account” [17].
2.1.2. Asthma in Adults
Asthma in adults has two distinct phenotypes: early-onset phenotype that originates in childhood
by 12–13 years of age, and late-onset phenotype that starts later in adulthood without any
symptoms during childhood [18-20]. Most of the adult asthma cases have its onset earlier during
childhood [21]. Adults with early-onset asthma are more likely to be atopic and have higher
frequency of asthma attacks, and adults with late-onset asthma are more likely to be females,
smokers and have higher levels of airflow obstruction, less atopy and shorter duration of disease
[20]. Late-onset asthma can be mild or severe, and generally has worse prognosis and poorer
response to the standard asthma treatment compared with childhood- or early-onset asthma [20,
22, 23]. Late-onset asthma in adults has been further classified into five different phenotypes
based on cluster analysis studies: eosinophilic inflammation-predominant asthma, mild-tomoderate well-controlled asthma, obese noneosinophilic asthma, smoking asthma, and severe
and obstructive asthma [24].
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2.1.3. Overdiagnosis and Underdiagnosis of Asthma
Challenges in asthma diagnosis can lead to both overdiagnosis and underdiagnosis [25]. Asthma
was excluded in one-third of Canadian adults with a physician-diagnosed asthma following
objective evaluation using spirometry and methacholine challenge test [26]. Overdiagnosis was
associated with older age at diagnosis, higher FEV1 percent of predicted, being male, lack of
daily use of asthma medication and lack of daily use of inhaled corticosteroids [26]. Another
recent study also reported that current asthma was ruled out in one-third of the adults with
physician-diagnosed asthma, and these patients were nearly 12% less likely to undergo airflow
limitation test at the time of diagnosis in the community [27]. Asthma overdiagnosis has also
been reported among British children by general practitioners in primary care [28]. However,
some of the patients with physician-diagnosed asthma may have outgrown asthma over the
course of time. Asthma overdiagnosis is not surprising because use of heterogenous diagnostic
criteria by the physicians and lower rates of diagnostic tests have been reported over the last few
decades. A study was conducted to compare the reported practices with the Canadian Consensus
recommendations among five specialty groups of physicians: family physicians/general
practitioners, respirologists, internists, pediatricians and allergists/clinical immunologists [29].
This study was done in 10 provinces and 2 territories in 1996–1997. While virtually 100%
respondents reported using medical history and physical examination for diagnosis, use of
objective measurement of airflow obstruction varied greatly among physicians in different
speciality. A lower rate of use of spirometer to assist with diagnosis was reported by physicians
in pediatrics and family practice for both children aged six years or younger (2.4% and 13.6%,
respectively) and adults and children over six years of age (31.1% and 42.7%, respectively),
while the highest proportion of spirometry use was reported by physicians in respirology for both

14

groups (21.3% for children aged six years or younger and 97.9% for adults and children aged
more than six years). The rate of use of spirometry among primary care physicians (pediatricians
and family physicians) has been reported in other studies conducted in the United States in last
two decades [30-32]. Different diagnostic criteria and lower rate of use of spirometry to diagnose
asthma at primary care remains low even lately although the majority of the asthma cases are
diagnosed at the primary care level. A survey among pediatric pulmonologists and general
pediatricians from 25 different countries including the United States and Canada reported
heterogeneity in the diagnostic criteria used by the physicians to diagnose pediatric asthma and
64% of the general pediatricians did not use any diagnostic tests whereas 91% of the
pulmonologists used spirometry before and after bronchodilator as part of their diagnosis [33].
On the other hand, asthma has also been found to remain undiagnosed in both children
and adults [34-36]. While “all that wheezes is not asthma” [37], underdiagnosis remains a
frequent problem in children in whom asthma tends to be misdiagnosed as chronic bronchitis,
bronchiolitis or pneumonia, leading to inadequate or inappropriate therapy [38]. More than onethirds of Norwegian children with wheeze but without a physician-diagnosed asthma was
deemed to have asthma [39]. A case of cough variant asthma has been reported to remain
undiagnosed for 16 years in an adult patient [40]. Asthma in older adults (aged 64 years or more)
is often underdiagnosed and undertreated. The cause of the underdiagnosis is multifactorial:
reduced symptom perception, an assumption that dyspnea is normal in old age, misattribution of
symptoms to other causes (e.g., congestive cardiac failure), under use of diagnostic tools
including spirometry, self-limitation of activities, social isolation, depression and misconception
that adult-onset asthma is rare [41].
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2.1.4. Measuring Asthma Occurrence in Epidemiologic Studies
In absence of gold standard for defining and diagnosing asthma, measuring occurrence of
asthma, including prevalence in population studies has been challenging. As a result, different
operational definitions based on symptoms, physician diagnosis, medication use, bronchial
hyperresponsiveness or spirometry with or without specific time frame, alone or in combination,
have been used in epidemiological studies on childhood asthma. Indeed, 60 different definitions
to diagnose asthma in children aged 6–18 years were found in 122 cohort studies published
during 1998–2008, resulting asthma prevalence estimates ranging between 15.1% and 51.1%
[42]. On the other hand, a review of 117 cross-sectional prevalence studies published during
2010 through 2013 reported that 34 studies used 8 different definitions of “lifetime asthma”, 54
studies used 12 different definitions of “diagnosed asthma” and 61 studies used 29 different
definitions of “current asthma” [43]. Furthermore, poor agreement between bronchial
hyperresponsiveness and clinical assessment of asthma by a physician has also been noted in
population-based studies that compared the validity of asthma symptom questionnaires and/or
bronchial hyperresponsiveness testing against asthma diagnosis from clinical examination by a
physician or self-report of physician-diagnosed asthma [44, 45].
The choice of instruments and methods used in population-based studies depends on the
objective and targeted effect measures as well as on practicalities such as feasibility, cost and
time. Written questionnaires are typically used in surveys to measure asthma and respiratory
symptoms in the population. A measurement tool with good validity and reliability can ensure
accurate measurement of asthma. Since the symptoms of asthma are non-specific and often
subject to individual perception, this can lead to errors in reporting. The International Study of
Asthma and Allergies in Childhood (ISAAC) developed a video questionnaire and compared it
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with a written questionnaire among 13-14 years old Canadian children to assess the prevalence
of asthma symptoms (wheezing). The prevalence of wheezing ever, current wheeze, wheeze on
exercise, and nocturnal wheeze was higher based on the responses to the written questionnaire
compared with the video questionnaire among children with diagnosed asthma and there was
limited agreement between the questionnaires [46]. Video questionnaire had a slightly lower
accuracy than the written questionnaire when evaluated against a clinical diagnosis of asthma
[47]. Reported physician-diagnosed asthma in questionnaire may be preferable in terms of
feasibility but is not a robust method of assessing disease burden because the diagnostic criteria
may vary from physician to physician and depend on the availability of diagnostic tests at point
of care. However, earlier studies conducted during 1980s reported low sensitivity and high
specificity of reported physician-diagnosed asthma when validated against bronchial challenge
test [45]. Parent report of asthma in 7-year-old children had a 79.8% estimated sensitivity and
80.8% estimated specificity when validated against a pediatric allergist diagnosis of asthma in a
cohort study [48], while parent report of physician-diagnosed asthma in school children aged 9–
12 years had a 75% estimated sensitivity and 92% estimated specificity when compared against
clinical diagnosis and reversible bronchoconstriction or positive methacholine challenge [49].
Using general practitioner recorded asthma (from patients records in General Practice Research
Database) as the gold standard, parent report of a doctor-diagnosed asthma in children aged less
than 9 years of age had an 88.5% estimated sensitivity and 95.7% estimated specificity in UK
[50]. In addition, there is the potential that asthma remission status may not be informed by the
physicians.
Use of health administrative databases remain another preferred source of data for studies
ascertaining disease burden, including asthma. While validated case definitions can reduce false
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positive and help objective diagnosis, use of health administrative data is not free from
disadvantages. Notable drawbacks are exclusion of cases for individuals not seeking medical
care, seeking care from physicians who do not report services and individual or population not
covered by unified single-payer health care system.
2.1.5. Etiology of Asthma
The etiology of asthma remains largely unknown, leading to a lack of primary preventive
options. However, two general theories regarding the origin have been suggested, and several
specific risk factors have been identified.
2.1.5.1.Fetal Origin of Adult Disease Hypothesis
The fetal origin hypothesis, also known as the Barker hypothesis or developmental plasticity
hypothesis, was first postulated by David J. P. Barker [51]. Fetal programming or impaired
intrauterine growth and development have been implicated in the origin of diseases such as
coronary heart disease, stroke, hypertension and non-insulin-dependent diabetes mellitus [52-56].
Fetal origin of hypertension has also been implicated in animal models where prenatal exposure
to maternal general and protein undernutrition were associated with increased systolic blood
pressure and mean arterial blood pressure [57]. Several studies have suggested that asthma has
its origin in fetal life and infancy similar to other common chronic diseases [58]. Developmental
influences on airway structure and airway inflammation could possibly play a part in asthma,
particularly intrauterine exposures that lead to postnatal airway inflammation [59]. It is also
possible that fetal nutrition and environmental exposures causing epigenetic modifications of
DNA expression could exert indirect effects on airway and lung growth.
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2.1.5.2.Hygiene Hypothesis
The hygiene hypothesis proposes that “the decreasing incidence of infections in western
countries and more recently in developing countries is at the origin of the increasing incidence of
both autoimmune and allergic diseases” [60]. In 1989, a study reported an inverse relationship
between family size and development of atopic disorders, hay fever or eczema suggesting that
reduced cross-infection opportunity in the family due to declining family size, better household
amenities and higher personal cleanliness led to the observed increase in atopic diseases [61]. It
was proposed that allergic diseases were prevented by early childhood infections transmitted by
unhygienic contact with older siblings or prenatally from mother infected through contact with
older children, thereby postulating the ‘hygiene hypothesis’ of atopic diseases [61]. As a result,
different factors affecting microbial exposure such as water and food, sanitation, antibiotics,
vaccination, birth practices and farm living have been investigated along with changes in
lifestyle factors such as dietary practices. Animal models and some intervention trials in human
have provided the proof of the principle of hygiene hypothesis with possible underlying
mechanisms [60]. However, infectious disease specialists have expressed concerns that the term
‘hygiene hypothesis’ will adversely affect infectious disease risk perceptions and the importance
of the risk control measures among the general population. It has been suggested that the
hypothesis should rather be renamed as ‘microbial exposure’ or ‘microbial deprivation’
hypothesis to focus on the impact of pathogens on atopic diseases to dissipate the possible
negative impact on good hygiene behaviour [62]. There is another emerging hypothesis that
involves microorganisms but in the opposite direction from the hygiene hypothesis. This
relatively new overarching ‘microbiome hypothesis’ suggests that certain microbiome pathogens

19

could possibly be “determinants of asthma development, persistent, severity and risk of
exacerbations” [63].
2.1.5.3.Risk Factors of Asthma
The risk factors of asthma have been extensively investigated over the last couple of decades and
continues to be investigated to generate further knowledge. Several comprehensive reviews,
including systematic reviews and meta-analyses have summarized and/or synthesized existing
evidence on the role of different risk factors.
A wide range of demographic, developmental, lifestyle, infection, medication, diet and
inhaled exposures have been implicated as risk factors for childhood asthma development. Such
factors include age (nonlinear), sex (age dependent), family history, genetics, urbanization, highincome lifestyle, low birth weight, fast infant weight gain, preterm birth, cesarean section
delivery, atopic sensitization, rhinitis, stress, high body mass index (BMI), sedentary behavior,
infections with respiratory syncytial virus, rhinovirus, pertussis, paracetamol, beta-agonists,
antibiotics, environmental tobacco exposure, child smoking, air pollution, occupational exposure,
house dust mite and molds [64]. An extensive review of existing literature in 2008 reported
different prenatal (maternal smoking, diet and nutrition, stress, use of antibiotics and cesarean
section delivery) and childhood (allergic sensitization, environmental tobacco smoke, exposure
to animal, breastfeeding, decreased lung function in infancy, family size and structure, socioeconomic status, antibiotics, infections and sex) risk factors of asthma [65].
Parental asthma, prenatal environmental tobacco smoke, and prematurity were found to
be well-established risk factors for childhood asthma in a recent systematic review and metaanalysis. However, there were also mild-to-moderate causal effects of pregnancy related
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(maternal weight gain or obesity, maternal use of antibiotics or paracetamol, and maternal
stress), perinatal (birth by cesarean section delivery), or postnatal (severe respiratory syncytial
virus infection, overweight or obesity, indoor exposure to mold or fungi, and outdoor air
pollution) factors on childhood asthma that warranted confirmation in further appropriately
designed prospective or interventional studies [66]. Another systematic review of literature on
the association between development of asthma in children up to 9 years of age and different
exposures, namely second-hand smoke, inhaled chemicals, damp housing/mold, dietary
exposures, respiratory virus infection and medications included 135 papers including 15
systematic reviews, 6 meta-analyses and 14 intervention studies [67]. This review suggested that
observational studies likely suffered from publication bias, reverse causation bias and
confounding. While consistent evidence of the association between asthma and second-hand
smoke, inhaled chemicals, mold, ambient air pollutants, some deficiencies in maternal diet and
respiratory virus infections were found, less consistent evidence of exposures to pets,
breastfeeding and infant dietary exposures as risk factors for asthma were noted. Furthermore,
the consistent association observed between early life exposure to antibiotics and paracetamol
and childhood asthma might reflect reverse causation [67].
History of early childhood wheezing before two years of age, male sex, low birth weight,
childhood allergy, single parent, maternal smoking during pregnancy, maternal medication use,
parental atopy and low socioeconomic status increased the risk of incidence of physiciandiagnosed asthma in preschool children [68]. Maternal asthma, young age, smoking, previous
miscarriages, high number of previous deliveries, cesarean section, low gestational age, and low
ponderal index (birth weight/birth length3) were associated with an increased risk of asthma
before 3 years of age, while only maternal asthma, low gestational age and low ponderal index
21

were associated with an increased risk of asthma at 3 years of age or later suggesting different
risk factors for early and late-onset asthma [69]. However, increasing ponderal index was
associated with an increased risk of asthma in adolescents [70].
Studies have also examined the association between fetal growth indicators and other
prenatal factors and the risk of asthma using anti-asthma medications in children. Maternal
asthma, male child, maternal smoking during pregnancy, increased number of cigarettes smoked
per day, having older siblings, maternal age <21 years, and maternal non-cohabitation were
associated with an increased risk of receiving a prescription for asthma (both a β-agonist and an
inhaled glucocorticoid) in infants during the first year of life in a birth cohort study in Denmark
[71]. In this study, increasing birth weight, preterm births, lower gestational age, placental
weight ≥750 g and ponderal index ≥2.7 were also associated with an increased risk of receiving
asthma medications. In another study, being the first-born child, maternal age more than 44
years, involuntary childlessness for more than a year, maternal smoking during pregnancy,
maternal diabetes mellitus of any kind, pre-eclampsia, cesarean section, instrumental vaginal
delivery, preterm birth, low birth weight, small-for-gestational age, APGAR score <7 at 5
minutes, respiratory problems, mechanical ventilation, sepsis and/or pneumonia and neonatal
phototherapy and/or icterus were associated with an increased prescription of anti-asthmatic
among Swedish children [72]. Prescription of asthma medication were used as a surrogate
measure for asthma in these studies. Asthma medications are prescribed for treating wheezing
due to other causes as well and have high sensitivity but low specificity.
Sex of the Child
There is an age-dependent effect of sex on the risk of asthma. Asthma is more common in boys
until 13 years of age and thereafter is more prevalent in girls [64]. Biological sex differences as
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well as sociocultural and environmental differences have been implicated in the differential sex
effect on asthma [73]. Biological sex difference is caused by factors such as sex hormones,
genetic susceptibility, differential lung development and immunological factors. A complex
interplay among the sex hormones likely play a major role; estrogen and progesterone may
increase the prevalence and severity of asthma in females and androgens may be protective.
Genetic factors lead to increased female susceptibility for asthma. Sex differences in lung
development and maturation, and physical growth of lung from birth into adulthood also affect
asthma susceptibility and severity in females. Sex hormones also play an immunomodulatory
role in the sex differences [73].
Parental History of Asthma
Parental asthma is a well-known risk factor of asthma [66, 74]. A systematic review and metaanalysis of 33 studies reported that children with maternal asthma had a higher odds of asthma
compared with children without maternal asthma (OR 3.04, 95%CI: 2.59, 3.56) and children
with paternal asthma had a higher odds of asthma compared with children without paternal
asthma (OR 2.44, 95%CI: 2.14, 2.79); maternal asthma conferred greater risk than paternal
asthma (3.04 vs 2.44, p=0.037) [75]. However, the effects were attenuated when the analysis was
limited to physician-diagnosed asthma or in children aged 5 years or older although maternal
asthma conferred greater risk than paternal asthma. It has been suggested that non-genetic in
utero and/or post-natal factors may play a key role in transmission of asthma susceptibility from
mother to child.
Exposure to Cigarette Smoking
Passive smoking is associated with increased asthma incidence and severity of asthma, and it has
been suggested that the duration of exposure plays an important factor in asthma induction [76,
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77]. A systematic review and meta-analysis of evidence from 79 prospective studies suggests
that exposure to pre or postnatal maternal, paternal or household smoking increased the risk of
incident asthma in childhood by 21% to 85% and the strongest effect was from maternal
smoking during pregnancy on asthma in children aged two years or younger [78].
Active smoking also increases the risk of asthma in adolescence (RR 3.9, 95% CI: 1.7,
8.5), and the highest risk of asthma from active smoking (RR 8.8, 95% CI: 3.2, 24.0) was among
children who smoked regularly and had exposure to maternal smoking during pregnancy [79].
Smoking causes pathophysiologic changes in the airways, including inflammation and airway
hyperresponsiveness leading to new-onset asthma. A ban on smoking in workplaces or public
places was associated with both an immediate reduction in hospital attendance for asthma [–
10·1% (95% CI: –15·2, –5·0), p=0·0001] and an annual rate reduction [–7·5% per year (95% CI:
–16·0, 0·9), p=0·081] in hospital attendance for asthma [80].
Pre-pregnancy Body Mass Index and Excess Maternal Gestational Weight Gain
Higher pre-pregnancy body mass index (BMI) and excess maternal gestational weight gain were
associated with an increased risk of asthma [81-84]. Obese (BMI>30) mothers had a higher odds
(OR 1.44, 95% CI: 1.12, 1.86) of having a child with asthma at 3 years of age [81]. Maternal
BMI ≥35 (aOR 1.87, 95% CI: 0.95, 3.68) and excessive gestational weight gain of ≥25 kg were
associated with doctor-diagnosed asthma ever during the first seven years of childhood [82].
Each 1-kg/m2 increase in maternal BMI was associated with a 2% to 3% higher odds of
childhood asthma [84]. Higher maternal BMI was also associated with an increased risk of
childhood asthma medication (inhaled corticosteroid) use [85]. Four different biological
mechanisms have been suggested in the association between maternal obesity and childhood
asthma. Maternal obesity exerts effects through maternal and infant excess pro-inflammatory
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factors/cytokines or reduction of anti-inflammatory factors, altered maternal/gut colonization,
and possibly through pregnancy complications and childhood obesity [86-88].
Pregnancy Complications
Pregnancy complications such as hemorrhage, anemia, cervix insufficiency, placental
dysfunction, rhesus immunization, preterm contractions, and preeclampsia and hyperemesis
increased the odds of incidence of asthma in children [89].
Preterm/premature Birth
A systematic review and meta-analysis based on 19 (5 cross-sectional, one case-control and 13
cohort) studies reported higher odds of asthma in children (OR 1.37, 95% CI: 1.30, 1.43) with
preterm delivery (gestational age <37 weeks) compared with children born at term [90].
However, the effect was found to be greater in studies with a younger study population compared
with studies in older population. Although the underlying mechanisms are not well understood,
three possible pathways (models) were suggested. The first model suggested that preterm
delivery per se increased the risk of asthma through anatomical and immunological immaturity.
According to the second model, there might be common genetic and environmental determinants
of asthma and preterm delivery, while both preterm delivery and those determinants
independently also increase the risk of asthma with the possibility that preterm birth modifies the
relationship between environmental exposures and asthma. The third model suggests that the
association between preterm delivery and asthma might be due to an association between
prenatal and postnatal exposures. A meta-analysis of data of 147,252 children from 31 European
birth cohorts also reported that preterm birth was associated with an increased risk (pooled OR
1.40, 95% CI: 1.18, 1.67) of asthma in school-aged children (aged 5–10 years) [91].
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Cesarean Section Delivery
A number of studies have found a positive association between cesarean section delivery and
asthma in children [92-102]. Some of these studies also examined the association separately for
planned/elective and emergency/acute cesarean section delivery and/or according to the timing
of cesarean section delivery in relation to membrane rupture. In one such study, the adjusted HR
for the association between emergency cesarean section and asthma was 1.59 (95% CI: 1.44,
1.75) and the adjusted HR for the association between planned cesarean section and asthma was
1.42 (95% CI: 1.25, 1.61), compared with spontaneous vaginal delivery [95]. In another study,
the adjusted HR for the association between acute cesarean section delivery and asthma was 1.06
(95% CI: 1.02, 1.10) and the adjusted HR for the association between elective cesarean section
and asthma was 1.24 (95% CI: 1.20, 1.28), compared with vaginal delivery [98]. It has also been
suggested that the risk of asthma following cesarean section delivery depends on when it was
performed with regard to membrane rapture. In yet another study, the adjusted incidence rate
ratio for the association between cesarean section delivery performed before rupture of
membranes and asthma was 1.20 (95% CI: 1.16, 1.23) and the adjusted incidence rate ratio for
the association between cesarean section delivery after rupture of membranes and asthma was
1.12 (95% CI: 1.09, 1.16), compared with vaginal delivery [99]. However, one study reported
that the risk of asthma during the first 7 years of life was decreased by 7% in children born by
cesarean section (aHR 0.93, 95% CI: 0.60, 1.40) [102].
Nevertheless, systematic reviews and meta-analyses examining evidence from different
studies suggest that there was a positive association between cesarean section delivery and the
risk of asthma in children There was a higher odds of childhood asthma (pOR 1.20, 95% CI:
1.14, 12.6) in a meta-analysis of findings from 23 (one cross-sectional, four case-control and 17
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cohort) studies [104]. Cesarean section was associated with a higher odds of asthma (pOR 1.18,
95% CI: 1.05, 1.32 from 13 studies) and hospitalization for asthma (pOR 1.21, 95% CI: 1.12,
1.31) in another meta-analysis [105].
Children born by vaginal delivery are exposed to maternal vaginal and intestinal
microbiota whereas children born by caesarean section delivery are exposed to skin and
environmental microbiota leading to differential acquisition of microbiota shortly after birth.
Cesarean section delays and alters the development of intestinal flora in child thereby altering
immune development [106] that may increase the risk of atopic disease in line with the hygiene
hypothesis [107]. Cesarean section delivery also delays the development of upper respiratory
tract microbiota in infancy, including reduced colonization of health-associated commensals and
hence could play a role in the development of asthma [108-110]. It is also possible that cesarean
section causes transient tachypnea in the newborn that increases the risk of asthma.
Low Birth Weight
Low birth weight (birth weight <2500 g) is associated with an increased risk of childhood
asthma. A meta-analysis of 13 cohort studies also suggested that children with low birth weight
are at increased risk of childhood asthma (RR 1.15, 95% CI: 1.08, 1.22) compared with children
with normal birth weight [111]. Another meta-analysis of 18 studies in children and adults also
suggested a higher odds of asthma in both children (OR 1.28, 95% CI: 1.09, 1.50) and adults
(OR 1.25, 95% CI: 1.12, 1.39) with low birth weight compared with those with normal birth
weight (2500–4000 g) [112]. There was also a higher odds of asthma at age 3–9 years with
decreasing birth weight [OR (per 100g) 1.04, 95% CI: 1.03, 1.05] in twins, and lower
birthweight twin pair had a higher odds of asthma compared with heavier co-twins within twin
pairs [113]. It is suggested that low birth weight might lead to developmental adaptations
27

resulting in impaired lung growth with smaller airways and decreased lung volume leading to
asthma.
Respiratory Tract Infections
Wheezing episodes due to viral respiratory infections by respiratory syncytial virus, human
rhinovirus, metapneumovirus, parainfluenza virus, corona virus have been associated with an
increased likelihood of subsequent development of childhood asthma [114-116]. This contradicts
the hygiene hypothesis. Whereas, lower respiratory tract infections in early infancy is associated
with reduced IgE levels and day-care attendance during early infancy reduced the risk of allergen
sensitization, conforming to the hygiene hypothesis [117-119].
Antibiotic Use
There is evidence that use of antibiotics within the first 6 months of life increases the risk of
asthma and allergy at 6 years of age [120], however, a study suggested that the association
observed between early antibiotic and wheezing is likely due to confounding rather than causal
[121]. It is likely that the effect of infections on the occurrence of asthma or allergic diseases
depend on specific pathogen, severity of infection, cumulative number of infections and the stage
of immune development of the child [114].
Breastfeeding
The association between childhood asthma and breastfeeding remained ambiguous for some time
because some studies reported benefit, while other studies reported no benefit or even an
increased risk of asthma in breastfed babies. A systematic review and meta-analysis reported that
breastfeeding was associated with reduction in asthma/wheezing, however, the protective effect
seemed strong at 0–2 years of age and decreased thereafter [122].
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Body Mass Index and Growth of the Child
Boys with high body mass index (BMI≥85th percentile) at 2–3 years of age had an increased risk
of incident asthma (HR 1.6, 95% CI: 1.1, 2.4) compared with their counterparts up to 14 years of
age [123]. A rapid growth in BMI during the first 2 years of life increased the risk of incident
asthma (HR 1.3, 95% CI: 1.1, 1.5) up to 6 years of age compared with children with a less
pronounced early childhood weight gain [124]. Children having a persistent high BMI during
childhood or a high BMI at 6 to 7 years of age had a higher odds of dyspnea (OR 1.68, 95% CI:
1.18, 2.39) at 8 years of age. However, a high BMI at an earlier age was not related to a higher
odds of asthma symptoms such as dyspnea and bronchial hyperresponsiveness at 8 years if the
child became normal weight by 6 or 7 years [125]. A 3-unit increase in BMI was associated with
an increased risk of asthma in middle-aged males and females (RR 1.21, 95% CI: 1.16, 1.26)
using asthma prescription as a surrogate marker of incident asthma [126]. Obesity likely
increases proinflammatory cytokines such as interleukin-6, leptin, tumor necrosis factor α, tumor
growth factor β1, eotaxin as well as modifies atopy and Th1-Th2 imbalance ultimately increasing
airway hyperreactivity; obesity also decreases expiratory residual volume and functional residual
capacity that reduces peripheral airway diameter and smooth muscle structure and function
[127].
Low Physical Activity
Children with low physical activity (no team sports played, sports participation ≤once per week
and television viewing ≥1 hour per day) had an increased risk of incident asthma (OR 1.32, 95%
CI: 0.95, 1.84) compared with children with high physical activity (≥1 team sport played, sports
participation ≥2 times per week and television viewing <1 hour per day) as suggested by the
results from a systematic review and meta-analysis of three cohort studies [128]. An inverse
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relationship between leisure-time physical activity in rural environment and asthma symptoms in
children aged 10–12 years was reported from a cross-sectional study [129].
Air Pollution
The strength of evidence on the association between several traffic-related air pollutants such as
nitrogen oxides (NOx), nitric oxide (NO), nitrogen dioxide (NO2), particulate matters [≤10 μm
and ≤ 2.5 μm in aerodynamic diameter (PM10 and PM2.5)], sulphur dioxide (SO2), carbon
monoxide (CO), ozone, black carbon and new-onset asthma is variable across studies [130]. A
systemic review and meta-analysis of findings from 14 cohort studies, 2 nested case-control
studies in a birth cohort and two cross-sectional studies reported an increased risk of childhood
asthma due to prenatal exposure to NO2 [pooled OR 1.07 (95% CI: 1.01, 1.14)], PM10 [pooled
OR 1.08 (95% CI: 1.05, 1.12)] and SO2 [pooled OR 1.02 (95% CI: 0.98, 1.07)] [131]. Exposure
to higher concentrations of NO, NO2, and CO during pregnancy and the first year of life was
associated with incident childhood asthma; aOR 1.08 (95% CI: 1.04, 1.12) for a 10-μg/m3
increase of NO, 1.12 (95% CI: 1.07, 1.17) for a 10-μg/m3 increase in NO2, and 1.10 (95% CI:
1.06, 1.13) for a 100-μg/m3 increase in CO [132]. Childhood exposure to black carbon, NO2,
NO, PM2.5 and PM10 increased the risk of childhood incident asthma or lifetime prevalence of
asthma in children [1.08 (95% CI: 1.03, 1.14) per 0.5 × 10−5 m−1 black carbon, 1.05 (95% CI:
1.02, 1.07) per 4 μg/m3 NO2, 1.48 (95% CI: 0.89, 2.45) per 30 μg/m3 NOx, 1.03 (95% CI: 1.01,
1.05) per 1 μg/m3 PM2.5, and 1.05 (95% CI: 1.02, 1.08) per 2 μg/m3 PM10] as reported by
another systematic review and meta-analysis of 21 studies [133].
Four mechanisms have been attributed to the effect of air pollutants on asthma
development and exacerbations: oxidative stress and damage, airway remodeling, inflammatory
pathways and immunological responses, and enhancement of respiratory sensitization to
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aeroallergens. However, air pollutants might exert different effects depending on the
concentration. At high concentrations seen in megacities in India and China, air pollutants might
have direct irritant and inflammatory effects, while at lower concentrations seen commonly in
high-income countries airway inflammation, airway hyperresponsiveness and oxidative stress
may play key roles [130]. However, the mechanisms in non-atopic asthma in children and adults
remain largely unknown.
Risk Factors for Non-atopic Asthma/wheeze in Children
A systematic review of risk factors for non-atopic asthma/wheeze in children and adolescents
evaluated 30 risk factors from 43 articles where family history of asthma/rhinitis/eczema,
dampness/mold in the household and lower respiratory tract infections in childhood were
identified as common risk factors of non-atopic asthma/wheeze [134].
Neonatal Risk Factors of Asthma and Asthma-associated Hospitalization
Different neonatal factors have been identified as risk factors of asthma and asthma-associated
hospitalization. Lower Appearance-Pulse-Grimace-Activity-Respiration (APGAR) scores at 1and 5-minutes following birth increased the risk of asthma in children [135, 136]. Neonatal
factors such as respiratory distress syndrome with or without bronchopulmonary dysplasia,
transient tachypnea of the newborn, sepsis or pneumonia, respiratory problems, mechanical
ventilation, low APGAR score, neonatal icterus and neonatal phototherapy also increased the
odds of hospitalization due to asthma in children [137, 138]. The association between neonatal
phototherapy and hospitalization was stronger for children hospitalized two or more times.
Risk factors for Adult-onset Asthma
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Active and passive cigarette smoking, female sex hormones, rhinitis, acute lower respiratory
infections, obesity and stressful life events have been implicated as risk factors for adult-onset
asthma [20].
2.1.6. Global Burden and Health Impact of Asthma
Asthma is one of the major chronic diseases of public health importance in the world. With
significant advancement in asthma management, asthma mortality rates have declined [139].
There has been a 23.5% reduction in age-standardized asthma death rates between 2007 and
2017 worldwide [140]. Hospital admission rates for asthma has also decreased over the last
several decades [139], however, there has not been any overall decline in asthma prevalence [64,
141]. Asthma affected an estimated 242–305 million people worldwide in 2017 and resulted in a
4.9% increase in age-standardized years lived with disability since 2007 [142]. Globally, asthma
ranked 25th among the leading causes of disease burden and was the 16th highest rank cause of
years lived with disability contributing an estimated 18.9–29.7 million disability-adjusted life
years lost across all ages in 2016 [143, 144]. In children, symptom prevalence varies greatly
globally, and asthma symptoms are more prevalent in affluent countries while symptoms tend to
be more severe in less affluent countries [145]. Three pediatric asthma related epidemics have
been reported from the developed countries during 1955–2010: “a double peaked mortality
epidemic (1960s and 1980s), a hospital admission epidemic (peaked around 1990) and a steadily
growing epidemic of children who report asthmatic symptoms on questionnaires” [146]. In
adults, the overall prevalence of doctor diagnosed asthma and clinical or treated asthma also
varied greatly among different counties in the world [147].
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Asthma causes substantial economic burden through direct and indirect costs [148].
Direct costs of asthma incur through physician visits, emergency visits, hospitalization, nursing
services, ambulance services, medications, devices, diagnostic tests, research and education with
medication and hospitalization accounting for the major cost. Indirect costs incur through lost
productivity at work and school (due to absenteeism and restricted days), travel and waiting time
associated with outpatient care and lost future potential income associated with morbidity and
mortality. Hospitalization and medications are the major drivers of direct cost, while work and
school loss are the major drivers of indirect cost. However, the indirect cost for children with
asthma is higher compared to adults because of lost productivity of parents or caregivers. A
systematic review of articles published between 1966 and January 2008 demonstrated significant
variation in the cost of asthma among different countries [148]. In this study, the estimated total
cost from national studies in the United States, Canada and Switzerland ranged from US$654
million in Canada to US$15,248 million in the United States; the estimated direct cost ranged
from US$397 per person in Canada to US$8,665 per person in the United States. Another
systematic review of studies on economic burden of asthma across the globe between 2008 and
2015 also reported variation in the estimated costs across different regions of the world [149].
The estimated annual costs varied from less than US$150 per person-year (Abu Dhabi, United
Arab Emirates) to more than US$3000 per person-year (United States); medication accounted for
the largest direct medical cost and varied from 51% (United States) to 68% (Canada) of total cost
in North America, while it varied from 45% (Spain) to 84% (Germany) of total cost in Europe.
Medication costs appear to be increasing in the United States and Canada. On the contrary, outpatient costs accounted for the major portion of total costs in the Middle-East and South-East
Asia. The estimated total cost of asthma in the United States in 2013 was US$81.9 billion, and
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asthma accounted for an estimated UD$3 billion due to missed work and school days, US$29
billion for asthma-related mortality and US$50.3 billion in medical costs during 2008–2013
[150]. In 2013, the total direct cost of pediatric asthma in the United States was US$5.9 billion
and the average annual cost per child ranged from US$1049–8039 [151]. Although asthmarelated hospitalizations have declined during 2000 through 2010, pediatric asthma caused
substantial medical and economic burden. Children with asthma aged 5–17 years missed 13.8
million school days per year in the United States in 2013 [152].
Asthma also results in intangible costs related to unquantifiable losses such as pain or
suffering, impairment of quality of life, limitations of physical activities and study or job
performance, job changes and psychological effects [153, 154]. Children with asthma have
higher rates of attention-deficit/hyperactivity disorder, diagnoses of depression, behavioral
disorders and learning disabilities [155]. While greater health-related quality of life impairment
is generally associated with severe disease, patients with mild asthma also experience depression
and impaired health-related quality of life as often as patients with severe asthma [156].
Australian adults with asthma also reported adverse health states such as poor life satisfaction,
poor health status, high psychological distress and reduced activity days [157]. Even children
with asthma-like symptoms but without any physician-diagnosed asthma have substantial health
consequences such as missed school days, limited activities, sleep disturbances, emergency care
visits and hospitalizations [158].
2.2.

Asthma Prevalence

2.2.1. Asthma Prevalence in Canadians
An estimated 2.2 million Canadian adults reported physician-diagnosed asthma in 2017
Canadian Community Heath Survey (CCHS) [159]. In individuals aged 12 years or older, the
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prevalence of reported physician-diagnosed asthma increased from 6.2% in 1994 to 7.5% in
1998 based on data from the NPHS; the prevalence remained around 8.4% from 2000 to 2005
based on data from the CCHS [160]. The prevalence estimates from these surveys were based on
an affirmative response to the query on having health professional-diagnosed asthma as a longterm condition (expected to last or have already lasted six months or more). According to the
Canadian Chronic Disease Surveillance System (CCDSS), the prevalence (age-standardized to
the 2011 Canadian population) of diagnosed asthma increased from 6.5% in 2000/2001 fiscal
year to 10.8% in 2011/2012 fiscal year in Canadians aged one year and older [161]. In 2011–
2012 fiscal year, the prevalence of asthma varied by age: it was 15% in 20–24 years old, 10.5%
in 25–29 years old, between 8% and 9% in 30–64 years old and between 9% and 10.6% in 65–84
years old. The rate of increase in prevalence over time also varied by age. CCDSS estimates are
based on health administrative data and defined prevalent asthma as “having at least two visits to
a physician with a diagnosis of asthma in the first diagnostic field in a two-year period, or at least
one hospital separation with a diagnosis of asthma ever in any diagnostic field, coded by the
International Classification of Diseases (ICD), ninth revision or ICD-9-CM 493 or ICD-10-CA
J45-46” [161]. This case definition was validated against respirologist diagnosis in previous
studies and was estimated to have a 84% sensitivity and 76% specificity in adults [162].
Population-based surveys are feasible methods of estimating disease burden and enable
the collection of relevant socio-demographic and lifestyle information from the respondents, but
disease ascertainment is dependent on self-report (as physician diagnosis is not practical) and
therefore subject to reporting errors. Use of administrative data, on the other hand, provides data
on diagnosis by physician, particularly if case definitions have been validated previously.
However, health administrative data do not include information on cases not seeking medical
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care, cases diagnosed by physicians not paid on a fee-for-service basis and who do not remit
service information, and 3% of the population not included in the single-payer provincial and
territorial health care plans, such as members of the Canadian Armed Forces, members of the
Royal Canadian Mounted Police and individuals residing in federal correctional facilities.
An increasing trend in asthma prevalence has also been observed in studies conducted at
provincial level during different spans of overlapping time periods using administrative data. In
Ontario, four studies reported an increase in the prevalence while one study reported a decrease
[163-166]. Overall, the age- and sex-standardized asthma prevalence (rates standardized to the
2005 Ontario population) increased from 8.5% in 1996 to 13.3% in 2005 in one study, with the
highest increase observed in adolescents and young adults [163]. In another study, a gradual
increase in asthma prevalence was observed during 1996–2009 among all age groups and it was
projected that the prevalence of asthma will be 12.5% (95% CI: 11.3, 14.2) in 2022 [164]. In yet
another study, the overall asthma prevalence decreased among 0–39 years old Ontarians,
however, the prevalence decreased slightly in individuals aged <25 years and was stable or
increased slightly in individuals aged more than 25 years between 1994/1995 and 2001/2002
[165]. In another study among Ontarians aged 35 years or older, the prevalence of age and sexstandardized asthma (rates standardized to the 2006 Ontario population) increased from 9.4% in
2002 to 11.9% in 2012 [166]. In British Columbia, a population-based surveillance of asthma
among the working population (aged 15–64 years) with employer-paid health premium reported
an increase in active asthma rates (defined as physician visit, hospitalization, workers’
compensation claims or prescription of asthma during a year) from 1999 to 2003 [167]. In
Manitoba, the overall prevalence of diagnosed asthma increased from 1.5% in 1984/1985 to
almost 4% in 1999/2010 among all age groups; the prevalence increased from 1.3% in
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1984/1985 to more than 5% during 2000–2005 among individuals aged more than 75 years
[168].

2.2.2. Age, Period and Cohort Effects
Investigation of three time-related effects – age, period and cohort effects – may help understand
trends in disease occurrence. The change in the frequency of disease occurrence according to age
is known as the age effect [169]; age effects “describe the common developmental processes that
are associated with particular ages or stages in the life course. In other words, age effects
represent accumulated exposure and/or physiological changes associated with the process of
aging” [170]. The period effect is the change in the frequency of disease occurrence that affects
all age group because of population-wide exposures [169]. Specific phenomena such as war,
famine, migration, pandemics of infectious diseases, health policies and legislations, public
health interventions, new treatment, changes in awareness and lifestyle can produce period effect
[171]. In epidemiology, “a cohort effect occurs when different distributions of disease arise from
a changing or new environmental cause affecting age groups differently. A cohort effect,
therefore, is conceptualized as a period effect that is differentially experienced through agespecific exposure or susceptibility to that event or cause (i.e., interaction or effect modification)”
[170]. For example, while population prevalence of risk factors of any disease or health outcome
increases or decreases over time, because of the unequal distribution across age groups, we
would see different prevalence of the disease or health outcome in different age groups over
time. The interaction between period and age leads to fluctuations in the outcome and is useful in
epidemiologic research to better comprehend trends in disease or health outcomes, particularly to
understand how different exposures impact health of population differentially across age to guide
public health policy [170].
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However, there is a duality in the concept of cohort effect. In sociology, cohort effect is
conceptualized as the changes according to the year of birth (birth cohort), irrespective of age
and calendar time. Cohort effect is considered as a structural factor that may arise from lifetime
experiences, accumulated exposures over time, or differential early life exposures. A birth cohort
experiences same historical and social events at the same age as they move together in life [171].
“As a result, the conditions, barriers, and resource that each cohort is born into and in which they
live their collective lives may uniquely shape the patterns of experiences of health and mortality
for that cohort” [170]. As such, age and period effects are considered as confounders of the
cohort effect, and therefore seeks to disentangle the separate effects of age, period and birth
cohort [172]. This conceptualization of age-period-cohort (APC) effect also leads to the
identification problem that results from the presence of two simultaneous conditions: 1) age,
period and cohort variables are mathematically linearly related to each other
(age=period−cohort), and 2) APC variables are linearly related to the outcome that is APC
variables are treated as independent and additive factors in a linear model [172]. Different
approaches have been proposed and used to overcome the non-identifiability problem although
not without some controversies [170, 171, 173].
A large number of studies have used the sociological perspective of cohort effect
traditionally using historical cross-sectional data to form synthetic cohorts that included different
individuals at each calendar period with the assumptions that synthetic cohorts mimic true
cohorts. Few studies have used the epidemiologic concept of cohort and assessed age, period and
cohort effects using data from prospective studies on ‘true’ (i.e., non-synthetic) cohorts [174].
The use of interaction between period and age in statistical models conforming to the
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epidemiologic concept is free from the identification problem encountered in the sociological
concept.
2.2.3. Studies on Asthma Prevalence using Age, Period and Cohort Effect Analytic
Framework
2.2.3.1.Outside Canada
The effects of age, period and cohort on asthma prevalence have been examined in the United
States and Japan. A study assessing the age, period and cohort effects on asthma prevalence in
Japanese school children aged 6–17 years from 1984 to 2004 found that the prevalence peaked at
13 and 14 years in boys and girls, respectively, followed by marked decline afterwards [175].
There were upward trends in asthma prevalence among Japanese children born during 1968
through 1997. Period effect was also observed with a decline in the prevalence from 1984
followed by an abrupt increase in 1999 and then declined again. Among Californian adults (aged
≥18 years), age effects on lifetime asthma prevalence peaked in young adulthood, then flattened
in 40–60 years old followed by a decline in older adults in 1984–1992 and 1994–2011 [176].
There was a positive trend from 1984 to 2003 followed by flattening of the trend starting from
2004. A positive trend in asthma prevalence was also observed in Californian adults born during
1949–1953. Both these studies attempted to disentangle the separate effects of age, period and
cohort from a sociological perspective of cohort effect.
2.2.3.2.Canada
No studies in Canada have explored effects of age, period and cohort on asthma prevalence
formally using age, period and cohort theoretical and analytic framework. One recent study
assessed the association between fine particulate matter PM2.5 with asthma incidence among
individuals aged >44 years in Canada between 2007 and 2014 and attempted to separate the
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effects of age from the effects of risk factors in relation to year [177]. However, this study
employed data from the Canadian Community Health Survey and possibly suffered from the
typical identification problem because age, period and birth cohort were all modeled as linearly
related to the outcome. This study reported that “The age group 45–64 had the highest number of
cases for asthma incidence (65%)”, and “A two-year increase of 10 μg/m3 in PM2.5 was
associated with an increased risk of 2.24% (95% CI: 0.93%; 5.38%) in asthma incidence”. The
effects of age, period and cohort on asthma occurrence are not comprehensible.
There is a dearth of published literature explicitly using the age, period and cohort effect
theoretical and analytic framework to examine the effects of age, period and cohort in asthma
prevalence in Canadian adults. Age-standardized or age-specific asthma prevalence estimates
reported in previous studies using non-model-based approaches suggest age and period effects on
asthma prevalence and that period effect might differ across age groups, although the studies did
not take into account several relevant factors. It is unknown whether age, period and cohort
effects on asthma prevalence exist when employing formal age, period and cohort effect
theoretical and analytical framework and after accounting for different socio-demographic
factors.
2.3.

Asthma course

2.3.1. Asthma Course and Prognostic Factors in Children
The course of asthma is characterized by periods of relapse and remission. Estimates of
remission rates in childhood asthma reported in literature vary from 11% to 49% [178-186]. The
wide variation in remission likely resulted from differences in study population, definition of
remission and follow-up period (Table 2.1). Evidence suggests that clinical remission does not
equate to complete remission as children with remission based on symptoms and medication use
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may continue to have subclinical active disease and likely associated airway remodeling [182].
Indeed, when followed for 15 years, children with asthma have been found to have up to 15
years gap in asthma activity, which was defined as two years or more between asthma healthcare
claims [187]. Among children aged 5 years or younger, 41% had 2–4 years of gap, 23% had 5–9
years and 5% had 10–15 years of gap in asthma activity; among children aged 6–17 years, 42%
had 2–4 years of gap, 25% had 5–9 years and nearly 6% had 10–15 years of gap in asthma
activity.
Different sociodemographic, environmental, clinical and diagnostic prognostic factors for
childhood asthma have been identified. A review of the prognostic factors of asthma in children
differentiated prognostic factors for preschool- and school-aged children [188]. In this review,
male sex, atopy, severe respiratory syncytial virus bronchiolitis in infancy, exposure to passive
cigarette smoking, increased inflammatory markers and no or delayed anti-inflammatory
treatment worsened the prognosis in preschool children; female sex, severe asthma with
persistent lung function abnormalities, severe bronchial hyper-responsiveness, active or passive
cigarette smoking and outdoor pollution worsened the prognosis of asthma in school aged
children. In a study on individuals aged under 40 years, a family history of asthma or allergy
decreased the chance of remission throughout life (HR 0.79, 95% CI: 0.64, 0.99), while early
contact with older children increased the chance of remission in childhood asthma (HR 1.50,
95% CI: 1.10, 2.04 [189]. Asthma remission was positively associated with male sex (OR 2.66,
95% CI: 1.00, 7.03) but inversely associated with sensitization to furred animals (OR 0.14, 95%
CI: 0.04, 0.55) and more severe asthma at 7 to 8 years of age (OR 0.19, 95% CI: 0.07, 0.54) in
another study that followed children with asthma from 7 to 19 years of age [185]. In children
followed from 9 to 26 years, airway hyperresponsiveness (OR 3.00, 95% CI: 1.71, 5.26),
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sensitization to house dust mites at 13 years of age (OR 2.41, 95% CI: 1.42, 4.09) and female sex
(OR 1.71, 95% CI: 1.04, 2.82) were associated with persistence of wheezing from 9 to 26 years
of age, while airway hyperresponsiveness (OR 3.03, 95% CI: 1.65, 5.55), sensitization to house
dust mites at 13 years of age (OR 2.18, 95% CI: 1.18, 4.00) and earlier age at wheezing onset
(OR 0.89 per year increase in age at onset, 95% CI: 0.85, 0.94) predicted asthma relapse [181].
Another study assessing remission of asthma from birth to 44 years of age reported that
individuals in remission had younger mean age at asthma onset (7.8 vs. 15.9 years) and a shorter
duration of asthma (5.6 vs. 16.1 years) than patients with current asthma; age at onset was
associated with remission in patients with asthma [190].

42

Table 2. 1: Summary of studies on asthma remission for children having asthma diagnosed during childhood and followed
through childhood or into adulthood
Study/location

Study sample

Kjellman et al.,
2000/Sweden
[178]

55 children with
asthma during
1973–1976

Halász et al.
2002/Hungary
[179]
Robertson,
2002/Australia
[180]
Sears et al.,
2003/New
Zealand [181]

155 individuals with
diagnosed asthma in
childhood
317 children with
episodic, persistent
and severe asthma
613 children with
asthma born
between April 1972
and March 1973
Vonk et al.,
119 allergic
2004/Netherlands asthmatic children
[182]
aged 5–14 years
during 1966–1969

Age at
diagnosis
5–14
years

Followup
Until aged
25–35
years

<18 years ≥28 years
of age

Definition of remission
Remission: free from asthma symptoms and
medication during the year prior to the last
follow-up
Complete remission: absence of symptoms and
medication both at the last and the penultimate
visit
Symptom free (no frequent cough, dyspnea, or
asthma attacks)

Remission,
percentage
Remission:
16%
Complete
remission:
11%
43%

7 and 9
years

42 years
of age

Free of wheezing in past three years

40%

9 years

26 years
of age

Free of wheezing at 26 years (absence of
wheezing after wheezing had been reported at
two or more successive prior assessments)

15%

5–14
years

Until aged
32–42
years with
a mean
follow-up
30 years

Complete remission: having no current wheeze
and no asthma attacks in the previous 3 years, no
use of inhaled corticosteroids, normal lung
function (FEV1 .90% predicted), and absence of
BHR (PC10 .16 mg/ml)
Clinical remission: absence of wheeze and asthma
attacks and no use of inhaled corticosteroids

Complete
remission:
22%
Clinical
remission:
30%
Total: 52%

43

Taylor et al.,
2005/New
Zealand [183]
To et
al.,2007/Canada
[184]

176 children with
asthma

Andersson et al.,
2013/Sweden
[185]

248 children with
asthma enrolled in
1996

Bag et al.,
2013/Turkey
[186]

52 children with
persistent allergic
asthma

9–15
years

18 years
of age

34,216 children born Before 6
in 1994 and had
years of
diagnosed asthma
age
before 6 years of age

6-year
follow-up
up to 11
years of
age
7–8 years 19 years
of age

2–10
years

Absence of reported wheezing that had been
current at ≥2 prior assessments

39%

No hospitalization or physician visit for asthma
during 6-year follow-up

49%

No use of asthma medication and no wheeze
during the past 12 months as reported at endpoint
and in 2 annual surveys preceding endpoint (i.e.,
for ≥3 years).
For 10–22 Clinical remission: no attack, no use of quickyears after reliever medications in the previous year and no
enrollment admission to the emergency department for
asthma
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21%

39%

2.3.2. Asthma Exacerbation in Children
Asthma exacerbation is an acute or subacute episode of progressive increase in asthma
symptoms such as shortness of breath, cough, wheezing or chest tightness, associated with
airflow obstruction [1, 191]. Asthma exacerbations cause considerable morbidity in children and
result in unscheduled visits seeking acute care, including emergency department visit,
hospitalization and even death [192]. Asthma exacerbations in children lead to school
absenteeism and parental loss of workdays [193, 194]. Among children with asthma, children
missing school days were more likely to experience asthma exacerbation or seek urgent or
emergency care compared to children without missed school days for asthma [194]. Nearly half
of school-aged children with asthma in the United States missed one or more school days in 2013
and more than half had one or more asthma attacks in 2016 [152]. Among children with asthma,
the prevalence of asthma attacks (62%), emergency department/urgent care center visits (31%),
and hospitalization (10%) were higher in children aged 0–4 years compared to children aged 12–
17 years (45%, 10% and 3%, respectively) [152]. The estimated cost of missed school days in
children in the United States amounted to US$0.9 billion in 2013 causing substantial economic
burden to the society [150].
Asthma causes substantial burden in Canadian children. During 2013–2014 fiscal year
(extending from April 1 to March 31), the overall prevalence of diagnosed asthma among
Canadians aged 1–19 years was approximately 15%; the prevalence was 5%, 13%, 18% and 20%
among 1–4, 5–9, 10–14 and 15–19 year-olds, respectively [195]. More than 9% of Ontarian
children aged 2–17 years with asthma had one or more emergency department visits from April
2003 to March 2005 [196], while approximately 10% of children with acute asthma visiting
emergency department required hospitalization in Alberta during 2004/2005 fiscal year [197].
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Asthma accounted for more than 6,000 hospitalizations among Canadians aged 1–19 years
resulting in a hospitalization rate of 79 per 100,000 population during 2015–2016 fiscal year
[198]. Hospitalization rates provide insights into the rate of severe asthma exacerbations.
Poor asthma control, severe exacerbation in the previous year, viral respiratory tract
infections, allergen sensitization, virus-allergen interaction, exposure to second-hand smoke,
acute exposure to pollutants such as NO2, and genetic factors have been implicated as risk factors
for exacerbations in children [115, 199]. A systematic review of findings from 68 studies
reported several factors associated with asthma attacks in children aged 5–17 years: previous
asthma attacks were associated with greatly increased risk of asthma attack; suboptimal drug
regimen, comorbid atopic/allergic disease, African-American ethnicity, poverty and vitamin D
deficiency were associated with moderately increased risk of attack; and exposure to
environmental tobacco smoke, younger age, obesity and low parental education were associated
with slightly increased risk of asthma attacks [200]. Prevention of asthma exacerbations
decreases emergency department visit, school absenteeism, parent’s missed work and prevents
future exacerbations [199].
2.3.3. Studies on Asthma Course in Children
Studies on asthma course could be instrumental in providing insights into asthma prognosis and
identifying opportunities to intervene early to alter the course. Published literature in the field of
asthma course in children have mostly focused on asthma development using trajectories of
wheeze, cough or atopy. A few studies have explored patterns of wheeze or wheeze and cough to
identify wheeze phenotypes [201-208] (Table 2.2). Some of these studies also examined the
association between wheeze phenotypes and childhood outcomes, including cough, wheeze,
asthma, atopy, bronchial hyperresponsiveness and lung function [201-203, 205, 207]. These
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studies followed children from birth or pre-school age from a time when they were not diagnosed
with asthma. Other studies have identified trajectories of asthma prevalence [209, 210] or
combined wheeze and atopy as measures of asthma in children [211] using group-based
trajectory modeling or with pre-defined asthma patterns [212] to identify asthma phenotypes and
used age of the child as the time axis (Table 2.2). However, none of these studies examined the
trajectories of asthma course in children with incident asthma using time since asthma diagnosis
as the time scale, and consequently they do not provide adequate information on the course of
asthma after diagnosis.
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Table 2.2: Summary of studies on asthma course in children
Study/country

Population

Henderson et
al., 2008/UK
[201]

6265 children in
Avon Longitudinal
Study of Parents
and Children
(ALSPAC) born to
mothers with
expected dates of
delivery between
April 1991 to
December 1992
1650 white
children in
Leicester recruited
in 1990

Spycher et al.,
2008/UK [202]

Savenije et al.,
2011/UK,
Netherlands
[203]

5760 children from
Avon Longitudinal
Study of Parents
(ALSPAC) study
and 2810 children
from Prevention
and Incidence of
Asthma and Mite
Allergy (PIAMA)

Duration and
frequency of
follow up
Birth to 7 years,
at seven time
points (6, 18, 30,
42, 54, 69 and
81 months after
birth)

Variable used for
trajectory/measures

Statistical
method

Trajectory classes

Wheezing/motherreported

Group-based
trajectory
modeling

Six phenotypes:
never/infrequent wheeze
(59.3%), transient early
wheeze (16.3%), prolonged
early wheeze (8.9%),
intermediate onset wheeze
(2.7%), late onset wheeze
(6.0%), and persistent
wheeze (6.9%)

Enrolled at 0-5
years, followed
up in 1992-1994

Chronic cough (cough
apart from cold) and
wheezing/parentreported

Group-based
trajectory
modeling

Five phenotypes: persistent
cough, transient cough,
atopic persistent wheeze,
nonatopic persistent wheeze,
and transient viral wheeze
Five phenotypes in PIAMA
study: never/infrequent
wheeze (75.0%), transient
early wheeze (16.7%),
intermediate onset wheeze
(3.1%), late onset wheeze
(1.7%), and persistent
wheeze (3.5%)

0–8 years of age, Wheezing/parentat 6, 18, 30, 42,
reported
54, 69, 81 and
91 months after
birth in
ALSPAC study
and at 12, 24,
36, 48, 60, 72,
84 and 96
48

Group-based
trajectory
modeling

Chen et al.,
2012/USA
[204]

Granell et al.,
2016/UK [207]

Tse et al.,
2016/USA
[208]

study born to
mother recruited
during 1991-1992
689 children from
the Columbia
Center for
Children’s
Environmental
Health (CCCEH)
birth cohort study,
data collected
between October
1998 to May 2011
12,303 children
from Avon
Longitudinal Study
of Parents
(ALSPAC) and
Children birth
cohort study

months after
birth in PIAMA
study
0–8 years,
Wheezing or whistling
followed up at 6, in chest/parent12, 24, 36 ,60,
reported
84, and 108
months or at 3,
9, 15, 18, 21, 30,
48, and 72
months

Birth to 16 ½
years of age, at
14 time pointsannually from 6
to 198 months

1,623 children
from a birth cohort
study

Birth to 9 years
of age, followed
annually from 1
through 9 years
of age

Group-based
trajectory
modeling

Four phenotypes:
never/infrequent (47.1%),
early-transient (37.5%),
early-persistent (7.6%), and
late-onset (7.8%).

Wheezing/parentreported

Group-based
trajectory
modeling

Wheezing/parentreported

Group-based
trajectory
modeling

Six phenotypes: never/
infrequent (59.9%),
preschool-onset remitting
(18.7%), mid childhoodonset remitting (7.5%),
school age–onset persisting
(4.3%), late childhood–onset
persisting (4.7%), and
continuous wheeze (4.9%).
Three phenotypes:
never/infrequent wheeze
(74.1%), early transient
wheeze (12.7%), and
persistent wheeze (13.1%).
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Soto-Ramirez
et al., 2013/UK
[210]

1456 children in
Isle of Wight birth
cohort enrolled
from January 1989
to February 1990

0–18 years,
followed up at 1
or 2, 4, 10 and
18 years

Sbihi et al.,
2017/Canada
[209]

68,195 birth cohort 0–10 years
born from 1999 to (1999–2009)
2002 in
Metropolitan
Vancouver, British
Columbia

Asthma (physician
Group-based
billing and hospital
trajectory
discharge
modeling
records)/administrative
data

Panico et al.,
2014/UK [211]

11,632 children
from the
Millennium Cohort
Study (MCS) of
infants born from
September 2000 to
January 2002

Wheeze, and other
atopic symptoms
(eczema and hay
fever)

Up to 7 years,
followed up
thrice at 3, 5 and
7 years

Asthma/parentreported
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Group-based
trajectory
modeling

Group-based
trajectory
modeling

Three trajectories separately
for asthma and wheezing as
well as for boys and girls.
Asthma trajectories: Boys:
developing asthma (18.2%),
growing out of asthma
(27.6%), and
never/infrequent asthma
(54.2%); Girls: developing
asthma (11.3%), intermittent
asthma (12.4%), and
never/infrequent asthma up
to age 18 years (76.3%).
Four trajectories: nonasthma
trajectory (88.8%), lateonset chronic asthma
trajectory (4.1%), earlyonset chronic asthma
trajectory (1.5%), and
transient asthma trajectory
(5.6%)
Four trajectories: low levels
of wheeze and other atopic
symptoms (54%), low levels
of wheeze and high
prevalence of other atopic
symptoms (29%), high
prevalence of both wheeze
and other atopic symptoms

Wu et al.,
2012/USA
[212]

13,256 children in
Tennessee born
during 1995-1996

Yii et al.,
177 patients with
2017/Singapore uncontrolled and
[213]
severe asthma
enrolled in 2011

0–10 years,
followed up at
7-8 years and 910 years

Asthma (physiciandiagnosed or asthmaspecific prescription
use)/administrative
data

“Lasagna” plot

Followed for
five years for
annual severe
exacerbations

Severe exacerbations
(hospitalization or ED
visit for asthma and
systematic
corticosteroids ≥3
days)/Nationwide
electronic records

Group-based
trajectory
modeling
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(9%), and high levels of
wheeze and low levels of
other atopic symptoms (8%)
Seven pre-defined
developmental patterns
based on asthma status at
three age periods: 3.5–5.5
years, 7–8 years and 9–10
years. Patterns: asthma at all
three age periods (24%),
asthma at first two age
periods (8%), asthma at first
and third age period (5%),
asthma at first age period
alone (17%), asthma at
second and third age periods
(14%), asthma at second age
period alone (12%), and
asthma at third age period
alone (20%).
Three trajectories:
infrequent severe
exacerbations (58.5%),
nonpersistently frequent
severe exacerbations
(32.0%), and persistently
frequent severe
exacerbations (9.5%)

2.3.4. Studies on Asthma Exacerbation Trajectories
Studies on asthma exacerbation trajectories among individuals with asthma are scarce. To our
knowledge, only one published study sought to identify latent trajectories of severe exacerbation
rates and factors associated with the trajectories among adult patients with difficult, severe and
uncontrolled asthma presenting to a specialist asthma clinic in Singapore [213]. Severe
exacerbation was defined as events requiring hospitalization or emergency department visit for
asthma and systemic corticosteroids for ≥3 days and data were obtained from electronic records
of prescriptions, emergency department consults and inpatient discharges. Three clinically
distinct trajectories of severe exacerbation over a five-year period were identified: infrequent
(few intermittent severe exacerbations), nonpersistently frequent (frequent severe exacerbations
at baseline with gradual decline in subsequent years) and persistently frequent (yearly frequent
severe exacerbations). Since the follow-up of patients with uncontrolled and severe asthma in
that study began some time after asthma diagnosis, asthma course trajectories from asthma
diagnosis were not identified. Considering the fact that the majority of the asthma diagnosed in
adults has origin in childhood, it would be difficult to study the trajectories after incident
diagnosis in adults without following them from childhood.
The trajectories of asthma exacerbation in children with incident asthma remain
understudied. Considering the waxing and waning nature of asthma course, it is likely that
among children with asthma there could be qualitatively distinct classes of underlying asthma
exacerbation trajectories instead of following a uniform disease course. Identifying the
trajectories and their predictors could enhance physicians’ ability to better prognosticate the
course of asthma at the time of asthma diagnosis.
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2.3.5. Methods for Studying the Longitudinal Course/Trajectory of Asthma
There are two fundamental methods to study the longitudinal course of different health
outcomes. One method examines the average course in the population, and the other classifies
population into groups that follow a specific trajectory. These two fundamental methods
correspond to the two methodological approaches commonly used: traditional hierarchical
modeling [214, 215] and group-based trajectory modeling (GBTM) [216]. These methods
describe individual-level heterogeneity in the course of different health outcomes. Hierarchical
models estimate the average developmental trend and the random variation around the average
trend using a single set of parameters for the population. Individual variation is described as the
variation around the population mean. This is based on the assumption that the parameters are
continuously distributed throughout the population according to the multivariate normal
distribution. This is suitable for diseases where population members follow a common pattern of
either increase or decline, although at different rates. When the course of a disease evolves over
time or age and a common growth process does not ensue, it is more reasonable to assume that
there would be qualitatively distinct trajectories across subpopulations rather than everyone will
have increasing or decreasing course of the disease. Such qualitatively distinct trajectories would
not be distinguishable by the traditional growth curve modeling using hierarchical models.
Asthma, having periods of remission and relapse, would likely violate the assumption of having
a common course for everyone in the population. GBTM helps describing complex disease
course by identifying groups of individuals with similar trajectories and explaining individuallevel heterogeneity in terms of group differences [217, 218]. Trajectory groups are used as tools
to approximate the unknown distribution of trajectories across population as these trajectory
groups are latent, not observed.
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2.4.

Gestational Diabetes Mellitus as a Risk Factor for Asthma in the Offspring

2.4.1. Gestational Diabetes Mellitus
2.4.1.1.Definition and Diagnostic Criteria
Until recently, gestational diabetes mellitus (GDM) had long been defined as any glucose
intolerance that begins or is first detected during pregnancy [219]. However, this definition was
imprecise, as it did not differentiate between undiagnosed pre-existing diabetes and new onset
diabetes during pregnancy and whether the new-onset diabetes persisted after the pregnancy. The
American Diabetes Association currently defines GDM more precisely as “diabetes that is first
diagnosed in the second or third trimester of pregnancy that is not clearly either pre-existing type
1 or type 2 diabetes”, and recommends testing for undiagnosed diabetes at first prenatal visit in
women with risk factors while testing for GDM during 24–28 weeks of gestation without
previously known diabetes [220]. Nevertheless, there is a lack of international consensus on the
diagnostic criteria for GDM (Table 2.3). The Canadian Diabetes Association (CDA)
recommends early screening (<20 weeks of gestation) in women with high risk of undiagnosed
type 2 diabetes [221]. The CDA recommended preferred approach for GDM diagnosis during
24–28 weeks of gestation consists of an initial 50g glucose challenge test, followed by if
abnormal with a 75g oral glucose tolerance test [221]. GDM is diagnosed if one plasma glucose
value is abnormal. The CDA also includes an alternate one-step approach (Table 2.3).
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Table 2. 3: Diagnostic criteria for gestational diabetes mellitus
Organization

Diagnostic criteria

Canadian Diabetes

Preferred approach: 50g glucose challenge test with plasma glucose 1-

Association (CDA)

hour later-

2013 [221, 222]

•

7.8–11.0 mmol/L: 75g OGTT measure when fasting and at 1hour and 2-hour. Any one the following value is met or
exceeded

•

-

Fasting: ≥5.3 mmol/L

-

1-hour: ≥10.6 mmol/L

-

2-hour: ≥9.0 mmol/L

≥11.1 mmol/L

Alternate approach: If one of the following values is met or exceeded
after 75g OGTT plasma glucose is measured when fasting and at 1and 2-hour
-

Fasting: ≥5.1 mmol/L

-

1-hour: ≥10.0 mmol/L

-

2-hour: ≥8.5 mmol/L

American Diabetes

One-step strategy

Association (ADA)

75-g oral glucose tolerance test (OGTT) when fasting and at 1-hour

2018 [223]

and 2-hour. Any of the following values are met or exceeded•

Fasting: 92 mg/dL (5.1 mmol/L)

•

1-hour: 180 mg/dL (10.0 mmol/L)

•

2-hour: 153 mg/dL (8.5 mmol/L)

Two-step strategy
Step 1: Perform a 50-g glucose loading test (GLT) (nonfasting), with
plasma glucose at 1-hour. If the plasma glucose level measured 1-hour
after the load is ≥130mg/dL, 135mg/dL, or 140mg/dL (7.2mmol/L,
7.5mmol/L, or 7.8mmol/L), then proceed to a 100-g OGTT.
Step 2: The 100-g OGTT should be performed when the patient is
fasting.
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The diagnosis of GDM is made if at least two* of the following four
plasma glucose levels (measured fasting and 1-hour, 2-hour, 3-hour
during OGTT) are met or
exceeded:
Carpenter-Coustan

National Diabetes Data
Group

*

Fasting

95 mg/dL (5.3 mmol/L)

105 mg/dL (5.8 mmol/L)

1-hour

180 mg/dL (10.0 mmol/L)

190 mg/dL (10.6 mmol/L)

2-hour

155 mg/dL (8.6 mmol/L)

165 mg/dL (9.2 mmol/L)

3-hour

140 mg/dL (7.8 mmol/L)

145 mg/dL (8.0 mmol/L)

The American College of Obstetricians and Gynecologists recently

noted that alternatively one elevated value can be used for diagnosis
World Health

One or more of the following plasma glucose level when fasting or at 1

Organization

and 2 h after ingestion of 75g oral glucose load:

(WHO) 2016 [224]

•

Fasting plasma glucose: 5.1–6.9 mmol/L (92–125 mg/dl)

•

1-hour: ≥ 10.0 mmol/L (180 mg/dl)

•

2-hour: 8.5–11.0 mmol/L (153–199 mg/dl)

National Institute for

In women with risk factors, 2-hour glucose tolerance test (OGTT) with

Health and Care

either of the following plasma glucose level:

Excellence (NICE)

•

Fasting plasma glucose: ≥ 5.6 mmol/L

2015 [225]

•

2-hour: ≥ 7.8 mmol/L

International

One or more of the following plasma glucose level when fasting or at 1

Association of

and 2 h after ingestion of 75g oral glucose load:

Diabetes and

•

Fasting plasma glucose: ≥ 5.1 mmol/L (92 mg/dl)

Pregnancy Study

•

1 h: ≥ 10.0 mmol/L (180 mg/dl)

Groups (ADPSG)

•

2 h: ≥ 8.5 mmol/L (153 mg/dl)

2010 [226]
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2.4.1.2.Prevalence of GDM
Globally, the prevalence estimates of GDM vary from <1% to 28% [227, 228]. In high-income
countries, the prevalence estimates vary between 1.7% and 11.6% [229]. The overall prevalence
of GDM is estimated to be 5.4% (range 3.8% to 7.8%) in Europe [230], 10.1% (95% CI: 6.5%,
15.7%) in Eastern and Southeastern Asia [231], and ranges from 0% to 13.9% in six African
countries [232]. An estimated 21.4 million women aged 20–49 years giving live births in 2013
were diagnosed with hyperglycemia in pregnancy comprising known diabetes in pregnant
women, previous undiagnosed diabetes in pregnancy and GDM, however, the majority (84%) of
the cases were likely to be GDM [233]. An increased trend in GDM prevalence has been
observed worldwide during last few decades [234-237]. Some of the countries in Asia
experienced an increasing trend in GDM prevalence [236]. In Canada as well, the rate of GDM
has increased considerably from 40.8/1000 deliveries in 2004/05 to 54.5/1000 deliveries in
2010/11 [238]. The rising global trend in GDM prevalence is likely to continue with the increase
in important risk factors such as increased maternal age and obesity.
2.4.1.3.Risk Factors of GDM
Several risk factors for GDM have been identified. Overweight and obesity were associated with
a higher odds of GDM in pregnant women (OR 2.14, [95% CI: 1.82, 2.53] among overweight,
OR 3.56 [95% CI: 3.05, 4.21] among obese and OR 8.56 [95% CI: 5.07, 16.04] among severely
obese) compared with pregnant women with normal weight in a systematic review and metaanalysis of findings from 20 studies [239]. Increased age (35 years or older), minority ethnic
family origin with a high prevalence of diabetes (e.g., African Middle Eastern, Asian, Hispanic
or Indigenous), using corticosteroid medication, having prediabetes, GDM in a previous
pregnancy, history of giving birth to a macrosomic baby (weighing 4.5 kg or more), family
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history of diabetes (first degree relative with diabetes) and polycystic ovary syndrome or
acanthosis nigricans are known risk factors of GDM [221, 225, 240].
A higher incidence of GDM was associated with systolic blood pressure higher than 109
mmHg and diastolic blood pressure higher than 65 mmHg in first trimester [241]. Women with
prehypertension (systolic blood pressure 140 mmHg/diastolic blood pressure 80–89 mmHg) or
hypertension (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg or
use of antihypertensive medication) during early pregnancy (<20 weeks) was associated with
increased odds of GDM (OR 1.56 [95% CI: 1.16, 2.10] and OR 2.04 [95% CI: 1.14, 3.65],
respectively); women with prepregnancy prehypertension or hypertension also had a higher odds
of GDM (OR 1.44 [95% CI: 0.95, 2.19] and OR 2.01 [95% CI: 1.01, 3.99], respectively) [242].
Pregnant women carrying a male fetus have a higher risk (RR 1.04, 95% CI: 1.02, 1.06) of
developing GDM [243]. Different pre-pregnancy lifestyle factors have also been implicated as
risk factors for GDM: dietary patterns (Western dietary pattern, high glycemic load, low
carbohydrate diet), food (red meat, processed and unprocessed red meat, sugar -sweetened cola,
fried food) and nutrients (heme iron, animal fat, cholesterol intake, monounsaturated fatty acids,
animal proteins, potatoes) [244, 245]. Vitamin D deficiency was also associated with an
increased risk of GDM (OR 1.53, 95% CI 1.33, 1.75) in a systematic review and meta-analysis
of evidence from observational studies [246]. In addition, maternal history of low birth weight,
low stature, low level of physical activity, excessive weight gain during pregnancy, parity,
previous fetal malformation, previous miscarriage/still birth and low socioeconomic status were
found to be associated with GDM [247-250].
There have been conflicting results for the association between smoking during
pregnancy and GDM [251-253]. A systematic review and meta-analysis reported an OR 1.03
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(99% CI: 0.85, 1.25) for the association between smoking during pregnancy and GDM from
unadjusted results in nine studies, however, the 99% confidence interval for the odds ratios was
compatible with a 15% decreased odds to a 25% increased odds of GDM [254]. The association
between GDM and smoking in this systematic review from the adjusted results in four studies
among five distinct populations was OR 0.95, 99% CI: 0.85, 1.07. Another recent systematic
review and meta-analysis of results from 12 studies reported similar findings (pooled OR 0.98,
95% CI: 0.88, 1.10); the OR for light smoking (1–10 cigarettes/day) was 1.10 (95% CI: 0.97,
1.25) and the OR for heavy smoking (≥10 cigarettes/day) during pregnancy was 1.02 (95% CI:
0.67, 1.53) compared with non-smoking [255].
2.4.1.4.Adverse Consequences of GDM
GDM is associated with different short- and long-term adverse consequences in the mother, fetus
and offspring. Adverse outcomes include pre-eclampsia, cesarean section delivery, preterm
delivery and future type 2 diabetes in mother; fetal macrosomia (birth weight >4.5 kg) and large
for gestational age in fetus; and perinatal mortality, obesity and metabolic syndrome (a cluster of
risk factors such as high blood pressure, high fasting blood sugar, excess body fat around the
waist, and low HDL cholesterol or high triglyceride levels) in the offspring [256-263]. A
growing body of evidence suggests that GDM may also increase the risk of asthma in the
offspring.
2.4.2. Rationale for Studying GDM as a Risk Factor for Asthma
There are several pathways that could link maternal GDM and asthma in the offspring (Figure
2.1). One pathway may involve fetal hyperglycemia resulting from maternal hyperglycemia.
Fetal hyperglycemia then causes fetal hyperinsulinemia. Maternal diabetes mellitus has
substantial effect on the growth of the fetal lung. Fetal hyperinsulinemia leads to neonatal
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surfactant deficiency [264], which could increase the risk of respiratory distress syndrome and
ultimately to asthma in the offspring [265, 266]. Fetal hyperglycemia also causes fetal immune
dysregulation and fetal hypoxia. Dysregulated cytokine profiles have been detected in the cord
blood of neonates born to mothers with diabetes mellitus, suggesting disruption of fetal immune
development. Insulin resistance developed during GDM modifies placental transcriptome with a
dominance of genes that regulate inflammatory responses and endothelial function, thereby
increasing the markers and mediators of inflammation, such as interleukins, leptin and tumor
necrosis factor [267]. Umbilical cord C-reactive protein and intracellular adhesion molecule
(ICAM-1), markers of subclinical inflammation, were also higher in offspring of mothers with
type 1 diabetes compared with offspring of mothers without diabetes [268]. Intrauterine hypoxia
also occurs as a complication of diabetic pregnancy. Fetal erythropoietin concentration, a marker
of fetal hypoxia, directly correlates with maternal HbA1c levels, and increased amniotic fluid
erythropoietin level is indicative of fetal hypoxia in diabetic pregnancy [265, 269]. Intrauterine
hypoxia and immune system dysregulation both are associated with asthma.
A second pathway could involve cesarean section delivery. Evidence suggests that
cesarean section could possibly play a role in childhood asthma development by affecting
intestinal and respiratory microbiota leading to altered immune development [106-110]. It is also
possible that cesarean section increases the risk of asthma through transient tachypnea in the
newborn [270, 271].
A third pathway could operate through preterm birth that leads to respiratory distress
syndrome and subsequently asthma in offspring [272, 273].
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Overall, the net effect of these postulated pathways is not known. Additionally, there may
be other pathways that are not known yet.

Figure 2. 1: Pathways between gestational diabetes mellitus and asthma in offspring
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2.4.3. Studies on GDM as a Risk Factor for Asthma in Children
A growing number of studies have investigated the role of maternal diabetes mellitus in
pregnancy in wheezing and asthma in offspring [274] but the results are inconclusive.
A study using population-based registers (Swedish Hospital Discharge Register and
Swedish Medical Birth Register) among Swedish children born between 1987 and 1999
compared 14,803 children hospitalized (by the end of 2001) for asthma after 2 years of age with
1,386,029 children born during the same time to identify risk factors of asthma [138]. The
children were followed up between 2 to 13 years with an average follow-up of 6.8 years.
Maternal diabetes during pregnancy (any type) was associated with a higher odds (OR 1.20, 95%
CI: 1.02, 1.42) of hospitalization for asthma. However, it is not clear if any (and if yes, which)
factors were adjusted for to obtain the estimate. A subsequent study was conducted to validate
the findings of the associations between the risk factors and asthma in children aged between 2
years and less than 15 years using two linked population-based registers (Swedish Medical Birth
Register and Swedish Prescribed Drug Register) [72]. In this second validating study, 61,256
Swedish children born between 1 January 1990 and 30 June 2003 and prescribed and redeemed
anti-asthmatic medication between 1 July 2005 and 31 December 2005 were compared with
1,338,319 children born in Sweden during the same time. Forty percent of children registered in
the drug registry had asthma diagnosis in the prescription. A total of 16,257 children were born
to mothers with diabetes and 916 among them received asthma medication. Maternal diabetes
mellitus of any kind was associated with a higher odds (aOR 1.19, 95% CI: 1.12, 1.28) of
prescription of anti-asthmatic medication after adjusting for year of birth, maternal age, parity,
smoking and involuntary childlessness. However, anti-asthmatic medication was used as a
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surrogate for childhood asthma and some of the children may have been prescribed antiasthmatic medication for reasons other than asthma.
A study conducted among 1,401 children born to pregnant mothers who were enrolled in
a study on the perinatal risk of asthma in infants of asthmatic mothers in the United States [120].
This study particularly examined the association between early antibiotic use and risk of
childhood asthma. Pregnancy related information were collected from the mothers before 24
weeks of gestation using a questionnaire. Mothers were interviewed between September 2003
and January 2007 at their child’s sixth birthday to determine the child’s asthma status in terms of
physician-diagnosed asthma. A total of 164 children reported asthma by six years of age and the
prevalence of maternal diabetes was 1.6%. Maternal diabetes was associated with a higher odds
of asthma in children by 6 years of age in the unadjusted model (OR 3.63, 95% CI: 1.46, 9.04).
However, the final adjusted model did not include maternal diabetes following the model
inclusion criteria used in the study using backward elimination process. So, the association
between maternal diabetes and asthma in children remains undetermined after controlling for
confounders.
Another population-based study aimed to identify early life factors for parent-reported
physician diagnosed incidence asthma in 8,499 preschool children following them up to 4 to 5
years of age [275]. The cumulative incidence of asthma was 13.7% during the 4-year study
period. Prenatal problem defined as history of diabetes or high blood pressure during pregnancy
had 31.8% prevalence and prenatal problem was associated with an increased risk of asthma (HR
1.20, 95% CI:1.06, 1.36) in bivariate analysis. Being combined with high blood pressure during
pregnancy, the effect of maternal diabetes on risk of asthma in offspring remains obscure even in
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the unadjusted model. Moreover, prenatal problem was not included in the final multivariable
model that was selected using modified stepwise methods.
In a population-based birth-cohort study the Study of Asthma, Genes and Environment
(SAGE) among 3,574 Canadian children born in Manitoba in 1995, parent-reported asthma was
present in 12.4% children at 7–8 years of age and 1.4% children had maternal history of diabetes
mellitus (type 1, type 2 or GDM requiring insulin or controlled by diet) [276]. Children with
maternal diabetes mellitus had a higher odds (OR: 1.95, 95% CI: 0.98, 3.86) of having reported
asthma compared with children having mothers without diabetes mellitus. This study adjusted
for family history of asthma, atopy, residence location and home exposure to mold,
environmental tobacco smoke but did not consider some important confounders such as sex of
the child, maternal age, maternal education, maternal smoking during pregnancy and household
income. This study was also unable to differentiate between type 1, type 2 diabetes and GDM,
and it is not clear if mothers were asked if they had diabetes during pregnancy. Some of the
mothers may have had prepregnancy diabetes while some others may also have diabetes
developed after birth of the child.
In another registry-based birth cohort study, 1,018,302 children born in Finland between
1991 and 2008 were followed up to 7 years of age or 2009 [277]. Information on all specialized
health care outpatient and inpatient visits in public hospitals were collected from Hospital
Discharge Register and information on children entitled to asthma medication reimbursement
were collected from Finland’s Social Insurance Institution database. A child was considered to
have asthma if the child had record of asthma medication reimbursement; 3.9% children received
reimbursement for asthma medication and 5.1% required hospital care for asthma. Maternal
diabetes mellitus was present in 1.4% of children born very preterm (<32 weeks), 2.2% of
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children born moderately preterm (32–33 weeks), 2.4% of children born late preterm (34–36
weeks) and 0.9% of children born at term (≥37 weeks). Among children born moderately
preterm (32–33 weeks), children born to mothers with diabetes mellitus (GDM, type 1 and type 2
diabetes) were at an increased risk of asthma [HR 1.62, 95% CI: 1.02, 2.58] by 7 years of age
compared with children born to mothers without diabetes. There was also weak evidence of an
increased risk of asthma in term (≥37 weeks) babies (HR 1.09, 95% CI: 0.99, 1.21). The
following potential confounders were controlled for in this study: mother’s age, smoking, first
delivery, assisted reproduction technology, antenatal steroid, number of fetuses, premature
rupture of membranes, level of hospital, mode of delivery, sex of the child, gestational weight,
admission to neonatal unit, ventilator and antibiotic therapy.
In yet another study, children born between 1995 and 2009 in hospitals in the United
States were followed from 5 years of age for a median duration of 8.1 years using electronic
medical records [278]. In that study, 3,856 children had exposure to maternal prepregnancy type
2 diabetes, 21,832 children had exposure to maternal GDM, and 118,908 children had no
exposure to maternal diabetes. During the follow-up, 19.5% children with exposure to GDM had
asthma diagnosed. Children with exposure to maternal GDM had an increased risk of asthma
(HR 1.09, p<0.0001) after adjusting for maternal age, parity, race/ethnicity, education, household
income, history of comorbidity, asthma, smoking during pregnancy and sex of the child.
Furthermore, the adjusted HR for the association between maternal GDM and asthma was 1.15
(p<0.0001) for children whose mothers required antidiabetic medication for GDM during
pregnancy compared with children without exposure to GDM, and the adjusted HR for the
association was 1.06 (p=0.01) for children whose mothers did not use medication for GDM
during pregnancy compared with children without exposure to GDM.
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A recent population-based cohort study was conducted among 216,197 children born
between 1991 and 2014 in a tertiary referral hospital to assess the association between GDM and
long-term respiratory related hospitalizations of the offspring [279]. This study used data from
two linked databases: the computerized perinatal database of the Obstetrics and Gynecology
Department and the computerized hospitalization database of the Soroka University Medical
Center, Israel. Children were followed up to 18 years of age or January 2014. The prevalence of
GDM was 4.9%. A total of 5,481 children were hospitalized for asthma during the study period;
22 children had mothers with pharmacologically-treated GDM, 242 children had mothers with
diet-treated GDM, and the remaining children did not have exposure to maternal GDM. The risk
of asthma-associated hospitalization during childhood was lower in children born to mothers
with pharmacologically-treated GDM (HR 0.94, 95% CI: 0.61, 1.42) or diet-treated GDM (HR
0.93, 95% CI: 0.82,1.06) compared with children born to mothers without GDM. While the point
estimate suggested a lower risk of asthma-associated hospitalization, the 95% confidence interval
indicates that the risk could be plausibly ranging from a 39% decrease to a 42% increase, so a
substantial positive association in children born to mothers with pharmacologically-treated GDM
was also compatible with their data. The following potential confounders were adjusted in this
study: maternal age, hypertensive disorders of pregnancy (e.g. chronic hypertension, gestational
hypertension and preeclampsia), gestational age, macrosomia (birth weight ≥4000 g), maternal
smoking status, gender of the child and maternal ethnicity. However, this study included women
who were diagnosed with diabetes during the first two trimesters of pregnancy and may have
included some women with prepregnancy diabetes.
Studies have also examined the association between maternal diabetes and wheezing in
children. A population-based study among 15,609 children examined the association between
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different maternal medical conditions or procedures during pregnancy and/or at birth and
wheezing by 6–7 years of age [280]. Data were collected by administering questionnaire to
parents. Among the children, 9.5% had transient early wheezing (no wheezing in the first two
years of life and no wheezing in the last 12 months), 5.4% had persistent wheezing (wheezing in
the first two years of life and wheezing in the last 12 months), 6.1% had late-onset wheezing (no
wheezing in the first two years of life but wheezing in the last 12 months) and the remaining
79% were non-wheezers (no wheezing in the first two years of life and in the last 12 months).
The prevalence of maternal diabetes (pregestational or GDM) was 1.5%. Children born to
mothers with diabetes mellitus had a higher odds [OR 1.72, 95% CI: 0.99, 3.00] of persistent
wheezing compared with children born to mothers without diabetes mellitus at 6–7 years of age.
The wide confidence interval was probably because of the low frequency of diabetes in mothers.
Another study pooling 85,509 children from 14 European birth cohorts examined the association
between maternal complications in pregnancy and wheezing in the offspring up to 12–24 years
of age [281]. In this study, cohort-specific prevalence of ever wheezing (at least one episode of
wheezing) varied from 20% to 47% and recurrent wheezing (at least four episodes of wheezing)
from 3% to 14%. Maternal diabetes was defined as prepregnancy diabetes or overt diabetes or
glucose intolerance in pregnancy. The prevalence of maternal diabetes varied between 0.8% and
19% among different cohorts. In the pooled analysis, there was an increased risk of ever
wheezing [adjusted pooled relative risk (apRR): 1.04, 95% CI: 0.97, 1.13] and an increased risk
of recurrent wheezing (apRR: 1.24, 95% CI: 0.86, 1.79) up to 12–24 months of life in children
with maternal diabetes mellitus. However, there was evidence of heterogeneity (p=0.027) across
the cohorts for the association between diabetes mellitus and recurrent wheezing.
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2.4.4. Cesarean Section Delivery as a Potential Intervenable Mediator in the Pathway
between Gestational Diabetes Mellitus and Asthma in the Offspring
Given that GDM is a known risk factor for cesarean section delivery [256] and there is a positive
association between cesarean section delivery and asthma in children [95, 106], the effect of
maternal GDM on the risk of asthma in the offspring may be partially mediated through cesarean
section delivery. Recently, there has been an alarming increasing trend in delivery by cesarean
section globally [282, 283]. An estimated 29.7 million (21% of global births) births occurred
through cesarean section in 2015 worldwide. While the increase in cesarean section was driven
by an increase in the proportion of births in health facilities and increase in cesarean section use
within health facilities, a substantially higher proportion of births have occurred in low obstetric
risk births without medical indications [283]. Cesarean section can lead to a range of short-term
and long-term adverse consequences for both mothers and children even though it can be a lifesaving intervention in medically indicated situations [284]. Different clinical and non-clinical
interventions have been evaluated and recommended to reduce unnecessary cesarean section
deliveries [285-287]. As such, cesarean section delivery could be a potential intervenable
mediator to reduce the risk of asthma in children.
2.5.

Summary

The current literature indicates gaps in knowledge in the three important areas of asthma
epidemiology pertaining to the objectives of this doctoral research. Specifically, it indicates the
need for examination of the age, period and cohort effects on the prevalence of asthma in
Canadian adults using age, period and cohort theoretical and analytic framework. The course of
asthma in children since asthma diagnosis in terms of asthma exacerbation using group-based
trajectory modeling remains unknown. There remains considerable uncertainty regarding the role
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of maternal GDM in the risk of asthma in the offspring. Overall, the existing literature suggests
the need for further research to address these gaps in knowledge.
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3.

Chapter 3: Age, Period and Cohort Effects on Asthma Prevalence in
Canadian Adults, 1994–20111

3.1.

Introduction

Asthma affects an estimated 339 million people globally [1]. In Canada, around 2.4 million (8%)
persons were estimated to have asthma in 2014 [2]. The Canadian Chronic Disease Surveillance
System (CCDSS) reported that in 2011/2012 fiscal year, the prevalence of asthma differed by
age: it decreased from 15% in 20–24 years old to 8.3% in 35–44 years old, remained stable at
less than 9% in 45–64 years old before increasing in old age from 9.2% in 65–69 years to 10.6%
in 80–84 years [3]. Similar age distribution of asthma prevalence was observed during
2000/2001 through 2011/2012 fiscal years in adults: the prevalence was higher in the 20–29
years old, decreased in 30–59 years old and then increased again in individuals aged 60 years
and older [3]. The prevalence of asthma in Canadians aged one year and older increased from
6.5% in 2000/2001 fiscal year to 10.8% in 2011/2012 fiscal year [3]. In adults, during this
period, the prevalence increased in all age groups but the rate of increase differed by age
suggesting some age-period interaction [3]. The estimated prevalence of asthma with recent
symptoms or medication use among Canadians aged 12 years or older also increased from 5.1%
in 1994 to 6.5% in 2005 [4].
Variation in trends in estimated disease prevalence can be explicated in light of three
time-related effects: age, period and cohort effects. Age effect is the change in the frequency of
disease occurrence according to age [5], while period effect is the change in the frequency of

1

A version of this chapter is in press in Annals of Epidemiology. Nasreen S, Wilk P, Mullowney T, Karp I. Age,
period and cohort effects on asthma prevalence in Canadian adults, 1994–2011. Ann Epidemiol, 2019.
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disease occurrence caused by factors such as health policies and legislations, public health
interventions and new treatment that affect all age groups [5, 6]. Cohort effect is conceptualized
in epidemiology as a period effect that is differentially experienced across ages (i.e., interaction
between calendar time and age) because of differential distribution of environmental or other
factors across age groups [7]. However, in sociology, a cohort effect is conceptualized as the
change according to the year of birth (birth cohort), irrespective of age and calendar time [6].
Above mentioned non-model-based results from the CCDSS shed some light on age,
period and cohort effects on asthma prevalence, but these effects have yet to be estimated within
a formal age, period and cohort analytic framework while accounting for socio-demographic
factors. Examining the effects of age, period and cohort can provide insights into the observed
trends in asthma prevalence and help identify subgroups with high asthma burden. We took the
opportunity to examine the effects of age, period and cohort on asthma prevalence in Canada
using data from a national longitudinal survey. The objectives of our study were to examine the
effects of age and period on asthma prevalence among Canadian adults during 1994/1995–
2010/2011 fiscal years and to assess if the period effect differed by age (cohort effect) adopting
the epidemiological perspective of cohort effect.
3.2.

Methods

3.2.1. Data Source
We utilized data from the National Population Health Survey (NPHS), household component
conducted by Statistics Canada. Details of the NPHS are available elsewhere [8]. Briefly, the
NPHS used stratified multi-stage sampling method and included 17,276 individuals aged 12
years or older in 10 Canadian provinces in first cycle in 1994/1995 fiscal year. These
respondents were longitudinally followed every two years until cycle 9 in the 2010/2011 fiscal
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year to collect information on socio-demographic factors, chronic health conditions, lifestyle
factors and health services utilization. Response rates decreased from 92.8% in cycle 2 to 69.7%
in cycle 9.
3.2.2. Study Sample
NPHS participants aged 18–80 years and living in Canada during survey cycles were included in
this study. The final analytical sample comprised of 13,616 individuals in cycle 1, 12,334 in
cycle 2, 11,296 in cycle 3, 10,364 in cycle 4, 9,391 in cycle 5, 8,593 in cycle 6, 8,205 in cycle 7,
7,194 in cycle 8 and 6,764 in cycle 9 (contributing a total of 87,757 observations).
3.2.3. Outcomes and Covariates
Health professional-diagnosed asthma (hereafter asthma) was self-reported by the respondents at
each survey cycle. Asthma was ascertained from an affirmative response to the question “We are
interested in ‘long-term conditions’ that have lasted or are expected to last 6 months or more and
that have been diagnosed by a health professional. Do you have asthma?” asked at each survey.
We also used a more conservative definition ‘active asthma’, which was a binary variable
defined as self-reported asthma and one or both of the following conditions: (1) self-reported
presence of wheezing, asthma symptoms or asthma attack in last 12 months and (2) intake of
asthma medication in the last one month (in the first survey cycle) or intake of asthma
medication in the last 12 months (in the remaining survey cycles).
Age and period were treated as continuous variables. Covariates controlled for included:
sex, province of residence, country of birth, race, educational attainment, household income,
exposure to environmental tobacco smoke and smoking status. Sex was categorized into “male”
and “female”; province of residence was categorized into “Atlantic” (New Brunswick, Nova
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Scotia, Prince Edward Island and Newfoundland and Labrador) and “non-Atlantic” (Ontario,
Quebec, Manitoba, Saskatchewan, Alberta and British Columbia) provinces considering
previously reported higher childhood asthma prevalence in Atlantic provinces [9]; country of
birth was categorized into “Canada” and “outside Canada”; race was categorized into “white”
and “non-white”; and educational attainment was categorized into “less than secondary school
graduation”, “secondary school graduation”, “some post-secondary” and “post-secondary
graduation”. Household income was adjusted based on total reported household income in past
12 months and the number of people living in the household and was categorized into the
following groups by Statistics Canada [10]: “lowest” (income <$15,000 and 1–2 persons;
<$20,000 and 3–4 persons; <$30,000 and ≥5 persons), “lower middle” (income $15,000–
$29,000 and 1–2 persons; $20,000–$39,000 and 3–4 persons; $30,000–$59,000 and ≥5 persons),
“upper middle” (income $30,000–$59,000 and 1–2 persons; $40,000–$79,000 and 3–4 persons;
$60,000–$79,000 and ≥5 persons) and “highest” (income ≥$60,000 and 1–2 persons; ≥$80,000
and ≥ 3 persons). Exposure to environmental tobacco smoke (ETS) was categorized into
“exposed” and “not exposed” based on current exposure. A respondent was considered to be
“exposed” from an affirmative response to the question “Does anyone in this household smoke
regularly inside the house?” A respondent’s smoking status was categorized into “never”,
“former” and “current” from the categories (daily smoker, occasional smoker [former daily
smoker], always an occasional smoker, former daily smoker, former occasional smoker and
never smoked) of a derived variable created by Statistics Canada. The derived variable was
created based on responses to the following three questions “At the present time do you smoke
cigarettes daily, occasionally or not at all?” “Have you ever smoked cigarettes at all?” and “Have
you ever smoked cigarettes daily?” Covariate information collected at each survey cycle were
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used, except race and country of birth information that were collected at enrollment (survey
cycle 1).
3.2.4. Missing Data
Data were missing for some of the variables from non-participation in one or more surveys
because of either loss to follow-up or intermittent nonparticipation (resulting in ‘non-monotone’
missingness). The variable-wise rate of missing data was calculated based on the total
observations (87,757) contributed by the respondents across all survey cycles. Among all
observations, 89% had information on all variables; <1% of observations had missing
information on asthma and race; while 2–3% of observations had missing information on
educational attainment, exposure to ETS and smoking status. We created a separate household
income category for 9.28% of observations with missing information on this variable.
3.2.5. Statistical Analysis
Descriptive statistics for covariates at survey cycle 1 and across survey cycles were calculated as
a mean (SD) or percentage. Age was categorized into groups (18–25, 26–30, 31–35, 36–40, 41–
45, 46–50, 51–55, 56–60, 61–65, 66–70, 71–75 and 76–80 years) for descriptive statistics.
Prevalence of asthma and active asthma according to age group across the survey cycles were
calculated. Generalized estimating equations (GEEs) with autoregressive correlation structure
were used to examine the age, period and cohort effects while accounting for repeated measures.
Specifically, modified Poisson regression models were fitted in the GEE framework to estimate
prevalence ratio with a robust error variance [11]. Age was centered around its grand mean, and
age and an age-squared term were included in the models to allow for potential non-linear
relationship between age and both outcomes [12]. Cubic age term was considered but excluded
because it was not statistically significant for both outcomes and its inclusion in the model
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decreased model fit based on the quasi-likelihood under the independence model criterion (QIC)
goodness of fit statistic for GEE models (Supplementary Table, S Table 3.1) [13]. In Model 1,
asthma was regressed on age, age2 and period to estimate age and period effects, and interaction
terms between age and period and age2 and period were included to estimate the cohort effect on
asthma.
In Model 2, sex, province of residence, country of birth, race, educational attainment,
household income, exposure to ETS and smoking status were added to Model 1 to estimate age,
period and cohort effects while controlling for these covariates. Similar models were used for
active asthma. We performed sensitivity analysis for active asthma excluding observations from
survey cycle 1 as the recall period for asthma medication intake was one month in survey cycle 1
compared with 12 months in survey cycles 2–9.
We performed model-based standardization, also known as G-computation, to estimate
the prevalence of the outcomes (asthma and active asthma) standardized to the population
distribution of the covariates [14, 15]. This involved four steps: expansion of dataset, outcome
modeling, prediction, and standardization by averaging [14].
Expansion of dataset: In the first step, three new expanded datasets were created: one for the
age effect, one for the period effect and the other for the cohort effect (age-period interaction).
For the age effect, the new expanded dataset contained the original data (with 87,757
observations) and seven copies of it. The original data was kept unchanged. Age was set to
different values in the seven copies: ‘20’ in the 1st copy, ‘30’ in the 2nd copy, ‘40’ in the 3rd copy,
‘50’ in the 4th copy, ‘60’ in the 5th copy, ‘70’ in the 6th copy and ‘80’ in the 7th copy. In all seven
copies, the outcome was deleted and assigned a missing value to reflect unobserved
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counterfactual outcome. For the period effect, the new expanded dataset contained the original
data (with 87,757 observations) and nine copies of it. The original data was kept unchanged.
Period was set to different survey cycles in the nine copies: ‘cycle 1’ in the 1st copy, ‘cycle 2’ in
the 2nd copy, ‘cycle 3’ in the 3rd copy, ‘cycle 4’ in the 4th copy, ‘cycle 5’ in the 5th copy, ‘cycle 6’
in the 6th copy, ‘cycle 7’ in the 7th copy, ‘cycle 8’ in the 8th copy and ‘cycle 9’ in the 9th copy. In
all nine copies, the outcome was deleted and assigned a missing value to reflect unobserved
counterfactual outcome. For the cohort effect, the new expanded dataset contained the original
data (with 87,757 observations) and 21 copies of it. The original data was kept unchanged. Both
age and period were set to different values in these 21 copies: each of the seven age values
described in the expanded dataset for the age effect (20, 30, 40, 50, 60, 70 and 80) were set at
three different periods (survey cycles 1 [1994/1995], 5 [2002/2003] and 9 [2010/2011]). The
outcome was deleted and assigned a missing value to reflect unobserved counterfactual outcome
in all 21 copies.
Outcome modeling: In the second step, the outcome was modeled adjusted for the covariates
using Model 2 described above in each expanded new dataset. Only original data in the expanded
datasets contributed to the estimation of the parameters of the model because the outcome is
missing in the copies.
Prediction: In the third step, the parameter estimates from the original data were used to predict
the probabilities of unobserved counterfactual outcomes in the copies in each expanded dataset.
The predicted probabilities represent counterfactual estimates of the population prevalence of the
outcome.
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Standardization by averaging: In the last step, we computed average of the predicted
probabilities in each copy in the expanded datasets to obtain standardized prevalence. For the
effect of age, the prevalence was standardized for period and the covariates; for the effect of
period, the prevalence was standardized for age and the covariates; and for the cohort effect, the
prevalence was standardized for the covariates. Standardized prevalences were then plotted to
depict age, period and cohort (age-period interaction) effects, respectively.
Data analyses were conducted in SAS software v 9.4 (SAS Institute, Cary, North
Carolina) [16]. GEE was conducted with GENMOD procedure in SAS [17]. Standardized survey
sampling weights were used in all analyses to take into account the unequal probabilities of
selection.
3.3.

Results

3.3.1. Socio-demographic Characteristics of the Respondents
At cycle 1, the mean age of the respondents was 43 years, which increased to 55 years in cycle 9.
Nearly half of the respondents were male; the majority were born in Canada, were white and did
not have exposure to environmental tobacco smoke; 30% were current smoker (Table 3.1).
Across survey cycles, the mean age was 48 years (Table 3.1).
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Table 3. 1: Characteristics of respondents at cycle 1 and across survey cycles, National
Population Health Survey, 1994/1995-2010/2011
Characteristics

Cycle 1

Across survey cycles

N= 13,616

N=87,757

Age in years, mean (SD*)

43.1 (15.8)

48.2 (14.9)

Male (%)

49.3

51.1

Country of birth, Canada (%)

78.8

80.0

White (%)

89.6

90.3

Non-white (%)

9.7

9.1

Missing (%)

0.7

0.6

8.2

8.2

Less than secondary school graduation (%)

25.1

19.4

Secondary school graduation (%)

16.4

14.3

Some post-secondary (%)

25.7

25.6

Post-secondary graduation (%)

32.5

38.5

Missing

0.3

2.3

Lowest income (%)

16.4

9.1

Lower middle income (%)

28.0

19.7

Upper middle income (%)

35.1

32.7

Highest income (%)

15.4

29.3

Missing (%)

5.1

9.3

Unexposed (%)

60.7

72.5

Exposed (%)

35.2

24.4

Missing

4.1

3.1

36.2

33.5

Race

Province of residence, Atlantic (%)
Educational attainment

Household income

Exposure to environmental tobacco smoke

Smoking status
Never smoked (%)
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*

Former smoker (%)

29.5

40.0

Current smoker (%)

30.2

24.6

Missing (%)

4.1

2.9

SD, standard deviation

3.3.2. Asthma Prevalence
The prevalence of asthma increased from 5.2% in 1994/1995 to 9.0% in 2010/2011, across all
age groups but the rate of increase differed among age groups (Table 3.2). The prevalence of
active asthma across all age groups also increased from 4.6% in 1994/1995 to 7.0% in 2010/2011
(Table 3.3).
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Table 3. 2: Prevalence of asthma among respondents according to age groups across the survey cycles, National Population
Health Survey, 1994/1995-2010/2011
Age
group,
years

Cycle 1
Cycle 2
Cycle 3
Cycle 4
Cycle 5
Cycle 6
Cycle 7
Cycle 8
(1994/199 (1996/1997 (1998/19 (2000/200 (2002/200 (2004/2005 (2006/2007 (2008/2009
5),
), N=12329 99),
1),
3),
), N=8534 ), N=8114 ), N=7125
N=13596
N=11289 N=10310 N=9313
n (%)
n (%)
n (%)
n (%)
n (%)
n (%)
n (%)
n (%)
18-25
140 (7.2)
101 (7.6)
81 (9.5)
37 (8.9)
26-30
109 (7.7)
93 (8.2)
78 (8.0)
80 (9.2)
70 (8.0)*
46 (9.4)
21 (11.6)
31-35
88 (5.0)
107 (7.0)
106 (8.5) 94 (8.9)
73 (8.7)
76 (9.7)
69 (9.5)
55 (10.7)
36-40
78 (4.8)
96 (5.9)
94 (5.9)
90 (6.7)
95 (8.6)
87 (9.3)
60 (7.4)
59 (8.8)
41-45
50 (3.6)
63 (4.5)
86 (6.3)
105 (7.6)
105 (7.6)
84 (6.9)
95 (8.6)
74 (8.9)
46-50
58 (4.7)
63 (5.2)
51 (4.5)
57 (4.8)
70 (6.2)
92 (8.0)
100 (8.5)
86 (7.7)
51-55
28 (2.9)
35 (3.7)
62 (6.2)
77 (7.7)
60 (6.0)
71 (7.2)
79 (7.3)
101 (9.8)
56-60
39 (4.6)
46 (5.6)
43 (5.5)
44 (5.5)
55 (6.8)
63 (7.6)
75 (8.7)
45 (5.4)
61-65
40 (5.3)
38 (5.3)
40 (5.4)
42 (6.1)
49 (7.2)
42 (6.3)
45 (6.6)
58 (8.0)
66-70
37 (5.4)
39 (5.9)
48 (8.0)
39 (6.6)
36 (6.4)
36 (6.4)
49 (8.0)
43 (7.5)
71-75
27 (4.72)
35 (6.0)
26 (4.7)
37 (7.1)
42 (8.3)
43 (8.6)
34 (7.1)
31 (6.6)
76-80
16.5 (4.5) 20 (5.2)
31 (7.4)
41 (9.1)
30 (7.3)
31 (8.3)
32 (8.2)
36 (9.8)
Total
712 (5.2)
735 (6.0)
748 (6.6) 743 (7.2)
685 (7.4)
673 (7.9)
658 (8.1)
588 (8.3)
*
18–24 years and 26–30 years age groups combined because frequencies for 18–24 years were not reportable
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Cycle 9
(2010/2011)
, N=6718
n (%)

39 (14.5)
69 (11.4)
72 (9.9)
73 (7.5)
92 (8.9)
67 (7.4)
81 (10.5)
42 (7.5)
31 (6.2)
36 (9.7)
601 (9.0)

Table 3. 3: Prevalence of active asthma among respondents according to age groups across the survey cycles, National
Population Health Survey, 1994/1995-2010/2011
Age
group,
years

Cycle 1
Cycle 2
Cycle 3
Cycle 4
Cycle 5
Cycle 6
Cycle 7
Cycle 8
(1994/199 (1996/1997 (1998/19 (2000/200 (2002/200 (2004/2005 (2006/2007 (2008/2009
5),
), N=12329 99),
1),
3),
), N=8534 ), N=8114 ), N=7125
N=13596
N=11289 N=10310 N=9313
n (%)
n (%)
n (%)
n (%)
n (%)
n (%)
n (%)
n (%)
18-25
123 (6.4)
81 (6.1)
50 (5.9)
30 (7.1)
26-30
95 (6.7)
69 (6.1)
61 (6.2)
49 (5.7)
46 (5.3)*
30 (6.1)
12 (6.9)
31-35
82 (4.6)
86 (5.6)
91 (7.3)
72 (6.8)
55 (6.6)
59 (7.6)
55 (7.6)
42 (8.2)
36-40
61 (3.8)
74 (4.6)
79 (5.0)
75 (5.6)
81 (7.3)
59 (6.3)
43 (5.3)
46 (6.9)
41-45
47 (3.4)
48 (3.5)
71 (5.1)
80 (5.8)
67 (4.8)
63 (5.1)
69 (6.2)
52 (6.3)
46-50
44 (3.6)
51 (4.3)
34 (3.0)
47 (4.0)
60 (5.3)
69 (6.0)
79 (6.7)
66 (5.9)
51-55
22 (2.3)
26 (2.8)
56 (5.6)
67 (6.6)
44 (4.4)
51 (5.2)
56 (5.2)
70 (6.8)
56-60
36 (4.2)
39 (4.7)
37 (4.8)
39 (4.9)
45 (5.6)
56 (6.7)
66 (7.6)
34 (4.1)
61-65
39 (5.2)
33 (4.7)
36 (4.9)
36 (5.2)
43 (6.3)
38 (5.7)
36 (5.2)
51 (7.0)
66-70
36 (5.2)
34 (5.2)
37 (6.1)
32 (5.4)
29 (5.2)
29 (5.1)
40 (6.5)
36 (6.3)
71-75
27 (4.6)
31 (5.3)
24 (4.3)
31 (6.0)
37 (7.5)
38 (7.6)
23 (4.8)
27 (5.9)
76-80
16 (4.4)
17 (4.4)
25 (5.9)
35 (7.8)
24 (6.1)
25 (6.6)
27 (7.1)
33 (9.1)
Total
630 (4.6)
589 (4.8)
601 (5.3) 592 (5.7)
532 (5.8)
517 (6.1)
506 (6.2)
457 (6.4)
*
18–24 years and 26–30 years age groups combined because frequencies for 18–24 years were not reportable
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Cycle 9
(2010/2011)
, N=6718
n (%)

22 (8.4)
52 (8.7)
54 (7.4)
55 (5.6)
76 (7.3)
51 (5.7)
65 (8.5)
40 (7.1)
25 (5.0)
31 (8.3)
472 (7.0)

3.3.3. Age, Period and Cohort Effects on Asthma Prevalence
Asthma prevalence was negatively associated with age and positively associated with age2
variables (Table 3.4, Model 1). There was also a positive association between asthma prevalence
and period. Asthma prevalence was negatively associated with period-age interaction term
suggesting some cohort effect. Similar results were observed after controlling for the covariates
(Table 3.4, Model 2).
Model-based standardization demonstrated the curvilinear relationship between asthma
prevalence and age. The standardized prevalence of asthma was 12% at 20 years, 6% at 50–60
years and 8% at 80 years (Figure 3.1a). There was a gradual increase in standardized asthma
prevalence with period from 5% in 1994/1995 to 11% in 2010/2011 (Figure 3.1b). Period effect
differed across individuals of different age (Figure 3.1c). While the standardized asthma
prevalence increased between 1994/1995 and 2002/2003, and between 2002/2003 and 2010/2011
for everyone, individuals aged 20 years had the highest standardized asthma prevalence and
steepest increase in standardized prevalence across three survey cycles. Individuals aged 80
years had the least increase in standardized asthma prevalence.
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Table 3. 4: Age, period and cohort effects on prevalence of asthma among Canadian adults, National Population Health
Survey, 1994/1995-2010/2011

Intercept
Age
Age2
Period
Period*age
Period*age2
Sex
Female
Male
Race
Non-white
White
Country of birth
Outside Canada
Canada
Province of residence
Atlantic
Non-Atlantic
Highest education attained
Less than secondary school graduation
Secondary school graduation
Some post-secondary

Model 1
Coefficients (95%
confidence intervals)
-3.1147 (-3.2458, -2.9837)
-0.0017 (-0.0066, 0.0032)
0.0006 (0.0003, 0.0009)
0.0937 (0.0763, 0.1111)
-0.0014 (-0.0024, -0.0003)
-0.0000 (-0.0001, 0.0000)

P-value
<0.0001
0.49
<0.0001
<0.0001
0.01
0.31

Model 2a
Coefficients (95%
confidence intervals)
-3.2814 (-3.4793, -3.0835)
-0.0038 (-0.0089, 0.0013)
0.0005 (0.0002, 0.0008)
0.0964 (0.0780, 0.1148)
-0.0011 (-0.0021, 0.0000)
-0.0000 (-0.0001, 0.0000)

P-value
<0.0001
0.15
0.0007
<0.0001
0.05
0.47

0.2749 (0.1293, 0.4206)
Reference

0.0002

-0.0791 (-0.4273, 0.2690)
Reference

0.66

-0.2748 (-0.5269, -0.0226) 0.03
Reference
-0.1747 (-0.3047, -0.0447) 0.0085
Reference
0.0719 (-0.0928, 0.2366)
-0.0703 (-0.2674, 0.1269)
-0.0170 (-0.1370, 0.1030)
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0.39
0.48
0.78

Post-secondary graduation
Reference
Household income
Lowest income
0.1263 (0.0218, 0.2308)
0.02
Lower middle income
0.0790 (0.0062, 0.1518)
0.03
Upper middle income
0.0444 (-0.0133, 0.1022)
0.13
Missing
0.0326 (-0.0520, 0.1172)
0.45
Highest income
Reference
Exposure to environmental tobacco smoke
Yes
-0.0070 (-0.0654, 0.0515) 0.82
No
Reference
Smoking status
Current smoker
0.0740 (-0.0279, 0.1759)
0.15
Former smoker
0.0718 (-0.0087, 0.1523)
0.08
Never smoked
Reference
GEE fit statistic
QIC
47859.5443
46526.5118
a
Adjusted for sex, race, country of birth, province of residence, educational attainment, household income, exposure to environmental
tobacco smoke and smoking
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Figure 3.1a. Age effect on asthma prevalence

Figure 3.1b. Period effect on asthma prevalence
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Figure 3.1c. Period effect on asthma prevalence according to age

Figure 3. 1: Model-based standardized prevalence of asthma among Canadian adults,
National Population Health Survey, 1994/1995-2010/2011. a: age effect, b: period effect, c:
period effect according to age
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3.3.4. Age, Period and Cohort Effect on Active Asthma Prevalence
Active asthma prevalence was negatively associated with age and positively associated with age2
variables (Table 3.5, Model 1). There was also a positive association between active asthma
prevalence and period. The interaction term between period and age2 was negatively associated
with active asthma prevalence suggesting presence of some cohort effect. After controlling for
the covariates, age and period effects on active asthma prevalence remained similar to the results
from the unadjusted model (Table 3.5, Model 2). Period-age2 interaction term was negatively
associated with active asthma prevalence. Sensitivity analysis excluding observations from
survey cycle 1 yielded similar results (Supplementary Table, S Table 3.2).
Model-based standardization demonstrated the curvilinear relationship between active
asthma prevalence and age. The standardized prevalence of active asthma was 8% at 20 years,
5% at 50–60 years and 6% at 80 years (Figure 3.2a). There was a gradual increase in
standardized active asthma prevalence with period from 4.5% in 1994/1995 to 8% in 2010/2011
(Figure 3.2b) but was lower and the slope of increase was less steep compared with the slope of
increase in standardized prevalence of asthma. The period effect differed across individuals of
different age between 1994/1995 and 2002/2003, and between 2002/2003 and 2010/2011 (Figure
3.2c). Individuals aged 20 years had the highest standardized prevalence across three survey
cycles. The increase in standardized active asthma prevalence was least steep in individuals aged
80 years.
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Table 3. 5: Age, period and cohort effects on prevalence of active asthma among Canadian adults, National Population Health
Survey, 1994/1995-2010/2011

Intercept
Age
Age2
Period
Period*age
Period*age2
Sex
Female
Male
Race
Non-white
White
Country of birth
Outside Canada
Canada
Province of residence
Atlantic
Non-Atlantic
Highest education attained
Less than secondary school graduation
Secondary school graduation
Some post-secondary

Model 1
Coefficients (95%
confidence intervals)
-3.2547 (-3.3898, -3.1195)
-0.0016 (-0.0068, 0.0037)
0.0006 (0.0003, 0.0009)
0.0788 (0.0598, 0.0977)
-0.0003 (-0.0015, 0.0009)
-0.0001 (-0.0001, -0.0000)

P-value
<0.0001
0.56
<0.0001
<0.0001
0.60
0.04

Model 2a
Coefficients (95%
confidence intervals)
-3.5602 (-3.7811, -3.3393)
-0.0042 (-0.0096, 0.0013)
0.0005 (0.0002, 0.0008)
0.0828 (0.0629, 0.1026)
-0.0000 (-0.0012, 0.0012)
-0.0000 (-0.0001, 0.0000)

P-value
<0.0001
0.13
0.0005
<0.0001
0.98
0.08

0.3282 (0.1729, 0.4835)
Reference

<0.0001

-0.2020 (-0.5612, 0.1572)
Reference

0.27

-0.3038 (-0.5595, -0.0482) 0.02
Reference
-0.1802 (-0.3335, -0.0270) 0.02
Reference
0.1794 (-0.0033, 0.3620)
0.0353 (-0.1871, 0.2576)
0.0447 (-0.0708, 0.1602)
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0.05
0.76
0.45

Post-secondary graduation
Reference
Household income
Lowest income
0.1099 (-0.0107, 0.2306)
0.07
Lower middle income
0.0623 (-0.0310, 0.1556)
0.19
Upper middle income
0.0205 (-0.0499, 0.0910)
0.57
Missing
0.0683 (-0.0366, 0.1732)
0.20
Highest income
Reference
Exposure to environmental tobacco smoke
Yes
-0.0055 (-0.0784, 0.0674) 0.88
No
Reference
Smoking status
Current smoker
0.1781 (0.0431, 0.3132)
0.0097
Former smoker
0.1801 (0.0614, 0.2989)
0.0029
Never smoked
Reference
GEE fit statistic
QIC
40614.2094
39453.5812
a
Adjusted for sex, race, country of birth, province of residence, educational attainment, household income, exposure to environmental
tobacco smoke and smoking
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Figure 3.2a. Age effect on active asthma prevalence

Figure 3.2b. Period effect on active asthma prevalence
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Figure 3.2c. Period effect on active asthma prevalence according to age

Figure 3. 2: Model-based standardized prevalence of active asthma among Canadian
adults, National Population Health Survey, 1994/1995-2010/2011. a: age effect, b: period
effect, c: period effect according to age
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3.4.

Discussion

Using a national longitudinal survey, this study examined the age, period and cohort effects on
the prevalence of asthma, including active asthma, among Canadian adults for 16 years while
controlling for socio-demographic factors. Our findings suggest that the prevalence of asthma
and active asthma among Canadian adults differed by age (age effect), increased over time
(period effect) and the period effect was somewhat different among individuals of different age
during the study period (cohort effect).
The age effect on the prevalence of asthma and active asthma among Canadian adults
indicates that the prevalence was highest among young adults, lowest for middle-aged adults and
then increased slightly in old age. Our finding is similar to the non-model-based estimates from
the studies that did not use formal age, period and cohort framework but suggested age effect on
asthma prevalence among Canadians in 2011/2012 fiscal year [3], Ontarians during 1996–2015
[18, 19] and the study showing age effect on active asthma prevalence in 2011/2012 fiscal year
[3]. However, these studies used administrative data and prevalent asthma was defined as at least
two physician visits with a diagnosis of asthma within two consecutive years, or at least one
hospitalization with a diagnosis of asthma; active asthma was defined as prevalent asthma with at
least one physician visit or asthma hospitalization in a year. Additionally, the time frame of these
studies differed from our study, although there was some overlap. The decreasing prevalence of
asthma until middle age could be related to a similar relationship between asthma incidence and
age. Indeed, in Canadians during 1996 through 2015, asthma incidence decreased with age in
young and middle-aged adults before increasing again in older adults [3, 20]. Comparable age
effects on asthma incidence have also been observed in Swedish adults [21]. Nevertheless, the
reduction of asthma incidence has to be substantial to reduce the prevalence in young and
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middle-aged adults in our study considering the chronic nature of asthma. It is possible that
asthma remained undiagnosed, resulting in a lower prevalence of asthma in young and middleaged adults in our study. Some young and middle-aged adults with asthma in our study remained
symptom-free leading to lower prevalence of active asthma compared with older adults. Forty
percent of adults aged 18–64 years with asthma in Ontario had two or more years of gaps in
asthma activity compared with adults 65 years and older during 15 years of follow-up [22].
Different rates of asthma remission have been reported in adults in different settings: 6% in
middle-aged adults and elderly individuals in Italy [23], 30% in Italian young adults [24], 14.6%
in Swedish adults [21] and 18.6% in adults in northern Europe [25]. On the other hand, the
increased prevalence of asthma, including active asthma in older adults may reflect increased
incidence, and uncontrolled or frequent symptomatic asthma with declining lung functions and a
low remission rate [26-29], as well as changes in lifestyle and increased access to health care and
medication through government funded health care system in Canada. Indeed, age effect can
arise from a combination of biological process and social experiences [6]. In addition, it is also
possible that chronic obstructive pulmonary disease was misdiagnosed as asthma in older adults
because of the overlap in clinical symptoms between these two conditions [30].
The prevalence of asthma increased over the course of 16 years among Canadian adults
in our study similar to the temporal trends of asthma prevalence reported previously in Canada
[19, 31]. Contrary to our finding of an increasing prevalence of active asthma, the agestandardized active asthma prevalence was reported to decrease slightly in Canadians from 2.8%
in 2000/2001 fiscal year to 2.3% in 2011/2012 fiscal year in the CCDSS [3]. Active asthma in
the CCDSS was defined as having at least one physician claim in the first diagnostic field or at
least one hospital admission for asthma in any diagnostic field in a given fiscal year. The
126

decreasing trend in active asthma prevalence in the CCDSS might reflect improving asthma
management and control, thereby reducing the need for medical care and hospitalization. The
increasing active asthma prevalence in our study might reflect the milder cases, cases that were
under control by taking medication not necessitating medical care or cases that did not seek
medical care and not hospitalized. The prevalence of ‘current asthma’, defined as still having
asthma among those with ever diagnosed asthma by a health professional using data from
surveys, in adults also increased in the United States from 7.2% in 2000/2001 to 8.5% in
2008/2009 [32]. The cause behind this increasing secular trend remains unclear. The increasing
prevalence, despite decreasing incidence of asthma [3], and decreased asthma-associated
mortality [3, 33], likely reflect better asthma management and the chronic nature of asthma. It is
also possible that asthma was over diagnosed because of increased awareness or, in adults 35
years and older, because of ‘diagnostic exchange’ in the sense that the increased asthma
prevalence was driven by a decrease in the prevalence of bronchitis [34]. As such, the increased
prevalence would reflect an artifact rather than true increase in asthma prevalence. In our study,
across all survey cycles, the prevalence of active asthma was lower than the prevalence of
asthma, which is expected as all asthma cases may not experience frequent symptoms or require
regular intake of asthma medications. The increasing prevalence has implications for public
health policy makers to address health care needs and planning asthma management. Future
studies should seek to identify the underlying factors for the observed temporal trend beyond the
sociodemographic and lifestyle factors controlled for in our study.
In our study, the increase in prevalence of asthma over time somewhat differed by age,
reflected by the unparallel slopes of prevalence for different ages across three survey cycles and
steeper slopes in young adults in the graphs with standardized prevalence. Similar to our
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findings, the increase in age-standardized prevalence of asthma over time differed by age in the
CCDSS [3]. However, the difference in period effect according to age in our study was largely
attenuated for the restricted definition of active asthma albeit some variation in the slopes for
prevalence over period was observed.
3.4.1. Strengths and Limitations
The use of data from a population-based longitudinal survey gave us the opportunity to assess
the effects of age, period and cohort over a period of 16 years. We were able to adjust for
potential confounding by some socio-demographic factors that are not usually available in
administrative data. Furthermore, we were able to include more asthma cases, including active
asthma cases because medical care delivered by physicians outside fee-for-service and asthma
cases not seeking medical care would not be captured by administrative data, including the
CCDSS [3]. Model-based standardization enabled us to visualize population-wide effect of age
and period on prevalence of asthma, including active asthma, and to assess the variation in
period effect across different ages using population standardized prevalence.
Asthma diagnosis, symptoms and medication intake were self-reported by the
respondents and has the potential for errors in reporting. Compared to respondents with frequent
or severe symptoms, respondents with milder symptoms or longer symptom-free periods may
underreport asthma and/or asthma symptoms, which may result in an underestimation of the
prevalence of asthma or active asthma. There is a potential for overestimation of active asthma
prevalence in survey cycle 1 because of the shorter recall time for asthma medication between
survey cycle 1 and the remaining survey cycles. However, we performed a sensitivity analysis
excluding observations from survey cycle 1 and the results were similar. Our study was limited
to adults aged 18–80 years. An age cut-point of 80 years was chosen because of fewer
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respondents with asthma beyond this age and to minimize recall error. Furthermore, we did not
control for environmental risk factors of asthma (such as air pollution) because of lack of data on
them in the source database. Age, period and cohort effects may vary across different
populations and settings and the findings from this study may not be generalizable beyond the
study period and the Canadian population.
3.4.2. Conclusion
In conclusion, our findings suggest age and period effects on the prevalence of asthma, including
active asthma in Canadian adults from 1994/1995 to 2010/2011. The period effect on asthma
prevalence was experienced somewhat differently across age groups indicating some cohort
effect. Future research is warranted to see whether the age distribution of asthma burden, the
rising temporal trend along with the variation in asthma prevalence by age continues beyond our
study period and in future.
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3.5.

Supplementary Tables

S Table 3. 1: Model coefficients, P-value and fit statistics with inclusion of age3 in the models

Asthma
Intercept
Age
Age2
Age3
Period
Period*age
Period*age2
Period*age3
GEE fit statistic
QIC

Model without covariates
Coefficients (95% CI)
P-value

Model with covariatea
Coefficients (95% CI)
P-value

-3.1264 (-3.2601, -2.9927)
-0.0039 ( -0.0153, 0.0075)
0.0006 (0.0003, 0.0009)
0.0000 (-0.0000, 0.0000)
0.0943 (0.0752, 0.1134)
-0.0006 (-0.0024, 0.0011)
-0.0000 (-0.0001, 0.0001)
-0.0000 (-0.0000, 0.0000)

-3.2865 (-3.4861, -3.0869)
-0.0038 (-0.0157, 0.0081)
0.0005 (0.0002, 0.0008)
0.0000 (-0.0000, 0.0000)
0.0954 (0.0755, 0.1154)
-0.0006 (-0.0024, 0.0012)
-0.0000 (-0.0001, 0.0001)
-0.0000 (-0.0000, 0.0000)

<0.0001
0.51
<0.0001
0.65
<0.0001
0.47
0.66
0.20

47890.4771

<0.0001
0.53
0.0007
0.98
<0.0001
0.51
0.96
0.36

46569.2255

Active asthma
Intercept
-3.2517 (-3.3884, -3.1149)
<0.0001
-3.5552 (-3.7756, -3.3347) <0.0001
Age
-0.0004 (-0.0132, 0.0124)
0.96
-0.0028 (-0.0161, 0.0105)
0.68
Age2
0.0006 (0.0003, 0.0009)
0.0001
0.0005 (0.0002, 0.0008)
0.0008
3
Age
-0.0000 (-0.0000, 0.0000)
0.83
-0.0000 (-0.0000, 0.0000)
0.8116
Period
0.0772 (0.0562, 0.0983)
<0.0001
0.0816 (0.0594, 0.1037)
<0.0001
Period*age
-0.0003 (-0.0023, 0.0018)
0.80
-0.0001 (-0.0022, 0.0020)
0.90
2
Period*age
-0.0000 (-0.0001, 0.0000)
0.29
-0.0000 (-0.0001, 0.0000)
0.34
Period*age3
-0.0000 (-0.0000, 0.0000)
0.82
0.0000 (-0.0000, 0.0000)
0.96
GEE fit statistic
QIC
40654.9577
39484.6341
a
Adjusted for sex, race, country of birth, province of residence, educational attainment, household income, exposure to environmental
tobacco smoke and smoking
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S Table 3. 2: Sensitivity analysis on age, period and cohort effects on prevalence of active asthma among Canadian adults,
National Population Health Survey, 1994/1995-2010/2011
Model 1
Model 2a
Coefficients (95%
P-value
Coefficients (95%
P-value
confidence intervals)
confidence intervals)
Intercept
-3.2310 (-3.3817, -3.0802)
<0.0001
-3.5152 (-3.7563, -3.2741) <0.0001
Age
-0.0008 (-0.0068, 0.0052)
0.79
-0.0034 (-0.0098, 0.0031) 0.30
2
Age
0.0005 (0.0002, 0.0008)
0.0043
0.0004 (0.0000, 0.0007)
0.03
Period
0.0744 (0.0537, 0.0951)
<0.0001
0.0766 (0.0546, 0.0985)
<0.0001
Period*age
-0.0005 (-0.0019, 0.0009)
0.48
-0.0002 (-0.0016, 0.0012) 0.77
2
Period*age
-0.0000 (-0.0001, 0.0000)
0.23
-0.0000 (-0.0001, 0.0000) 0.52
a
Adjusted for sex, race, country of birth, province of residence, educational attainment, household income, exposure to environmental
tobacco smoke and smoking
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4.

Chapter 4: Asthma Exacerbation Trajectories and Their Predictors in
Children with Incident Asthma1

4.1.

Introduction

Asthma, a chronic disease characterized by periodic exacerbations and remissions, accounts for
substantial medical and economic burden in children. Asthma exacerbations cause considerable
suffering in children and can result in unscheduled emergency department visits, outpatient
visits, hospitalizations, and even death [1]. Furthermore, asthma exacerbations can have extramedical consequences such as school absenteeism and loss of parental or caregiver’s
productivity [2, 3]. Much of the clinical-epidemiological literature on asthma has focused on the
trajectories of wheezing to identify wheeze phenotypes and their subsequent association with
asthma development in children [4-6] and a few studies followed children since birth and
attempted to identify trajectories of asthma prevalence according to age [7-9]. However, none
have examined the trajectories of asthma course in children using time since asthma diagnosis as
the time scale to inform the course after diagnosis.
The trajectories of asthma course in terms of exacerbations in children remain
understudied. It is possible that among children with incident asthma there could be qualitatively
distinct groups of asthma exacerbation trajectories. Identifying the trajectory groups and their
predictors could enhance physicians’ ability to better prognosticate the course of asthma. The
objectives of this study were to identify trajectories of exacerbation in children with incident
asthma and to identify the predictors of these trajectories at the time of asthma diagnosis.

1

A version of this chapter has been published: Nasreen S, Wilk P, Mullowney T, Karp I. Asthma exacerbation
trajectories and their predictors in children with incident asthma. Ann Allergy Asthma Immunol 2019; 123: 293300.e292
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4.2.

Methods

4.2.1. Data Source
The data source for this study was the National Longitudinal Survey of Children and Youth
(NLSCY), Canada. Details of the NLSCY are available elsewhere [10]. Briefly, the NLSCY
used a multi-stage cluster sampling to select households in 10 Canadian provinces in 1994/1995
(cycle 1) with children aged 0–11 years. Out of the 22,831 children surveyed in cycle 1, 15,405
children were followed for 14 years and surveyed every two years through the final survey (cycle
8) in 2008/2009 when they were 14–25 years old. A maximum of two children (siblings) were
selected from each household. One person most knowledgeable about a child (aged 0–15 years)
and older children (>15 years) responded to survey questionnaires administered to collect
sociodemographic and lifestyle, environment and health-related data.
4.2.2. Study Population
An affirmative response to the question “Has this child ever had asthma that was diagnosed by a
health professional?” asked to the person most knowledgeable for children aged 0–15 years in
survey cycles indicated the presence of asthma. An affirmative response to the question “Have
you ever had asthma that was diagnosed by a health professional?” asked to children aged >15
years in survey cycles 4–5 indicated the presence of asthma. The first-time report of asthma
during survey cycles 2–8 indicated incident asthma diagnosed at some point during the two years
before the survey. Children meeting the following criteria were included in our study: having a
biological parent as the person most knowledgeable (parent hereafter), no asthma at survey cycle
1, and reported asthma diagnosed by a health professional during follow-up. Children with the
following conditions were excluded from the study: not having a biological parent as the person
most knowledgeable (n=958); asthma at survey cycle 1 (n=1,530), missing asthma information at
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survey cycle 1 (n=178); no health professional-diagnosed asthma during the follow-up
(n=10,617); information on asthma at less than 4 survey cycles (to be able to assess cubic pattern
of the trajectories) [11] (n=1,538); and inconsistent response (“no” after “yes”) on “ever
diagnosed with asthma” question between surveys (n=161). Another 20 children were excluded
because of: missing asthma information between surveys with a ‘no’ and a ‘yes’ response on
asthma, which precluded identification of time of incident asthma; older child from households
with two children to allow longer follow-up of the younger child; and children whose reported
sex changed between surveys before asthma diagnosis. A total of 403 children diagnosed with
incident asthma were retained for the analysis to identify trajectories during childhood. Followup of a child for our study started at asthma diagnosis and lasted for 6–12 years (up to 17 years
of age), depending on the age at survey cycle 1 and on the age at asthma diagnosis.
4.2.3. Outcome and Predictors
‘Asthma attack’ was considered as the measure of asthma exacerbation. An affirmative response
to the question “Has he/she had an attack of asthma in the last 12 months?” asked to parents of
0–15 year old children with asthma at each survey cycle, or “Have you had an attack of asthma
in the last 12 months?” asked to 16–17 year old children with asthma in survey cycles 4–5 was
considered as having an asthma attack. The following variables measured at or before incident
asthma diagnosis were considered as potential predictors for trajectory group membership based
on review of literature on prognostic factors in asthma [12-17] and available information in the
NLSCY: sex of the child, child having allergy as a proxy for allergen sensitization or atopy of
the child, at least one biological parent with a history of asthma or allergy, smoking habit of
parent or spouse of the parent as a proxy for exposure to environmental tobacco smoke at home,
number of siblings at home and age at asthma diagnosis. A child was considered to have allergy
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if the parent reported that the child had health-professional-diagnosed allergies in survey cycles
1–3, or if the parent reported that the child had at least one of the following health-professionaldiagnosed long-term conditions: food or digestive allergies, respiratory allergies such as hay
fever or any other allergies in the remaining survey cycles. Parents were considered to have a
history of asthma or allergy if either or both biological parents had at least one of the following
health professional-diagnosed long-term conditions: food allergies or other allergies in survey
cycles 1–3 or food or digestive allergies, respiratory allergies such as hay fever, any other
allergies, or asthma, in the remaining survey cycles. A child was considered to be exposed to
environmental tobacco smoke at home if parent or spouse reported to smoke cigarettes daily or
occasionally at the time of survey. Age at the survey cycle reporting incident asthma was
considered as the age at asthma diagnosis. Except for age at asthma diagnosis, predictor
information from the survey cycle prior to asthma diagnosis was used, considering a 12-month
recall period for asthma attack and because predictors should be established at the time of asthma
diagnosis (i.e., at the beginning of period of trajectory) [18]. By our study design, children
reporting incident asthma during survey cycles 2–5 and having information on asthma and
asthma attack in four or more survey cycles were included. So, the predictor information from
survey cycles 1–4 were used depending on the survey cycle of incident asthma report. Available
information from a prior survey cycle was used to replace missing predictor data assuming the
condition remained the same at the survey cycle prior to asthma diagnosis. Age at asthma
diagnosis and number of siblings were treated as continuous variables, while the other predictors
were represented by binary variables.
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4.2.4. Statistical Analysis
Descriptive statistics on characteristics of children at asthma diagnosis were computed and
summarized by means (standard deviation, SD) or medians (interquartile range, IQR) depending
on the distribution of the continuous variables and by percentages for categorical variables. At
first, a hierarchical logistic regression model was used to assess the overall pattern of asthma
attack after diagnosis [19, 20]. Latent class growth modeling, a semi-parametric approach, was
then used to identify distinct groups of children with similar patterns of asthma exacerbations
over time [18, 21]. Latent class growth modeling attempts to identify trajectory groups in the
population even if these trajectory groups are latent (“not identifiable ex ante on the basis of
measured characteristics”) [18] and thus unobservable. We first attempted to identify the number
of latent trajectory groups by testing models with up to five latent trajectory groups. Each model
included linear, quadratic and cubic polynomial terms for time since asthma diagnosis, so as to
allow for the possibility of a cubic shaped pattern of the relation between the logit of the
probability of asthma attack and time since asthma diagnosis. Among these, the model having
the lowest Bayesian Information Criterion was selected (Supplementary Material, S Table 4.1)
[22]. Examination of the results of statistical-significance testing of the three polynomial terms
for time since asthma diagnosis revealed that the quadratic and cubic terms were not statisticallysignificant. Thus, these terms were dropped from the model [11, 18], so that the final model only
included a linear term, suggesting a straight-line (rather than parabolic or S-shaped) pattern of
the relation between the logit of the probability of asthma attack and time since asthma
diagnosis. We used time since asthma diagnosis as the time axis in both hierarchical modeling
and group-based trajectory modeling. Details of these analytic methods are provided in
Supplementary Material, S Methods. Finally, bivariate and multivariable multinomial logistic

140

regression modeling was performed to identify the predictors of trajectory group membership.
Multinomial logistic regression models were fitted because the outcome ‘trajectory group’ had
more than two categories. Data on parental history of asthma or allergies and exposure to
environmental tobacco smoking at home were missing in 28 (7%) and 4 (1%) children,
respectively. We first performed a complete-case analysis, restricted to children having
information on all predictors. We also performed sensitivity analysis after conducting 10
imputations for the missing risk factor values employing multivariate imputation using chained
equations (MICE) [23]. We followed the rule of thumb regarding the number of imputations, that
is, the number of imputations should be equal to or more than 100 times the largest fraction of
missing information (FMI) [23].
We conducted a secondary analysis to identify asthma exacerbation trajectories restricted
to children with asthma diagnosed after six years of age, as some preschool children with
diagnosed asthma may outgrow their asthma after six years of age [24, 25]. To identify
predictors of trajectory group membership, we fitted bivariate and multivariable logistic
regression models. We performed a complete-case and sensitivity analyses, which involved
conducting 15 imputations (based on the rule of thumb described above) in this subset of
children for missing risk factors using MICE.
The questions on allergies for the parents were asked differently between survey cycles
1–3 and the remaining survey cycles. So, we conducted a sub-analysis for the predictors of
trajectory group membership by restricting the operational definition of parental allergy to
include parents having food allergy alone for the predictor parental asthma/allergy. This
redefined predictor was thus named ‘parental asthma/food allergy’. We conducted complete-case
analysis and sensitivity analysis after multiple imputation, which involved conducting 15
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imputations (based on the rule of thumb described above) for missing risk factors using MICE.
Analyses were performed for all children and in the subset of children with asthma diagnosed
after six years of age.
Hierarchical logistic regression modeling was performed using SAS’s PROC GLIMMIX
procedure with Laplace estimation to obtain maximum likelihood estimation of the parameters
(SAS Institute, Inc., Cary, NC, USA) [26]. Latent class growth modeling was performed using
the PROC TRAJ procedure and multinomial logistic regression in SAS [27]. Sensitivity analysis
was performed using Stata software (StataCorp LP, College Station TX, USA). All statisticalsignificance tests were carried out at the alpha level of 0.05 (2-sided).
4.3.

Results

We report findings on the trajectories and predictors following the recommended guidelines for
reporting on latent trajectory studies, including studies using latent class growth modeling [28].
4.3.1.

Characteristics of Children at Asthma Diagnosis

Among 403 children retained in the analysis, the median age at asthma diagnosis was six years,
the majority of children (61%) were male and one-fifth (20%) of the children had allergies at or
before asthma diagnosis (Table 4.1). The median duration of follow-up was 8 years (interquartile
range, IQR: 4 years); 170 (42%) children contributed data for six years, 104 (26%) children
contributed data for eight years, 79 (20%) children contributed data for ten years and remaining
50 (12%) children contributed data for 12 years of follow-up. Of the 403 children, 177 (44%)
were aged more than six years at asthma diagnosis. Among these 177 children, 136 (77%)
contributed data for six years and 41 (23%) contributed data for eight years of follow-up.

142

Table 4. 1: Characteristics of children at asthma diagnosis, National Longitudinal Survey
of Children and Youth (NLSCY), 1994/1995–2008/2009
Characteristics

Frequency (%)
(n=403)

*
†

Sex, male

246 (61)

Child has allergy

82 (20)

Parent has asthma or allergy

114 (28)

Exposure to environmental tobacco smoke at home

192 (48)

Number of siblings at home, mean (SD*)

1.02 (0.83)

Age of child at asthma diagnosis in years, median (IQR†)

6 (4)

SD, standard deviation
IQR, interquartile range

4.3.2. Overall Asthma Trajectory from Hierarchical Modeling
Table 4.2 presents the parameter estimates from the hierarchical logistic regression model. The
fixed-effects parameter estimate for the intercept was 0.68, implying that the estimated
probability of asthma attack was 0.66 at asthma diagnosis. The fixed-effects parameter estimate
for time since asthma diagnosis was −0.358, implying that the odds of having had asthma attack
decreased by 30% with each year increase in time since asthma diagnosis. The random-effects
parameter estimates for between-child variance in both the intercept and ‘growth’ rate of asthma
attack over time since asthma diagnosis were statistically significant (Table 4.2, random effects)
suggesting that asthma attack probability at diagnosis and asthma attack probabilities across time
since asthma diagnosis vary across children. The overall trajectory of asthma attack plotted from
the fitted model suggested that the probability of asthma attack decreased with time after asthma
diagnosis, from 0.63 at asthma diagnosis to 0.11 at 12 years following diagnosis (Figure 4.1).
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Table 4. 2: Overall trajectory of asthma attack in children with asthma, National
Longitudinal Survey of Children and Youth (NLSCY), 1994/1995–2008/2009
Estimate (SE*)

p-value

Intercept

0.68 (0.14)

<0.0001

Time†

-0.36 (0.03)

<0.0001

Between-child variance in intercepts

2.91 (0.49)

<0.0001

Between-child variance in ‘growth’ rate of asthma

0.04 (0.02)

0.003

Effect
Fixed effects

Random effects

attack over time†
Fit statistics
BIC‡

2291.93

-2 Log Likelihood

2267.94

*

SE, standard error
Time since asthma diagnosis
‡
BIC, Bayesian information criterion
†
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Figure 4. 1: Overall trajectory of estimated probability of asthma attack, hierarchical
logistic regression model, National Longitudinal Survey of Children and Youth, Canada,
1994/1995–2008/2009. Solid line represents the point estimate of the probability, and
dashed lines represent the 95% confidence interval estimates. Black circles represent
observed proportion of asthma attack. Proportion at 12 years since asthma diagnosis is not
reportable because of a small sample size (n<15) in this subpopulation.
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4.3.3. Trajectory Groups of Asthma Attack from Latent Class Growth Modeling
Asthma attack over time was best fitted by a three-group model. Figure 4.2A presents the
trajectories of each of the three groups and Supplementary Material, S Table 4.2 presents the
estimates of the trajectory parameters and model adequacy information. The first trajectory
group (low increasing) comprised of 21.3% children who had an initial low level of asthma
attack probability that gradually increased after diagnosis and remained higher than the asthma
attack probability for the second trajectory group from around seven years after asthma diagnosis
(Figure 4.2A). The second trajectory group (medium decreasing) comprised of 45.8% children
having a moderate level of initial asthma attack probability with initial steep decrease followed
by gradual decrease with almost zero asthma attack probability at the end of 12-year follow-up.
The third trajectory group (high decreasing) comprised of 32.8% children having very high
initial asthma attack probability that decreased gradually and had a higher level of asthma attack
probability than low increasing and medium decreasing trajectory groups at 12 years after
asthma diagnosis. The predicted and observed trajectories for the three trajectory groups
suggested good fit (Figure 4.2B). Among 104 children in the low increasing trajectory group, the
median age of asthma diagnosis was 7 (IQR 3) years and 57 (54.8%) children had asthma
diagnosed after six years of age; among 168 children in the medium decreasing trajectory group,
the median age at asthma diagnosis was 6 (IQR 4) years and 99 (58.9%) children had asthma
diagnosed before six years of age; and among 131 children in the high decreasing trajectory
group, the median age at asthma diagnosis was 5 (IQR 5) years and 80 (61.1%) children had
asthma diagnosed before six years of age.
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A

Figure 4.2A. Solid line depicts predicted trajectory and dashed line 95% confidence interval
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B

Figure 4.2B. Solid line depicts observed trajectory and dashed line the predicted trajectory

Figure 4. 2: Trajectories of asthma attack, latent class growth modeling, National
Longitudinal Survey of Children and Youth, Canada, 1994/1995–2008/2009.
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4.3.4. Predictors of Trajectory Groups
A total of 371 children had information on all potential predictors. According to the
multivariable model, children having more siblings at home were more likely to belong to the
medium decreasing and high decreasing trajectory groups, while children older at asthma
diagnosis were less likely to belong to the medium decreasing and high decreasing trajectory
groups than low increasing trajectory group (Table 4.3). The magnitude of the estimated
association was largest for having more siblings. Male children were less likely to belong to the
medium decreasing and high decreasing trajectory groups compared with the low increasing
group, but the 95% confidence intervals were wide to allow meaningful interpretation. Similarly,
imprecise results were obtained for children having allergy and exposure to environmental
tobacco smoke at home although there were positive associations with the probability of
belonging to the medium decreasing and high decreasing trajectory groups. The association
between having parents with asthma or allergy and trajectory group membership was ambiguous:
children having parents with asthma or allergy were less likely to belong to the medium
decreasing trajectory group but more likely to belong to the high decreasing trajectory group.
Sensitivity analysis with imputed data for missing predictors yielded similar results (Table 4.3).
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Table 4. 3: Predictors of trajectory groups of asthma attack in children with asthma, National Longitudinal Survey of
Children and Youth, 1994/1995–2008/2009
Group

Predictor

Odds ratio (95% confidence interval)

All children*
Complete case analysis (N=371)

Sensitivity analysis (N=403)

Bivariate

Multivariable

Bivariate

Multivariable

Medium

Sex of the child, male

0.76 (0.45–1.33)

0.74 (0.42–1.29)

0.94 (0.57–1.56)

0.91 (0.54–1.53)

decreasing

Child has allergy

1.07 (0.57–2.02)

1.19 (0.62–2.30)

1.26 (0.68–2.34)

1.38 (0.73–2.60)

Parent has asthma/allergy

0.69 (0.39–1.23)

0.67 (0.37–1.24)

0.69 (0.39–1.21)

0.64 (0.36–1.16)

Exposure to environmental

1.33 (0.79–2.24)

1.28 (0.75–2.18)

1.21 (0.74–1.99)

1.15 (0.69–1.91)

Siblings at home

1.37 (0.99–1.90)

1.60 (1.11–2.30)

1.36 (0.99–1.86)

1.53 (1.08–2.16)

Age at asthma diagnosis (years)

0.92 (0.83–1.02)

0.87 (0.78–0.98)

0.44 (0.84–1.02)

0.88 (0.79–0.98)

High

Sex of the child, male

0.83 (0.47–1.46)

0.70 (0.39–1.26)

1.01 (0.60–1.72)

0.87 (0.50–1.50)

decreasing

Child has allergy

1.02 (0.53–1.99)

1.11 (0.55–2.22)

1.11 (0.57–2.14)

1.14 (0.58–2.26)

Parent has asthma/allergy

1.45 (0.82–2.56)

1.36 (0.75–2.49)

1.47 (0.83–2.58)

1.36 (0.76–2.44)

Exposure to environmental

1.41 (0.82–2.42)

1.21 (0.69–2.13)

1.27 (0.75–2.15)

1.11 (0.64–1.92)

Siblings at home

1.26 (0.90–1.78)

1.59 (1.09–2.33)

1.34 (0.96–1.86)

1.62 (1.13–2.32)

Age at asthma diagnosis (years)

0.83 (0.74–0.93)

0.80 (0.71–0.90)

0.85 (0.77–0.94)

0.82 (0.74–0.92)

tobacco smoke at home

tobacco smoke at home
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Children with asthma diagnosed after six years of age†
Complete case analysis (N=160)

Sensitivity analysis (N=177)

Bivariate

Multivariable

Bivariate

Multivariable

High

Sex of the child, male

0.83 (0.44–1.56)

0.69 (0.35–1.38)

0.89 (0.49–1.61)

0.75 (0.40–1.43)

decreasing

Child has allergy

1.72 (0.85–3.50)

1.71 (0.81–3.61)

1.55 (0.78–3.08)

1.53 (0.75–3.15)

Parent has asthma/allergy

1.28 (0.65–2.54)

1.31 (0.62–2.79)

1.26 (0.64–2.48)

1.27 (0.60–2.69)

Exposure to environmental

1.57 (0.83–2.98)

1.79 (0.92–3.51)

1.52 (0.83–2.79)

1.70 (0.91–3.20)

Siblings at home

1.57 (1.03–2.41)

1.54 (0.99–2.39)

1.45 (0.97–2.17)

1.44 (0.95–2.18)

Age at asthma diagnosis (years)

1.22 (0.94–1.59)

1.23 (0.93–1.62)

1.18 (0.93–1.49)

1.20 (0.93–1.53)

tobacco smoke at home

*

Multinomial logistic regression, low increasing trajectory is the comparison group

†

Logistic regression, low decreasing trajectory is the comparison group
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4.3.5. Asthma Attack Trajectory Groups and Predictors in Children with Asthma
Diagnosed after Six Years of Age
Among 177 children with asthma diagnosed after six years of age, the pattern of asthma attack
over time was best represented by a two-group model. Figure 4.3A depicts the trajectories of
these two groups, and Supplementary Material, S Table 4.2 depicts the estimates of the trajectory
parameters and model adequacy statistics. The first trajectory group (low decreasing) comprised
of 59.7% of children having a low level of asthma attack probability that gradually decreased
during the follow-up (Figure 4.3A). The second trajectory group (high decreasing) comprised of
40.3% of children having very high initial asthma attack probability that decreased gradually
over the eight years of follow-up and had a higher level of asthma attack probability than low
decreasing trajectory group throughout the follow-up. The predicted and observed trajectories
for the two trajectory groups suggested good fit (Figure 4.3B).
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A

Figure 4.3A. Solid line depicts predicted trajectory and dashed line 95% confidence interval
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B

Figure 4.3B. Solid line depicts observed trajectory and dashed line the predicted trajectory

Figure 4. 3: Trajectories of asthma attack in children with asthma diagnosed after six years
of age, latent class growth modeling, National Longitudinal Survey of Children and Youth,
Canada, 1994/1995–2008/2009.

In the complete-case analysis (N=160), male children were less likely to belong to the
high decreasing trajectory group, while children having allergy, having parents with asthma or
allergy, children with exposure to tobacco smoke at home, having more siblings at home and
children older at asthma diagnosis were more likely to belong to the high decreasing trajectory
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group compared with the low stable trajectory group (Table 4.3). Similar results were obtained
with imputed data.

4.3.6. Sub-analysis with parental asthma/food allergy as a potential trajectory-predictor
Among 403 children, 65 (16%) children had parents with asthma/food allergy, and among 177
children with asthma diagnosed after six years of age, 23 (13%) children had parents with
asthma/food allergy. In the sub-analysis (Table 4.4), the results for the predictors of the
trajectory group membership remained similar to the results presented in Table 4.3 that included
parents with allergies (any type) or asthma. The estimated association between having parents
with asthma and/or food allergy and trajectory group membership was as follows: children
having parents with asthma or allergy were less likely to belong to the medium decreasing
trajectory group but more likely to belong to the high decreasing trajectory group.
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Table 4. 4: Sub-analysis for the predictors of trajectory groups of asthma attack in children with asthma, National
Longitudinal Survey of Children and Youth, 1994/1995–2008/2009
Group

Predictor

Odds ratio (95% confidence interval)

All children*
Complete case analysis (N=366)

Sensitivity analysis (N=403)

Bivariate

Multivariable

Bivariate

Multivariable

Medium

Sex of the child, male

0.85 (0.49–1.45)

0.76 (0.44–1.33)

0.94 (0.57–1.56)

0.86 (0.52–1.44)

decreasing

Child has allergy

1.24 (0.65–2.39)

1.30 (0.67–2.55)

1.26 (0.68–2.34)

1.31 (0.70–2.45)

Parent has asthma/food allergy

0.84 (0.41–1.72)

0.77 (0.36–1.62)

0.85 (0.42–1.73)

0.79 (0.38–1.63)

Exposure to environmental

1.38 (0.82–2.34)

1.34 (0.78–2.29)

1.20 (0.73–1.96)

1.15 (0.69–1.91)

Siblings at home

1.41 (1.01–1.96)

1.65 (1.14–2.39)

1.36 (0.99–1.86)

1.53 (1.08–2.16)

Age at asthma diagnosis (years)

0.91 (0.82–1.01)

0.86 (0.77–0.97)

0.92 (0.84–1.02)

0.88 (0.80–0.98)

High

Sex of the child, male

0.87 (0.50–1.53)

0.76 (0.42–1.36)

1.01 (0.60–1.72)

0.90 (0.52–1.56)

decreasing

Child has allergy

1.11 (0.56–2.21)

1.25 (0.62–2.54)

1.11 (0.57–2.14)

1.19 (0.61–2.34)

Parent has asthma/food allergy

1.43 (0.71–2.87)

1.20 (0.57–2.49)

1.38 (0.70–2.73)

1.19 (0.58–2.41)

Exposure to environmental

1.47 (0.85–2.53)

1.26 (0.72–2.23)

1.28 (0.76–2.16)

1.13 (0.66–1.93)

Siblings at home

1.28 (0.91–1.82)

1.65 (1.12–2.42)

1.34 (0.96–1.86)

1.62 (1.13–2.32)

Age at asthma diagnosis (years)

0.82 (0.74–0.92)

0.79 (0.70–0.89)

0.85 (0.77–0.94)

0.82 (0.73–0.92)

tobacco smoke at home

tobacco smoke at home
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Children with asthma diagnosed after six years of age†
Complete case analysis (N=157)

Sensitivity analysis (N=177)

Bivariate

Multivariable

Bivariate

Multivariable

High

Sex of the child, male

0.84 (0.44–1.58)

0.73 (0.37–1.43)

0.89 (0.49–1.61)

0.79 (0.43–1.48)

decreasing

Child has allergy

1.71 (0.83–3.52)

1.70 (0.80–3.60)

1.55 (0.78–3.08)

1.60 (0.79–3.24)

Parent has asthma/food allergy

-‡

1.07 (0.42–2.75)

1.04 (0.43–2.50)

1.06 (0.42–2.69)

Exposure to environmental

1.64 (0.86–3.13)

1.84 (0.93–3.61)

1.51 (0.82–2.77)

1.67 (0.89–3.12)

Siblings at home

1.63 (1.05–2.51)

1.59 (0.94–1.64)

1.45 (0.97–2.17)

1.43 (0.95–2.17)

Age at asthma diagnosis (years)

1.23 (0.94–1.60)

1.24 (0.94–1.64)

1.18 (0.93–1.49)

1.21 (0.94–1.54)

tobacco smoke at home

*

Multinomial logistic regression, low increasing trajectory is the comparison group

†

Logistic regression, low decreasing trajectory is the comparison group

‡

The model did not meet the required guidelines for the results to be released from the Research Data Center
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4.4.

Discussion

Using data from a population-based longitudinal survey, we identified three distinct trajectories
of asthma attack in children for a period of up to 12 years after incident asthma diagnosis: low
increasing, medium decreasing and high decreasing. We also identified two predictors of the
trajectory group membership: number of siblings at home and age at asthma diagnosis.
Knowledge on the trajectories could help physicians foresee disease course at the time of asthma
diagnosis.
While one-fifth of the children belonged to the low increasing trajectory group, the
majority of the children belonged to the medium decreasing and high decreasing trajectory
groups with substantially high probabilities of asthma attack during the initial phase of follow-up
immediately after asthma diagnosis. The median age of asthma diagnosis in children was 6 years
suggesting that half of the children were diagnosed when virus-induced wheezing is prevalent
and symptoms may have abated soon afterwards [24, 29, 30]. The median age at asthma
diagnosis was higher in children in the low increasing trajectory group compared with the
median age at asthma diagnosis in children in the medium decreasing and high decreasing
trajectory groups. Furthermore, more than half of the children in the low increasing trajectory
group had asthma diagnosed after six years of age, whereas more than half of the children in the
medium decreasing and high decreasing trajectory groups had asthma diagnosed before six years
of age. Our finding of children with asthma diagnosed before six years of age belonging to the
high decreasing trajectory group is comparable to the findings from previous studies that an
earlier age at asthma onset may lead to persistent asthma in childhood [29, 31]. In addition, our
findings suggest that children with preschool asthma belonging to the medium decreasing
trajectory group grow out of asthma, and that this may happen after six years of age. The reason
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for low level of exacerbation probability in children in the low increasing trajectory group
warrants exploration in future studies. Children belonging to the low increasing group may
require attention several years after asthma diagnosis to decrease the increasing probabilities of
asthma attacks while children belonging to the medium decreasing and high decreasing
trajectory groups could particularly benefit from reduction in exacerbation frequency during the
initial period after diagnosis. Overall, children belonging to the medium decreasing trajectory
group have better long-term prognosis than children belonging to the other two trajectory groups.
Lack of similar studies on individuals with diagnosed asthma and with follow-up beginning right
after asthma diagnosis in children or adult precluded us from comparing exacerbation trajectories
identified in our study.
Having more siblings at home was positively associated with membership in the medium
decreasing and high decreasing trajectory groups compared with the low increasing trajectory
group. Having more siblings at home may have increased exposure to respiratory infections via
contact with the siblings resulting in more asthma exacerbation immediately after asthma
diagnosis. Our finding is similar to the finding that larger sibship was associated with severe
asthma symptoms in children aged 6–7 years and 13–14 years in a worldwide study [32].
Nevertheless, our finding seems contrary to the finding from a study reporting that exposure to
older siblings was associated with an increased rate of asthma remission in childhood [33].
Assessing a factor for asthma remission measured at a particular age or time does not provide
information on the role of the factor over the course of asthma. In our study, children older at
asthma diagnosis experienced milder asthma course as they were less likely to belong to the
medium decreasing and high decreasing trajectory groups that had higher probabilities of asthma
attack. In other studies, younger age was found to be a risk factor for asthma attack [34] and a
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predictor of severe asthma exacerbation in children [35]. These findings are consistent with the
results from our study. However, age at asthma diagnosis was only weakly associated with
frequent episodic asthma in children in another study [36].
Exposure to environmental tobacco smoke is known to be positively associated with
asthma severity and hospitalization with asthma exacerbation [37, 38] and negatively associated
with asthma remission [14]. In our study, the estimated association between exposure to
environmental tobacco smoke at home and trajectory group membership in our study was
imprecise. Nevertheless, a study reported that exposure to second-hand smoke was “not
associated” with frequent episodic asthma compared with infrequent asthma in children [36].
Although exposure to environmental tobacco smoke is time-varying and can change during the
course of asthma, we considered exposure to environmental tobacco smoke before asthma
diagnosis as a predictor to be able to predict trajectory group membership at the time of asthma
diagnosis. An imprecise association was also found between allergy in child and trajectory group
membership. Parent-reported allergy in a child may have led to inaccurate documentation of
child’s allergy status, potentially resulting in an underestimation of the association. The point
estimates suggested allergy in child was a weak predictor, but the upper limits of the 95%
confidence interval indicated that our data are compatible with relatively strong associations too.
In addition, strong predictors of asthma course may not necessarily be strong predictors of our
outcome, ‘trajectory group’. Among children with asthma diagnosed after six years of age,
nearly three-fifths of the children belonged to the low decreasing trajectory group with better
prognosis compared with the two-fifths of the children belonging to the high decreasing
trajectory group. Our results weakly support the association between exposure to environmental

160

tobacco smoke at home, siblings at home and age at asthma diagnosis with high decreasing
trajectory group membership.
This study has several strengths. To our knowledge, this is the first study to identify
trajectories of exacerbation in children following incident asthma diagnosis using group-based
trajectory method that takes into account the dynamic nature of asthma course. Use of
population-based data enabled us to follow children up to 12 years after asthma diagnosis. We
may have been able to capture less severe asthma attacks that may not have necessitated urgent
medical care and would have been excluded if administrative data were used. Asthma attacks
managed at home, not seeking medical care or medical care received from non-fee-for-service
physicians who do not remit service information are not captured in administrative data [39].
Information on the predictors of the trajectory groups identified in this study would be readily
available to the physicians even at a primary care setting.
The findings of this study need to be interpreted in light of some limitations. Our sample
size was relatively small, which led to considerable uncertainty in estimated trajectory patterns,
as reflected by the wide confidence intervals of the trajectory curves. The small sample size may
also have precluded us from identifying predictors that distinguished between high decreasing
and medium decreasing trajectory groups. Thus, replication of our results in future studies is
warranted. Asthma diagnosis was based on parental and child report and subject to recall bias.
The prevalence of parent reported physician-diagnosed asthma has been found to be lower than
the prevalence based on health administrative data (16% vs. 21%) in urban Canadian school
children in cross-sectional setting [40]. However, validity of parent report of diagnosed asthma
in longitudinal setting remains undetermined. There were some discrepancies in response
regarding the child ever having asthma over the course of the NLSCY cycles suggesting that the
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question asked may not have been perceived by the respondents the way they were intended. We
excluded children with discrepant responses to obtain conservative estimates. We could not
ascertain the exact age at asthma diagnosis because the question on ever having asthma was
asked every two years and information on exact age or date of asthma diagnosis was not
available. It is possible that children may have been younger than the age we considered to have
asthma diagnosis. The recall period for asthma attack was 12 months prior to the interview,
which may have resulted in underreporting of asthma attack requiring treatment, particularly of
less severe events. As asthma attacks affect day-to-day lives of children and caregivers with or
without necessitating medical care, parents likely reliably recalled severe asthma attack events.
Nevertheless, we were unable to quantify asthma attack and ascertain severity because of a lack
of this information. Children younger at NLSCY cycle 1 or asthma diagnosed at a younger age
contributed more to the follow-up than children older at cycle 1 or asthma diagnosed at an older
age. Different contribution to the follow-up by the children may have resulted in
misclassification of trajectory group membership. We employed the traditional three-step
method for identifying latent trajectories and their predictors, which does not take into account
the uncertainty (classification error) in group allocation [28]. However, the odds of classification
error for the trajectory groups in our final models exceeded the threshold and suggest fewer
classification errors. We were unable to consider some potential predictors of the trajectory
groups such as respiratory tract infection, objective markers of atopy and bronchial hyperresponsiveness, severity of asthma and asthma medication because of lack of information in the
dataset [12]. Future studies should assess all potential predictors for trajectory group
membership. Missing predictor values could bias the association between predictors and
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trajectory group membership [41]. We performed sensitivity analysis after imputing missing
predictor values and the results were similar.
In conclusion, our study suggests that children with asthma follow three distinct
trajectories of asthma exacerbation. Membership in two of these trajectories was associated with
two predictors at asthma diagnosis (number of siblings at home and age at asthma diagnosis),
although the predictors were not able to distinguish between these two trajectories. Knowledge
on the trajectories at the time of asthma diagnosis could help prognosticate the course and
supplement the current paradigm of asthma management based on symptom control. Further
studies on children with asthma in other settings, following children from birth through their
entire childhood and using accurate measures of asthma and asthma attack, would provide
further evidence on distinctive asthma exacerbation trajectories in children and enable
comparison. Future studies are warranted to identify distinct predictors of the trajectory groups to
predict individual child’s exacerbation trajectory pattern. A comprehensive risk assessment
model should be developed in the future, incorporating predictors from this study and future
studies to aid prediction of distinct asthma exacerbation trajectory groups.
4.5.

Supplementary Material

S Methods:
A 2-level hierarchical logistic regression model [19, 20] with repeated observations as level-1
units nested within individuals as level-2 units was performed to assess the overall pattern of
asthma attack over time after asthma diagnosis and examine between-subject variability in
trajectories. The combined level-1 and level-2 model included fixed effects for intercept and time
since asthma diagnosis, and random effects for intercept and time since asthma diagnosis.
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Level 1 model:
𝐿𝑜𝑔𝑖𝑡 Pr(𝐴𝑠𝑡ℎ𝑚𝑎 𝑎𝑡𝑡𝑎𝑐𝑘𝑡𝑖 = 1) = 𝛽𝑜𝑖 + 𝛽1𝑖 𝑇𝑖𝑚𝑒 𝑠𝑖𝑛𝑐𝑒 𝑎𝑠𝑡ℎ𝑚𝑎 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠𝑡𝑖

β0i is the intercept and represents the log odds of having an asthma attack around the time of
asthma diagnosis for a child i. β1i represents the slope associated with time since asthma
diagnosis for child i at time t.
Level 2 model:
For the intercept:
𝛽0𝑖 = 𝛾00 + 𝑢𝑜𝑖
For the slope:
𝛽1𝑖 = 𝛾10 + 𝑢1𝑖
𝛾00 represents the log odds of having an asthma attack for a typical child, and 𝑢𝑜𝑖 is the level-2
error term representing a unique effect associated with child i. 𝛾10 is the average effect of time
since asthma diagnosis, and 𝑢1𝑖 is the random effect for the slope associated with time since
asthma diagnosis for child i.
Combined model:
𝐿𝑜𝑔𝑖𝑡 Pr(𝐴𝑠𝑡ℎ𝑚𝑎 𝑎𝑡𝑡𝑎𝑐𝑘𝑡𝑖 = 1) = 𝛾00 + 𝛾10 𝑇𝑖𝑚𝑒 𝑠𝑖𝑛𝑐𝑒 𝑎𝑠𝑡ℎ𝑚𝑎 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠𝑡𝑖 + 𝑢𝑜𝑖 + 𝑢1𝑖

Here, i = 1, 2,……, n individuals at time (survey cycle) t and t = 2,…..8 survey cycles. 𝛾00 is the
overall intercept and represents the log odds of having an asthma attack around the time of
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asthma diagnosis for a child i , 𝛾10 is the effect of time since asthma diagnosis, 𝑢𝑜𝑖 is the random
intercept or child-level error, and 𝑢1𝑖 is the random effect for the slope associated with time since
asthma diagnosis for child i.
The intercept in a logistic regression model is the log odds of the dependent variable
when all the independent variables are set to zero. Because we have one independent variable
‘time since asthma diagnosis’ in our hierarchical model, the intercept can be interpreted as the
log odds of having an asthma attack around the time of asthma diagnosis. The fitted model was
used to estimate time-specific probabilities of having an asthma attack, which were then plotted
to depict the average trajectory of asthma attack following asthma diagnosis.
We used a logistic model for binary logit distribution in latent class growth
e  0 + 1 Timeit +  2 Timeit + 3 Timeit
j

modeling:[18]  =
j
it

1+ e

j

j

2

j

3

 0j + 1jTimeit +  2jTimeit2 +  3jTimeit3

j
where  it is the probability of the observed

j
binary outcome yit = 1 given membership in group j, p ( yit = 1) with the assumption that the

*
observed binary outcome yit = 1 (individual i had asthma in time t) if the latent variable yit  0
*
and yit = 0 (individual i did not have asthma in time t) if yit  0 . Trajectory parameters were

estimated using maximum likelihood with default start values. Identification of the trajectory
groups involved a two-stage process [18]. In the first stage, the number of latent trajectory
groups to include in the model was chosen. We tested five candidate models with cubic
polynomial function in each model: the first model with one latent trajectory group, the second
model with two latent trajectory groups, the third model with three latent trajectory groups, the
fourth model with four latent trajectory groups and the fifth model with five latent trajectory
groups (S Table 4.1). Among the five models tested, we chose the model with the lowest
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Bayesian Information Criterion (BIC). BIC is a commonly used criterion for model selection and
it is calculated as log (L) − 0.5k log (N) where L is the value of the model’s maximized
likelihood, N is the sample size and k is the number of parameters estimated by the model; the
model with the lowest BIC is preferred [18, 22]. In the second stage, we chose the order of the
polynomial defining the shape of each trajectory group in the model selected in the first stage.
Including cubic polynomial function in the models in the first stage allowed for the possibility of
cubic pattern of relationship between the logit of the probability of asthma attack and time since
asthma diagnosis. Non-significant quadratic and cubic terms were removed but linear terms were
retained in the model regardless of significance [11]. Thus, the final model included a linear
term, depicting a straight-line trajectory pattern for each trajectory group. Adequacy of the final
model was assessed by three diagnostics: average posterior probability of each group exceeded
0.70, odds of correct classification (OCC) for each group exceeded 5, and the model estimated
probability of group membership differed <50% from the proportion assigned to a group based
on largest posterior probability [18]. The OCC was calculated using the following formula:

𝑂𝐶𝐶𝑗 =

𝐴𝑣𝑒𝑃𝑃𝑗 /1−𝐴𝑣𝑒𝑃𝑃𝑗
̂ 𝑗 /1−𝜋
̂𝑗
𝜋

, where AvePPj denotes the average posterior probability of group j and

𝜋̂𝑗 is the model-estimated probability of membership in group j.
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S Table 4. 1: Models tested in latent class growth modeling
No. of trajectory groups

BIC*

Sample size per group based on
most likely group membership

All children (N=403)
1
2
3
4
5

-1294.47
-1163.76
-1160.35
-1170.10
-1182.41

403
251/152
232/108/63
-†
-†

Children with asthma diagnosed after six years of age (N=177)
1
-486.79
177
2
-438.52
99/78
3
-450.37
64/45/68
4
-461.57
-†
5
-475.74
-†
*
BIC, Bayesian Information Criterion. Lowest BIC is preferable
†
Indicates values not reportable because of small sample size (n<15) in one or more groups
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S Table 4. 2: Latent trajectory groups of asthma attack in children with asthma, National Longitudinal Survey of Children
and Youth, 1994/1995–2008/2009
Groups

Model
estimated
group
membership,
%

All children (N=403)
Low
21.3
increasing

Medium
decreasing

High
decreasing

45.8

32.8

Assigned
group
membership
using
maximum
probability
rule, n (%)

Average
Odds of
Parameter
posterior
correct
probability classification
(AvePP)

Estimate
(SE)*

t-statistic

BIC†

104 (25.8)

0.72

-1154.05

168 (41.7)

131 (32.5)

0.84

0.88

9.48

Intercept

-3.36 (2.48)

-1.36

0.14 (0.31)

0.46

6.20

Time to asthma
diagnosis
Intercept

0.69 (0.55)

1.26

-0.46 (0.12)

-3.95

15.01

Time to asthma
diagnosis
Intercept

2.21 (0.26)

8.59

Time to asthma
diagnosis

-0.22 (0.04)

-5.89

Intercept

-0.90 (0.25)

-3.60

Time to asthma
diagnosis

-0.35 (0.08)

-4.21

Children with asthma diagnosed after six years of age (N=177)
Low
59.7
99 (55.9)
0.96
16.20
decreasing

168

-430.29

High
decreasing

*

40.3

78 (44.1)

0.87

9.92

SE, standard error, †BIC, Bayesian Information Criterion
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Intercept

1.97 (0.36)

5.47

Time to asthma
diagnosis

-0.27 (0.07)

-4.16

4.6.
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5. Chapter 5: The Effect of Gestational Diabetes Mellitus on the Risk of
Asthma in the Offspring3
5.1.

Introduction

Gestational diabetes mellitus (GDM) is diabetes that is “first diagnosed in the second or third
trimester of pregnancy that is not clearly either preexisting type 1 or type 2 diabetes” [1]. The
prevalence estimates of GDM varies from <1% to 28% worldwide [2, 3] and has increased
significantly over the last few decades [4-8]. It is likely that the rising trend in GDM will
continue with the increase in the prevalence of risk factors, such as older maternal age and
obesity. GDM is associated with different short- and long-term consequences in mother (preeclampsia, caesarean section delivery, preterm delivery and future type 2 diabetes), fetus (fetal
macrosomia, large for gestational age, fetal hypoxia, immune dysregulation, impaired surfactant
production and delayed lung maturation) [9-12] and offspring (perinatal mortality, obesity and
metabolic syndrome) [13]. Some of these consequences, notably cesarean section delivery [1416], have also been implicated as risk factors for asthma. In addition, GDM could be increasing
the risk of asthma in the offspring through other pathways. So, if indeed there is an effect of
GDM on asthma in offspring, GDM can be contemplated to have not only an indirect component
mediated by cesarean section delivery but also a direct component through other pathways
independent of cesarean section delivery. Knowledge on both the total effect of GDM and direct
effect beyond cesarean section delivery could help identify opportunities for interventions to
reduce the risk of asthma in children. Previous studies have investigated the total effect of GDM
on childhood asthma. However, results from these studies are inconclusive because some studies

3
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suggested that GDM increased the risk of asthma in the offspring [17-22], while others suggested
that GDM did not increase the risk of asthma [23]. The direct effect of GDM accounting for the
mediating role of cesarean section delivery remains unknown.
In this study, we set to investigate the total effect of GDM on the risk of asthma in
offspring and the controlled direct effect of GDM not mediated by cesarean section delivery by
assuming a fixed value of cesarean section delivery. In addition, we assessed the joint effect of
GDM and maternal smoking during pregnancy on the risk of asthma in the offspring given that
maternal smoking in pregnancy is a known prenatal and intervenable risk factor for asthma in
children [24, 25].
Methods
5.2.1. Data Source
Data from the National Longitudinal Survey of Children and Youth (NLSCY) were used for this
study. Details of the NLSCY are available elsewhere [25]. Briefly, the NLSCY was a
longitudinal population-based survey that collected information every two years from infancy to
early adulthood. The first survey cycle of the NLSCY was conducted in 1994/1995 among
22,831 children aged 0–11 years living in 10 provinces of Canada using a multi-stage cluster
sampling. In the longitudinal part of this survey, 15,405 children included in cycle 1 (1994/1995
original cohort) were followed every two years until the last cycle (cycle 8) in 2008/2009. A
maximum of two children were included from each household. One person most knowledgeable
(PMK) about the child was interviewed using questionnaire to collect information on sociodemographics, pregnancy with child and birth-related conditions for young children, and health
professional-diagnosed chronic conditions in parents and children, children’s physical
development, learning, behavior, and social environment. Maternal pregnancy-related
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information at enrollment was available for children aged 0–6 years. New cohorts of children
aged 0–6 years, known as Early Childhood Development (ECD) cohorts, were added in each
subsequent cycle to monitor early childhood development. The ECD cohort enrolled in cycle 2
of the 1994/1995 original NLSCY included younger siblings of the members of the original
cohort. The ECD cohorts included one child per household except for twins. Same questionnaire
was used for all ECD cohorts as in the original cohort.
5.2.2. Study Population
We pooled data from cohorts of children enrolled in NLSCY cycles 1–7 for this study
(Supplementary Table, S Table 5.1). Children having a biological parent as the PMK, full
information on the model variables and information on asthma in at least two survey cycles were
included in this study. We excluded children with reported asthma defined as a positive response
to the question “Has this child ever had asthma that was diagnosed by a health professional?” by
the PMK at enrollment into the corresponding cohort (n=1,053). Children with prevalent asthma
at enrollment were excluded because our study outcome was incident asthma. Children with
reported asthma diagnosed during 0–2 years of age were also excluded as it is difficult to
accurately diagnose asthma in young children (n=693) [27], and the majority of the children with
wheezing before two years of age do not develop asthma later in childhood [28]. Some children
with reported asthma had inconsistent asthma response on “ever diagnosed with asthma” during
the follow-up (‘no’ response in a survey after ‘yes’ response in a previous survey) and were
excluded (n=394). In households where more than one child was enrolled in the same or different
cohorts, only one randomly selected child was retained and others were excluded (n=404). This
led to an analytic sample of 19,933 children.
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5.2.3. Study Outcome and Exposure
Incident asthma was the binary study outcome and defined as the first-time report of having
health professional-diagnosed asthma. Children were followed until incident asthma, the end of
the NLSCY survey follow-up, or loss to follow-up, whichever happened first. Loss to follow-up
was defined as missing outcome data in two consecutive survey cycles.
Maternal gestational diabetes mellitus during pregnancy with the child was the binary
exposure variable and was ascertained by a positive response to the question “During pregnancy
with this child did you suffer from any of the following: Pregnancy diabetes?”
5.2.4. Covariates
The following characteristics of children and mothers relevant for our analyses were measured at
NLSCY enrollment and included: the sex of the child, the birth weight of the child, maternal age
at birth of the child, maternal asthma, maternal smoking during pregnancy, maternal high blood
pressure in pregnancy, multiple gestation (e.g. twin, triplet or more), cesarean section delivery,
preterm delivery, maternal race, maternal educational attainment, annual household income, and
urban residence. Mothers were considered to have asthma if they were reported to have had
health professional-diagnosed asthma. Maternal high blood pressure in pregnancy and maternal
smoking in pregnancy were ascertained from an affirmative response to the questions “During
the pregnancy with this child did you suffer from high blood pressure?” and “Did you smoke
during your pregnancy with this child?” Cesarean section delivery was ascertained from response
to the question “Was the delivery vaginal or cesarean?” Preterm delivery was ascertained from
response to the following two questions: “Was this child born before, after or on his due date?”
and “How many days or weeks before/after the due date was this child born?” Multiple gestation
was ascertained from response to the question “Was this a single birth or twins, or triplets?”
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Maternal age at birth and parity were represented as continuous variables. Maternal educational
attainment was categorized into “less than secondary”, “secondary school graduation”, “some
post-secondary” and “college or university degree (including trade)”. Annual household income
was grouped into six categories: “$40,000 or more”, “$30,000 to $39,999”, “$20,000 to
$29,999”, “$15,000 to $19,999”, “$10,000 to 14,999” and “less than $10,000”. Birth weight was
categorized into three groups: “normal birth weight (2500 to 3900 g)”, “low birth weight (<2500
g)” and “high birth weight (≥4000 g)”. The remaining variables were represented as binary
variables. Preterm delivery was categorized into “gestational age ≥259 days” and “gestational
age ≤258 days”.
5.2.5. Statistical Analysis
Descriptive statistics for the child and maternal characteristics according to GDM status were
computed and summarized by means (standard deviation, SD) or medians (interquartile range,
IQR), depending on the distribution of the continuous variables and by percentages for
categorical variables.
Total effect of GDM on asthma in offspring
In the counterfactual approach to causal inference, if an exposure is A with two levels (a* = 0 and
a = 1) and the outcome is Y, then the total effect can be defined as a measure of “how much the
outcome would change overall for a change in the exposure from level a* = 0 to a = 1” [29]. To
estimate the total effect of GDM on the risk of asthma in offspring, we fitted pooled logistic
regression model to emulate a Cox proportional hazards model [30-32]. First, we estimated the
crude hazard ratio (HR) conditional on time since enrollment (hereafter time) and quadratic
effect of time (time2). Then we estimated the HR additionally adjusting for the confounders
informed by the directed acyclic graph (DAG) drawn for the relationship between GDM and
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asthma in the offspring using the web application DAGitty [33] (Figure 5.1). According to the
DAG, we needed to adjust for the following potential confounders: sex of the child, maternal
prepregnancy overweight/obesity, maternal age at birth of the child, maternal smoking during
pregnancy, maternal high blood pressure in pregnancy, multiple gestation, maternal educational
attainment, annual household income and urban residence. But we were unable to adjust for the
unmeasured confounder maternal prepregnancy overweight/obesity. Thus, we conducted a
sensitivity analysis to calculate bias-corrected estimates (described below). We also adjusted for
the NLSCY cohort membership indicating the NLSCY survey cycle of enrollment.
Direct effect of GDM on asthma in offspring
The direct effect can be distinguished as controlled and natural direct effects in the
counterfactual approach under certain no-confounding assumptions [29, 34]. If an exposure is A
with two levels (a*=0 and a=1), the outcome is Y and the mediator is M, then “The controlled
direct effect (CDE(m)) expresses how much the outcome would change on average if the
mediator were fixed at level m uniformly in the population but the treatment were changed from
level a* =0 to level a=1. The natural direct effect (NDE) expresses how much the outcome would
change if the exposure were set at level a =1 versus level a* =0 but for each individual the
mediator were kept at the level it would have taken, for that individual, in the absence of the
exposure. This NDE captures what the effect of the exposure on the outcome would remain if we
were to disable the pathway from the exposure to the mediator” [29]. However, estimation of the
NDE requires absence of exposure-induced confounders of mediator-outcome relationship in
addition to the absence of confounding of the exposure-outcome, mediator-outcome and
exposure-mediator relationships [29]. In our study, we had exposure-induced confounders of
mediator-outcome relationship. According to the DAG, preterm delivery and birth weight were
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GDM-induced confounders of cesarean section delivery-asthma in offspring relationship (Figure
5.1). So, we were only able to estimate the CDE that can be conceived as the effect of GDM on
asthma in offspring with a fixed value of the mediator cesarean section delivery (here, in a
hypothetical scenario, delivery not by cesarean section for all children).
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Figure 5. 1: Directed acyclic graph showing the paths between gestational diabetes mellitus and asthma in offspring
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We fitted a pooled marginal structural logistic regression model with inverse probability
weighting to estimate the controlled direct effect of GDM on the risk of asthma in offspring, not
mediated by cesarean section delivery [29, 35]. Our model was a partial marginal structural
model because it included covariates in addition to the exposure and mediator. For the inverse
probability weighting, we calculated a weight for the mediator, cesarean section delivery for an
observation at a time point. We fitted pooled logistic regression models to estimate the
numerator and denominator inputs for the mediator weight. The numerator input was the
probability of having the value of cesarean section delivery that a child actually had, conditional
on having the exposure GDM the child actually had. The denominator input was the probabilities
of having the value of the cesarean section delivery that a child actually had conditional on GDM
(exposure), potential confounders of the GDM-asthma, GDM-cesarean section delivery and
cesarean section delivery-asthma associations (i.e., sex of the child, maternal age at pregnancy,
maternal asthma, maternal smoking in pregnancy, high blood pressure in pregnancy, multiple
gestation, maternal race, maternal educational attainment, annual household income and urban
residency), exposure-induced confounders of the mediator-outcome association (i.e., preterm
delivery and birth weight), and NLSCY cohort membership, time, and time2. The mean of the
mediator weight was 1.00 (range= 2.46). To estimate the controlled direct effect of GDM on the
risk of asthma in offspring, we fitted a weighted pooled logistic regression model with
generalized estimating equations to estimate the parameters. The logit of incident asthma
probability was regressed on GDM, cesarean section delivery, an interaction term between GDM
and cesarean section delivery, the confounders of the GDM-asthma association (i.e., sex of the
child, maternal age at pregnancy, maternal smoking during pregnancy, maternal high blood
pressure during pregnancy, multiple gestation, maternal educational attainment, annual
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household income, urban residency), NLSCY cohort membership, time and time2 using the
mediator weight.
Joint effect of GDM and maternal smoking during pregnancy on asthma in offspring
A multivariable pooled logistic regression model was fitted by regressing the logit of incident
asthma probability on GDM, maternal smoking during pregnancy, an interaction term between
GDM and maternal smoking during pregnancy, time, time2 and NLSCY cohort membership, and
the confounders sex of the child, maternal age at birth, maternal asthma, maternal educational
attainment, maternal race, annual household income and urban residence. The interaction term
between GDM and maternal smoking during pregnancy represented interaction on multiplicative
scale. This is equivalent to: HR for exposure to both GDM and maternal smoking during
pregnancy/[HR for exposure to GDM multiplied by HR for exposure to maternal smoking during
pregnancy]. We also examined interaction on additive scale [36]. The additive interaction was
assessed by estimating the relative excessive risk due to interaction (RERI) and synergy index
[36-38]. The RERI is “the risk that is additional to the risk that is expected on the basis of the
addition of the ORs under exposure, calculated as the difference between the expected risk and
the observed risk” [37]. Synergy index is “the excess risk from exposure to both exposures when
there is interaction relative to the risk from exposure without interaction” [37]. Synergy index
was also calculated because RERI varies across strata defined by covariates and is not easy to
interpret from models after including covariates to control for confounding. Synergy index does
not vary across strata of covariates and is the measure of choice for additive interaction in
multivariable models [37]. For calculation of RERI and synergy index, a new composite variable
with four categories was computed: one category for joint exposure to both risk factors (+ +), a
category for exposure to one of the risk factors only (+ - or - +), and a joint reference category
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for no exposure (background risk or - -). A pooled logistic regression model was then fitted to
estimate the HRs using the new indicator variable adjusting for the variables included in the
pooled logistic regression model for multiplicative interaction. RERI was calculated using the
following formula: RERI = HR+ + − HR+ − − HR− + + 1 and synergy index was calculated using
the following formula: [HR+ + − 1] / [(HR+ − − 1) + (HR− + − 1)]. A RERI value of “0” and
synergy index of “1” indicates no interaction effect. We also calculated the attributable
proportion due to interaction (AP), which is “the proportion of disease or mortality that is due to
interaction among persons with both exposures”. AP was calculated using the following formula:
AP = RERI/HR+ + and an AP value of ‘0’ indicates no interaction [37]. The results of the
interaction are reported according to the recommended guidelines [36].
Sensitivity analyses for unmeasured confounding for the total effect
To assess the effect of a possible unmeasured binary confounding factor maternal prepregnancy
overweight/obesity on the estimates of the total effect of GDM on the risk of asthma in offspring,
we performed a sensitivity analysis under a range of potential bias conditions [29]. The estimated
prevalence of overweight and/or obesity in pregnant women in general varies between 10% and
60% globally [39, 40] and in women with GDM varies between 35% and 71% [41-43]. In the
sensitivity analyses, we allowed the prevalence of maternal prepregnancy overweight/obesity to
vary between 10% and 60% among mothers without GDM and between 35% and 75% among
mothers with GDM, and the association between maternal prepregnancy overweight/obesity and
asthma in offspring to vary between HR of 2.0 and 10.0. The following bias factor formula was
used [29]: 𝐵𝑚𝑢𝑙𝑡 (𝑐) =

1+(𝛾−1)𝑃(𝑈=1|𝑎,𝑐)
1+(𝛾−1)𝑃(𝑈=1|𝑎∗ ,𝑐)

where γ is the effect of the unmeasured confounder U

on the outcome Y conditional on the exposure (A=a if exposed and A=a* if unexposed) and
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measured confounders (C=c). Bias corrected HR was estimated by dividing the estimated HR
with the calculated bias factor.
We also estimated the minimum strength of association on the hazard ratio scale that an
unmeasured confounder would need to have with both the exposure GDM and the outcome
incident asthma in offspring to fully explain away (i.e., nullify) the observed GDM-asthma in
offspring association conditional on the measured confounders. This is known as the “E-value”
and was calculated using the following formula [44, 45]: HR + sqrt {HR x (HR – 1)}.
SAS software v 9.4 (SAS Institute Inc., Cary, North Carolina) was used in all analyses.
5.2.

Results

Among the 19,933 children, a total of 1,178 children (5.9%) had mothers with GDM. A higher
proportion of mothers with GDM smoked during pregnancy and had high blood pressure during
pregnancy compared with mothers without GDM (Table 5.1). As expected, a higher proportion
of children whose mothers had GDM had high birth weight, were delivered by cesarean section
and were born preterm compared with children whose mothers did not have GDM. Maternal race
was black in 227 (1%) children. The frequencies of maternal race according to the GDM status
are not reportable because of small sample size (n<15) among mothers with GDM. The median
follow-up was 4 years (IQR: 4). A total of 1,639 children in the cohort reported incident asthma
during the follow-up, and 119 of them had mothers with GDM.

186

Table 5. 1: Characteristics of children and mothers, National Longitudinal Survey of
Children and Youth, 1994/1995–2008/2009
Characteristic

Mothers did not

Mothers had

have GDM*,

GDM*,

frequency (%)

frequency (%)

N=18,755

N=1,178

9,415(50)

591 (50)

Normal (2500 to 3900 g)

15,193 (81)

899 (76)

Low birth weight (<2500 g)

922 (5)

76 (6)

High birth weight ((≥4000 g)

2,640 (14)

203 (17)

Maternal age at birth in years, mean (SD†)

29 (5.2)

30 (5.4)

Maternal asthma

1,160 (6)

84 (7)

Maternal smoking during pregnancy

3,390 (18)

260 (22)

Maternal high blood pressure in pregnancy

2,004 (11)

241 (20)

Multiple gestation

345 (2)

26 (2)

Cesarean section delivery

4,004 (21)

362 (31)

Preterm delivery (gestational age ≤258 days)

1,750 (9)

183 (16)

Less than secondary school graduation

2,040 (11)

148 (13)

Secondary school graduation

3,081 (16)

222 (19)

Some post-secondary

4,042 (22)

277 (24)

College or university degree

9,592 (51)

531 (45)

<$10,000

328 (2)

20 (2)

$10,000–$14,999

895 (5)

73 (6)

$15,000–$19,999

827 (4)

74 (6)

$20,000–$29,999

1,862 (10)

141 (12)

$30,000–$39,999

2,437 (13)

157 (13)

≥$40,000

12,406 (66)

713 (61)

Sex of the child, male
Birth weight

Maternal educational attainment

Annual household income
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Urban residence

14,887 (79)

925 (79)

Cycle 1

1,047 (6)

56 (5)

Cycle 2

2,707 (14)

200 (17)

Cycle 3

5,212 (28)

351 (30)

Cycle 4

1,761 (9)

109 (9)

Cycle 5

1,887 (10)

122 (10)

Cycle 6

3,029 (16)

160 (14)

Cycle 7

3,115 (17)

180 (15)

NLSCY‡ cohort membership

*

GDM, gestational diabetes mellitus
SD, standard deviation
‡
NLSCY, National Longitudinal Survey of Children and Youth
†

In the unadjusted time-conditional model, the HR for the total effect of GDM was 1.27
(95% CI: 1.05, 1.54). After adjusting for the potential confounders, the association attenuated
slightly (HR: 1.25, 95% CI: 1.03, 1.51), suggesting that there may not have been material
confounding by the controlled-for characteristics in our study (Table 5.2). When estimating the
controlled direct effect of GDM on incident asthma in offspring by adjusting for the cesarean
section delivery, the HR was 1.17 (95% CI: 0.91, 1.49) (Table 5.3).
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Table 5. 2: Total effect of gestational diabetes mellitus on asthma in the offspring, National
Longitudinal Survey of Children and Youth, 1994/1995–2008/2009
Variables

HR (95% CI)*

P-value

Gestational diabetes mellitus

1.25 (1.03, 1.51)

0.03

Sex of the child, male

1.47 (1.33, 1.62)

<0.0001

Maternal age at birth in years

0.99 (0.98, 1.00)

0.18

Maternal smoking during pregnancy

1.08 (0.95, 1.23)

0.26

Maternal high blood pressure in pregnancy

1.19 (1.03, 1.38)

0.02

Multiple gestation

1.45 (1.04, 2.03)

0.03

Less than secondary school graduation

1.03 (0.86, 1.23)

0.73

Secondary school graduation

1.01 (0.87, 1.17)

0.91

Some post-secondary

1.09 (0.96, 1.24)

0.17

College or university degree

Reference

Maternal educational attainment

Annual household income
<$10,000

1.62 (1.17, 2.23)

0.004

$10,000–$14,999

1.57 (1.26, 1.95)

<0.0001

$15,000–$19,999

1.35 (1.07, 1.70)

0.01

$20,000–$29,999

1.23 (1.04, 1.45)

0.01

$30,000–$39,999

1.14 (0.98, 1.33)

0.09

≥$40,000

Reference

Urban residence

1.14 (1.01, 1.30)

0.04

Time since enrollment

1.64 (1.53, 1.76)

<0.0001

Time since enrollement2

0.97 (0.96, 0.97)

<0.0001

NLSCY† cohort membership

1.09 (1.06, 1.13)

<0.0001

*

Adjusted for maternal age at birth of the child, maternal smoking during pregnancy, maternal
educational attainment, sex of the child, annual household income, urban residency, time since
enrollment, time since enrollment2 and NLSCY cohort membership
†
National Longitudinal Survey of Children and Youth
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Table 5. 3: Controlled direct effect of gestational diabetes mellitus on asthma in the
offspring, National Longitudinal Survey of Children and Youth, 1994/1995–2008/2009
Variables

HR (95% CI)*

P-value

Gestational diabetes mellitus

1.17 (0.91, 1.49)

0.22

Cesarean section delivery

1.17 (1.03, 1.33)

0.02

Gestational diabetes mellitus*Cesarean section

1.17 (0.77, 1.77)

0.46

Sex of the child, male

1.44 (1.30, 1.60)

<0.0001

Maternal age at birth in years

0.99 (0.98, 1.00)

0.10

Maternal smoking during pregnancy

1.08 (0.95, 1.23)

0.25

Maternal high blood pressure in pregnancy

1.20 (1.03, 1.40)

0.02

Multiple gestation

1.48 (1.01, 2.18)

0.04

Less than secondary school graduation

1.03 (0.86, 1.23)

0.75

Secondary school graduation

1.01 (0.87, 1.18)

0.86

Some post-secondary

1.08 (0.95, 1.23)

0.23

College or university degree

Reference

delivery interaction

Maternal educational attainment

Annual household income
<$10,000

1.63 (1.18, 2.25)

0.003

$10,000–$14,999

1.64 (1.31, 2.04)

<0.0001

$15,000–$19,999

1.29 (1.02, 1.64)

0.03

$20,000–$29,999

1.24 (1.05, 1.47)

0.01

$30,000–$39,999

1.13 (0.97, 1.33)

0.11

≥$40,000

Reference

Urban residence

1.14 (1.00, 1.29)

0.05

Time since enrollment

1.67 (1.54, 1.81)

<0.0001

Time since enrollement2

0.96 (0.96, 0.97)

<0.0001

NLSCY† cohort membership

1.09 (1.05, 1.12)

<0.0001

*

The controlled direct effect of gestational diabetes mellitus (GDM) not mediated by cesarean
section delivery using marginal structural model with inverse probability weights. The model
included GDM, cesarean section delivery, an interaction term between GDM and cesarean
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section delivery, confounders of GDM-asthma relationship (i.e., sex of the child, maternal age at
pregnancy, maternal smoking during pregnancy, maternal high blood pressure during pregnancy,
multiple gestation, maternal educational attainment, annual household income, urban residency),
NLSCY cohort membership, time since enrollment and time since enrollment2 and applying the
mediator weight
†
National Longitudinal Survey of Children and Youth

The measure of interaction between GDM and maternal smoking during pregnancy on
the multiplicative scale, the ratio of the HR for both exposure and the product of the HRs for the
two exposures individually), was 1.23 (95% CI: 0.79, 1.90; P = 0.35), meaning that the estimated
joint effect on the HR scale of GDM and maternal smoking during pregnancy was greater than
the product of the estimated effects of GDM alone and maternal smoking during pregnancy alone
so suggesting a positive multiplicative-scale interaction. The estimated RERI was 0.30 (95% CI:
−0.32, 0.93), meaning that on the additive scale, the estimated joint effect of GDM and maternal
smoking during pregnancy was greater than the sum of the estimated effects of GDM alone and
maternal smoking during pregnancy alone, suggesting a positive additive-scale interaction (Table
5.4). The synergy index was 2.15, meaning that there was excess risk from exposure to both
GDM and maternal smoking during pregnancy when there is interaction relative to the risk from
exposure without interaction suggesting a positive interaction on the additive scale. The
attributable proportion due to interaction was 0.19 meaning that 19% of asthma in offspring is
due to interaction among children with both GDM and maternal smoking in pregnancy.
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Table 5. 4: Interaction between maternal gestational diabetes mellitus and maternal smoking during pregnancy on the risk of
asthma in the offspring
Maternal smoking during pregnancy
Mother did not smoke
N asthma/no

Mother smoked

HR (95% CI)

asthma
Mother did not have GDM

1211/33509

N asthma/no

HR (95% CI)

309/7452

86/1974

during pregnancy

1.06 (0.92, 1.21); 1.07 (0.93, 1.22);
P = 0.42

Mother had GDM

maternal smoking

within strata of GDM

asthma
1.0

HR (95% CI) for

P = 0.35

1.20 (0.96, 1.51); 33/530

1.56 (1.09, 2.25); 1.24 (0.80, 1.95);

P = 0.11

P = 0.02

HRs (95% CI) for GDM

1.21 (0.97, 1.52);

1.44 (0.99, 2.10);

within strata of maternal

P = 0.09

P = 0.06

P = 0.34

smoking during pregnancy
Measure of interaction on additive scale: RERI (95% CI) = 0.30 (−0.32, 0.93)
Measure of interaction on multiplicative scale: ratio of HRs (95% CI) = 1.23 (0.79, 1.90)
HRs are adjusted for sex of the fetus/child, maternal age at birth of the child, maternal educational attainment, maternal asthma,
maternal race, annual household income, and urban residence, time since enrollment, time since enrollment2 and NLSCY cohort
membership
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Sensitivity analyses across the range of potential bias conditions demonstrated that in
scenarios where the prevalence of prepregnancy overweight/obesity was higher in mothers with
GDM than in mothers without GDM, the HR for the association between GDM and incident
asthma in offspring decreased with increasing prevalence of prepregnancy overweight/obesity in
mothers with GDM and with increasing effect size of prepregnancy overweight/obesity on
asthma in the offspring. Thus, the bias-corrected HR estimates suggest that the HR for incident
asthma would be overestimated in these scenarios. However, the HR for the association between
GDM and incident asthma in offspring would be underestimated in scenarios where the
prevalence of prepregnancy overweight/obesity among mothers without GDM is higher than the
prevalence among mothers with GDM (Table 5.5). The E-value for the estimated total effect of
GDM suggests that the observed HR of 1.25 could be explained away by an unmeasured
confounder that was associated with both GDM and asthma in offspring by an HR of 1.81-fold
each, above and beyond the measured confounders (and other potential sources of error), but a
weaker confounding could not do so. The E-value for the lower 95% limit of the total effect was
1.21.
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Table 5. 5: Bias-corrected hazard ratios for quantifying the total effect of GDM on asthma,
considering unmeasured confounder maternal prepregnancy overweight/obesity with a
range of determinants of bias
Prevalence of unmeasured
confounder maternal
prepregnancy
overweight/obesity
No GDM (%)

GDM (%)

10
10
10
10
10
10
10
10
10
20
20
20
20
20
20
20
20
20
30
30
30
30
30
30
30
30
30
40
40
40
40
40
40

35
40
45
50
55
60
65
70
75
35
40
45
50
55
60
65
70
75
35
40
45
50
55
60
65
70
75
35
40
45
50
55
60

Bias-Corrected Hazard Ratio

The effect size of the unmeasured maternal prepregnancy
overweight/obesity in Hazard Ratio
2.0
4.0
6.0
8.0
10.0
1.02
0.79
0.68
0.62
0.57
0.98
0.74
0.63
0.56
0.52
0.95
0.69
0.58
0.51
0.47
0.92
0.65
0.54
0.47
0.43
0.89
0.61
0.50
0.44
0.40
0.86
0.58
0.47
0.41
0.37
0.83
0.55
0.44
0.38
0.35
0.81
0.52
0.42
0.36
0.33
0.79
0.50
0.39
0.34
0.31
1.11
0.98
0.91
0.87
0.84
1.07
0.91
0.83
0.79
0.76
1.03
0.85
0.77
0.72
0.69
1.00
0.80
0.71
0.67
0.64
0.97
0.75
0.67
0.62
0.59
0.94
0.71
0.63
0.58
0.55
0.91
0.68
0.59
0.54
0.51
0.88
0.65
0.56
0.51
0.48
0.86
0.62
0.53
0.48
0.45
1.20
1.16
1.14
1.12
1.11
1.16
1.08
1.04
1.02
1.01
1.12
1.01
0.96
0.93
0.92
1.08
0.95
0.89
0.86
0.84
1.05
0.90
0.83
0.80
0.78
1.02
0.85
0.78
0.75
0.72
0.98
0.81
0.74
0.70
0.68
0.96
0.77
0.69
0.66
0.63
0.93
0.73
0.66
0.62
0.60
1.30
1.34
1.36
1.38
1.39
1.25
1.25
1.25
1.25
1.25
1.21
1.17
1.15
1.14
1.14
1.17
1.10
1.07
1.06
1.05
1.13
1.04
1.00
0.98
0.97
1.09
0.98
0.94
0.91
0.90
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40
40
40
50
50
50
50
50
50
50
50
50
60
60
60
60
60
60
60
60
60

65
70
75
35
40
45
50
55
60
65
70
75
35
40
45
50
55
60
65
70
75

1.06
1.03
1.00
1.39
1.34
1.29
1.25
1.21
1.17
1.14
1.10
1.07
1.48
1.43
1.38
1.33
1.29
1.25
1.21
1.18
1.14

0.93
0.89
0.85
1.52
1.42
1.33
1.25
1.18
1.12
1.06
1.01
0.96
1.71
1.59
1.49
1.40
1.32
1.25
1.19
1.13
1.08
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0.88
0.83
0.79
1.59
1.46
1.35
1.25
1.17
1.09
1.03
0.97
0.92
1.82
1.67
1.54
1.43
1.33
1.25
1.18
1.11
1.05

0.86
0.81
0.76
1.63
1.48
1.36
1.25
1.16
1.08
1.01
0.95
0.90
1.88
1.71
1.57
1.44
1.34
1.25
1.17
1.10
1.04

0.84
0.79
0.74
1.66
1.49
1.36
1.25
1.16
1.07
1.00
0.94
0.89
1.93
1.74
1.58
1.45
1.34
1.25
1.17
1.10
1.03

5.3.

Discussion

In this study, we estimated the total effect of maternal GDM on the risk of asthma in the
offspring using data from a large Canadian population-based longitudinal study. We also
examined the controlled direct effect of GDM not mediated by cesarean section delivery and the
joint effect of GDM and maternal smoking during pregnancy on the risk of asthma in the
offspring. Our findings suggest that maternal GDM increases the risk of asthma in the offspring.
Similar to our findings, maternal diabetes was associated with around 20% higher odds of
asthma in children followed from 2 years of age in two studies using proxy measures for asthma
(i.e. hospitalization for asthma and asthma medication) [19, 20]. Another study reported a higher
association between maternal diabetes and asthma (OR 1.95, 95% CI: 0.98, 3.86) in children at
7-8 years of age [21]. That study, however, did not adjust for important confounders such as sex,
gestational age and birth weight of the child as well as maternal age and socioeconomic status,
which may have resulted in the stronger association compared with our study. In yet another
study, the HR for the association between maternal GDM and asthma was 1.09 (p<0.0001)
among children followed from 5 years of age; and when compared with children having mothers
without GDM, the HR for the association was 1.15 (p<0.0001) for children whose mothers
required antidiabetic medication for GDM during pregnancy and the HR for the association was
1.06 (p=0.01) for children whose mothers did not use medication for GDM during pregnancy
[18]. But unfortunately, that study has not been published in a journal yet and cannot be judged
based on limited information provided in the abstract. One study reported a decreased rate of
asthma-associated hospitalization in children having mothers with diet-treated GDM (HR 0.93,
95% CI: 0.82, 1.06) and pharmacologically-treated GDM (HR 0.94, 95% CI: 0.61, 1.42)
compared with children having mothers without GDM [23]. Nonetheless, the HR ranging from a
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39% reduction to a 42% increase, a substantial positive association for pharmacologically-treated
GDM was also compatible with their data reflected by the 95% confidence interval.
If indeed GDM is a risk factor for asthma, approaches to prevent GDM might help in
prevention of asthma in the offspring. Different lifestyle modification strategies, dietary
supplementation, and pharmacological and non-pharmacological approaches have been
evaluated as potential GDM prevention strategies. Among these interventions, healthy eating
alone, healthy eating with physical activity, myoinositol (a vitamin B complex) supplementation
and probiotic treatment have shown some promising results in high-risk women in reducing
GDM but require replication [46, 47]. Identification of effective measures to prevent GDM,
particularly in women at risk of developing GDM would be the first step in this regard followed
by evaluating effectiveness in preventing outcomes in offspring, including asthma.
When considering the controlled direct effect of GDM on the risk of asthma not mediated
by cesarean section delivery, GDM appeared to increase the risk of asthma in the offspring. The
point estimate suggests that in this hypothetical scenario where cesarean section delivery was not
practiced (i.e., none of the children delivered by cesarean section), GDM would still have
retained much of its effect on the risk of asthma in the offspring on the population level.
However, the effect estimate was imprecise considering the width of the 95% confidence
intervals. This could further suggest that there are other intermediaries in the pathway between
GDM and asthma in the offspring or the effect of GDM on asthma in the offspring varies
according to the duration, severity and control of hyperglycemia or both. Future studies should
examine the direct effect of GDM according to GDM severity or treatment status and aim to
identify other intervenable mediators to effectively reduce the risk of developing asthma in
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children whose mothers had GDM, considering the absence of confirmed effective GDM
prevention strategies.
The estimated joint effect of GDM and maternal smoking during pregnancy on asthma in
offspring supports some positive interaction between GDM and maternal smoking during
pregnancy on both multiplicative and additive scales. However, the evidence is weak as reflected
by the 95% confidence intervals that were also compatible with negative interaction. Hence,
further studies are warranted to generate additional evidence in this regard.
This study has some strengths. First, the use of data from a national population-based
large longitudinal study enabled us to follow children up to 16 years of age. Second, we were
able to adjust for relevant potential confounders except for maternal prepregnancy overweight or
obesity. Third, we had longitudinal data and we used longitudinal data analysis, particularly
pooled logistic regression to emulate a Cox proportional hazards model to estimate the effect of
GDM on the risk of asthma in the offspring. Fourth, we sought further explanation beyond the
total effect of GDM by examining the controlled direct effect accounting for the mediating role
of cesarean section delivery. Last, we also examined the joint effect of GDM and maternal
smoking during pregnancy on the risk of asthma in the offspring that has not been assessed
before. We assessed interaction on both multiplicative and additive scales.
The results of this study need to be interpreted in light of some limitations. First,
information on asthma was based on reported physician-diagnosed asthma and therefore, subject
to misclassification of asthma status. Parent-reported physician-diagnosed asthma had 59% to
89% sensitivity and 81% to 96% specificity when validated against medical records, health
claims diagnosis or pediatric allergist diagnosis of asthma in previous studies [21, 48-50].
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Because NLSCY was not an asthma-focused study, misclassifications are expected to be nondifferential with regard to maternal GDM status. As a result, the non-differential
misclassification of asthma will bias associations toward the null. Second, we were unable to
differentiate between pregestational and gestational diabetes mellitus of mothers reporting
diabetes during pregnancy with the child, as mothers were not asked if they had diabetes before
pregnancy. However, most of the diabetes mellitus during pregnancy are likely to be GDM [51].
Third, there may have been inaccuracies in reporting of pregnancy- and birth-related
information, including the exposure, GDM. Nevertheless, studies have suggested high
reproducibility and accuracy of maternal recall of pregnancy and birth-related events occurring
even ≥30 years ago [52, 53]. As a result, we believe that misclassification of exposure and
pregnancy- and birth-related confounders was relatively minor and consequently was not a major
source of bias. Fourth, there may also have been errors in reporting of the socio-demographic
confounders resulting in residual confounding. Moreover, we did not have information on a
potential confounder maternal prepregnancy overweight/obesity, which has not been considered
in previous studies. We conducted sensitivity analysis across a range of scenarios of unmeasured
confounding by maternal prepregnancy overweight/obesity to estimate bias corrected total effect,
which suggested that in plausible scenarios, the association is likely overestimated. We also
estimated the E-value, the minimum strength of association required by an unmeasured
confounder with both GDM and asthma in offspring to explain away the observed estimated total
effect of GDM on the risk of asthma. While the sensitivity analyses for unmeasured confounder
maternal prepregnancy overweight/obesity or any confounder suggest overestimation of the
effect measure or the potential for explaining away the observed effect, non-differential
misclassification of the outcome could bias the estimate towards the null. As such, the net effect
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of unmeasured confounders and nondifferential misclassification of exposure remains unknown.
Future studies should collect data on maternal prepregnancy anthropometric and metabolic status
and consider it as a potential confounder when examining the association between GDM and
asthma in offspring. This, together with accurate diagnosis of asthma in children, would help
estimate relative unbiased effect of GDM on asthma in the offspring. Last, despite a relatively
large sample size, our estimates of additive and multiplicative interaction were imprecise, likely
because of low prevalence of GDM and low incidence of asthma in our study.
In conclusion, the findings from our study suggest, albeit weakly, that GDM increases the
risk of asthma in the offspring overall and directly beyond the mediating role of cesarean section
delivery, and there may be an interaction between GDM and maternal smoking in pregnancy.
Joint interventions on preventing GDM and smoking in pregnancy or identification of
intervenable intermediaries (other than cesarean section delivery) in the pathway between GDM
and asthma in the offspring could provide opportunities for prevention of asthma.
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5.4.

Supplementary Table

S Table 5. 1: Different cohorts of children in the study population and their participation in survey cycles of the National
Longitudinal Survey of Children and Youth, 1994/1995–2008/2009
Cohort

1994/1995
Original cohort
ECD* 1996

Enrollment
survey
cycle(year)

Age at
enrollment
(years)

Cycle 1
0–1
(1994/1995)
Cycle 2
0–1
(1996/1997)
*
ECD 1998
Cycle 3
0–1
(1998/1999)
*
ECD 2000
Cycle 4
0–2
(2000/2001)
*
ECD 2002
Cycle 5
0–2
(2002/2003)
*
ECD 2004
Cycle 6
0–6
(2004/2005)
*
ECD 2006
Cycle 7
0–5
(2006/2007
*
ECD, early childhood development

Surveyed cycles

Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 Cycle 7 Cycle 8
√
√
√
√
√
√
√
√
√
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√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√
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6. Chapter 6: Integrated Discussion
6.1.

Introduction

The overall goal of this research was to further our understanding on three aspects of asthma
epidemiology: trends in asthma burden in adults, course of asthma in children with asthma and
the role of prenatal factor maternal gestational diabetes mellitus in the risk of asthma in the
offspring. The overarching theme across these topics ultimately relates to the control of asthma
morbidity and mortality.
This chapter summarizes the findings with regard to existing literature and discusses their
potential implications, strengths and limitations of this research, and provides suggestions for
future research.
6.2.

Summary of Key Findings vis-à-vis Previous Findings

6.2.1. Objective One
This study examined the age, period and cohort effects on the prevalence of asthma, including
active asthma (defined as diagnosed asthma, and asthma symptoms and/or intake of asthma
medication), among Canadian adults for 16 years from 1994 through 2011 using age, period and
cohort effect theoretical and analytic framework.
Among Canadian adults, the prevalence of asthma had a curvilinear relationship with age
(age effect): it was highest during early adulthood (12% in 20-year-olds), was half of the
prevalence in young adults in adults aged 50–60 years (6%) and in between the prevalence in
young and late adulthood in 80-year-olds (8%). The prevalence of active asthma was highest
during early adulthood (8% in 20-year-olds), lower in adults aged 50–60 years (5%) and slightly
higher in old age (6% in 80-year-olds). Our empirical finding of age effect on asthma prevalence
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is in line with the non-model-based estimates that did not use formal age, period, cohort
framework demonstrating age effect on asthma prevalence, including active asthma prevalence
among Canadians during 1996–2015 using administrative data [1-3].
The prevalence of asthma and active asthma increased over time during our study period
(period effect): asthma prevalence increased from 5% in 1994/1995 to 11% in 2010/2011 and
active asthma prevalence increased from 4.5% in 1994/1995 to 8% in 2010/2011 independent of
age and sociodemographic and lifestyle factors. An increasing temporal trend of agestandardized asthma prevalence was also observed in prior studies applying non-model-based
and non-age-period-cohort analytic approaches in Canada during 1996–2012 [1, 3]. Contrary to
our finding, the prevalence of age-standardized active asthma prevalence was reported to
decrease slightly in Canadians from 2.8% in 2000/2001 to 2.3% in 2011/2012 in the CCDSS (1).
The active asthma definition in the CCDSS comprised of at least one physician claim in the first
diagnostic field or at least one hospitalization for asthma in any diagnostic field in a given fiscal
year. As a result, the decline in active asthma prevalence observed in the CCDSS may be
indicative of improved asthma management and control that required less health care utilization.
Our definition of active asthma (having asthma symptoms or taking asthma medication) was able
to capture milder cases, cases that were under control by taking medication not necessitating
medical care or cases that did not seek medical care. This may have led to the finding of
increasing prevalence of active asthma in our study.
In our study, the period effect on asthma prevalence was different among individuals of
different age between 1994/1995 and 2002/2003, and between 2002/2003 and 2010/2011 (cohort
effect): the steepest increase in prevalence was in individuals aged 20 years and least increase
was in individuals aged 80 years. An increase in prevalence of asthma over time varying by age
209

from 2000/2001 to 2011/2012 was reported in the CCDSS [1]. For active asthma prevalence in
our study, the steepest increase was in individuals aged 20 years and was least steep in
individuals aged 80 years.
6.2.2. Objective Two
This study examined the overall trajectory and groups of trajectories of asthma exacerbation in
children with incident asthma and identified the predictors of trajectory groups.
The median age of asthma diagnosis was six years. The overall trajectory of asthma
attack probability decreased from 0.63 at asthma diagnosis to 0.11 at 12 years after asthma
diagnosis, and asthma attack probability at diagnosis and asthma attack probabilities across time
since asthma diagnosis varied across children.
Three distinct trajectories were identified in children with incident asthma regardless of
age at asthma diagnosis: low increasing (21.3% of children), medium decreasing (45.8% of
children) and high decreasing (32.8% of children). The asthma attack probability estimates in the
low increasing group increased gradually from the initial low level after diagnosis and remained
higher than the asthma attack probability estimates in the medium decreasing group from around
seven years after asthma diagnosis. The asthma attack probability estimates in the medium
decreasing group decreased from moderate level after diagnosis to almost zero probability at the
end of follow-up. The asthma attack probability estimates in the high decreasing group
decreased after diagnosis but remained higher than other two groups at 12 years after diagnosis.
Overall, children belonging to the medium decreasing trajectory group had better long-term
prognosis than children belonging to the other two trajectory groups. Among children in the low
increasing trajectory group, more than half of the children (54.8%) had asthma diagnosed after
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six years of age, while more than half of the children in the medium decreasing (58.9%) and high
decreasing (61.1%) trajectory groups had asthma diagnosed before six years of age. Some
studies have examined the trajectories of wheezing, cough, atopy or asthma prevalence in
children followed from birth. However, the stark differences between these studies and our study
in terms of study population (all children regardless of asthma status vs. children with diagnosed
asthma), outcome (trajectories of wheezing, cough, atopy or asthma prevalence vs. trajectories of
asthma exacerbation), onset of follow-up (birth vs. asthma diagnosis) and time axis for outcome
pattern (age of child vs. time since asthma diagnosis) precluded us from making any meaningful
comparison.
With regard to the determinants, two predictors were independently associated with
trajectory group membership in our study: number of siblings at home and age at asthma
diagnosis. In our study, children having more siblings at home were more likely to belong to the
medium decreasing and high decreasing trajectory groups than the low increasing trajectory
group; children older at asthma diagnosis were less likely to belong to the medium decreasing
and high decreasing trajectory groups than the low increasing trajectory group. Asthma
exacerbation patterns in the medium decreasing and high decreasing trajectory groups reflect
more frequent asthma attacks in these two trajectory groups compared with the low increasing
trajectory group. Our study is novel in examining the course of asthma in terms of trajectory
groups. Thus, there are no previous studies using the outcome ‘trajectory group’. Still, studies on
severe asthma or asthma exacerbation somehow relate to our findings on the predictors. Studies
examining the relationship between sibship and severe asthma in children reported a positive
association between larger sibship and severe asthma symptom [4]. Younger age is a known risk
factor for asthma attack [5] and a predictor of severe asthma exacerbation in children [6].
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6.2.3. Objective Three
This study examined the association between maternal GDM and the risk of asthma in the
offspring and the joint effect of maternal GDM and maternal smoking during pregnancy on the
risk of asthma in the offspring.
Among 19,933 children, the prevalence of maternal GDM was 5.9% and a total of 1,639
children reported incident asthma during the follow-up. Maternal GDM was positively associated
with incident asthma in the offspring (HR 1.25, 95% CI: 1.03, 1.51). This is comparable to the
findings from most of the previous studies [7-10]. However, there are also other studies that
suggested a decreased risk of asthma-associated hospitalization in children having mothers with
diet-treated GDM and pharmacologically-treated GDM compared to children having mothers
without GDM, although a 42% increase in the risk for pharmacologically-treated GDM was also
compatible with their data [11].
After accounting for the mediating role of cesarean section delivery and adjusting for the
confounders, the HR for the association between GDM and incident asthma in the offspring was
1.17 (95% CI: 0.91, 1.49). Thus, the evidence supporting the controlled direct effect of GDM on
the risk of asthma in the offspring is weak. We were unable to identify any literature examining
the controlled direct effect of GDM not mediated by cesarean section delivery.
There was some evidence of positive interaction on the multiplicative scale (HR 1.23,
95% CI: 0.79, 1.90; P = 0.35) because the joint effect of GDM and maternal smoking during
pregnancy on the HR scale was greater than the product of the estimated effects of GDM alone
and maternal smoking during pregnancy alone. On the additive-scale, the estimated joint effect
of GDM and maternal smoking during pregnancy was greater than the sum of the estimated
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effects of GDM alone and maternal smoking during pregnancy alone on the basis of risk
differences suggesting a positive additive-scale interaction (RERI 0.30, 95% CI: −0.32, 0.93).
However, the evidence of interaction in our study is weak because our data is also compatible
with negative interaction as reflected from the lower limits of the 95% confidence intervals.
Previous studies have not examined the joint effect of maternal GDM and maternal smoking
during pregnancy on the risk of asthma in the offspring.
6.3.

Potential Implications

6.3.1. Theoretical Implications
The first implication of the findings from this study primarily relates to enhancing theoretical
understanding by addressing the gaps in knowledge with respect to three particular aspects of
asthma. This study provides further understanding of the overall trends in asthma prevalence, the
age groups with higher prevalence and the rates of prevalence increase in Canadian population
employing the age, period and cohort effect theoretical and analytic framework for the first time.
The differential asthma prevalence across adult life in our study indicates the groups with higher
asthma burden in Canadian population. Even the relatively lower prevalence of asthma in older
adults compared to younger adults reflected from the age effect would translate into substantial
burden in the aging population.
The three distinct trajectories of asthma exacerbation in children at the time of asthma
diagnosis and the two predictors of the trajectory group membership identified in this study is a
first step in looking at asthma course in children in terms of longitudinal pattern of exacerbation
from a group-based trajectory perspective beyond individual trajectory. These findings will add
to the existing knowledge base on asthma course and pave the way to future studies on asthma
course employing trajectory group perspective.
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Our finding of the association between maternal GDM and the increased risk of asthma in
the offspring increases understanding the etiology of asthma and mechanisms of the effect. This
also adds to the growing body of evidence for GDM as a possible risk factor for asthma. The
evidence of a joint effect of maternal GDM and maternal smoking during pregnancy also adds
knowledge in this regard.
6.3.2. Future Research and Public Health Implications
The findings from this research have implications related to future research agenda and public
health perspective. Different contemporary analytic methods employed in this research will
encourage researchers to use these methods in future research.
Future studies need to examine if the increasing prevalence of asthma, including active
asthma in adults over the study period observed in this study continues into the foreseeable
future. This will help to compare trends at different time periods examined in different studies
and in understanding the long-term trends in asthma burden in Canadian population. The trends
over the recent past observed in our study will also help policy makers to some extent gauge
health care needs and resource allocation for the population. There are likely underlying driving
factors other than the sociodemographic and lifestyle factors accounted for in our study for the
observed temporal trend of asthma prevalence. Considering the considerable improvement in air
quality and decreased prevalence of smoking over the last few decades, future studies could
explore other environmental factors alone or together with epigenetic changes to shed light into
the underlying causes.
Future studies should replicate our study on asthma exacerbation trajectory and their
predictors and seek to identify additional predictors to differentiate different trajectories. The
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ultimate goal of future research would be to develop a risk assessment tool including all
predictors to help physicians better prognosticate the long-term course of asthma in children and
supplement the current paradigm of asthma management based on symptom control. Such
approach to aid asthma management through prognostication of asthma course would help in
secondary prevention of asthma in children.
The findings from the third study in this dissertation have implications related to the
primary prevention of asthma in children. None of the different dietary, pharmacological,
immunotherapy, allergen or surgical interventions tested alone or in combination for prevention
of asthma has provided adequate evidence to move forward with implementation in clinical or
public health practices. As such, primary prevention of asthma in children remains elusive and
alternative or novel approaches are being sought. Our finding of the association between
maternal GDM and the increased risk of asthma in the offspring places GDM as a potential
unique out of the box candidate for asthma prevention and opens avenues to facilitate the
development, evaluation and improvement of novel preventive measures to reduce asthma
occurrence in children.
6.4.

Strengths and Limitations

6.4.1. Strengths of Research
This doctoral research addressed three domains of asthma, a chronic disease with substantial
public health burden, and has several notable strengths. First, the use of two national longitudinal
surveys allowed us to expand the knowledge base on three epidemiological aspects of asthma,
including distribution, course and determinants of occurrence. The NLSCY and NPHS provide a
unique source of sociodemographic and health related data collected from individuals across
Canada followed for more than a decade. Population-based nature of these two longitudinal
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surveys enabled us to include more asthma cases as asthma cases not seeking medical care or
medical care delivered by physicians outside fee-for-service were captured by these surveys. We
were also able to take into account different socioeconomic and lifestyle factors necessary to
address our objectives.
Second, to our knowledge, this is the first study to examine the age, period and cohort
effects on asthma prevalence in Canadians using age, period and cohort theoretical and analytic
framework, including epidemiological conceptualization of the cohort effect. The use of data
from the NPHS, a population-based longitudinal survey gave us the opportunity to assess the
effects of age, period and cohort over a period of 16 years. Model-based standardization allowed
us to visualize population-wide effect of age and period, and the difference in period effect
across different ages on asthma prevalence using population standardized prevalence.
Third, there is a dearth of literature on the course of asthma in children in terms of
exacerbation following asthma diagnosis. To the best of our knowledge, this is the first study to
identify trajectories of exacerbation in children following incident asthma diagnosis considering
the dynamic nature of asthma course. The trajectories of asthma manifestation and their
determinants in individuals with diagnosed asthma will add knowledge to this understudied area.
Use of population-based data from the NLSCY enabled us to follow children for up to 12 years
after asthma diagnosis. We considered factors readily available to the physicians, specifically in
primary care setting as predictors of the trajectory groups bearing in mind the practicality of our
findings.
Fourth, our study contributes to the evidence on and help fill in the knowledge gap on the
effect of maternal GDM on the risk of asthma in the offspring. We also looked at the direct effect
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of GDM on the risk of asthma after accounting for the mediating effect of cesarean section
delivery and considering the intricate relationships among the exposure, mediator, outcome and
confounders. We also examined the joint effect of maternal GDM and maternal smoking during
pregnancy on the risk of asthma in the offspring that could suggest additional avenues for
prevention of asthma in children.
Last, this research employed state-of-the-art analytic methods to address the knowledge
gaps. Model-based standardization was conducted to better depict the effects of age, period and
cohort on asthma prevalence. Hierarchical logistic regression was performed to examine the
overall asthma course and latent class growth modeling was performed to identify group-based
asthma course in children. Pooled logistic regression to emulate Cox proportional hazards model
and marginal structural models with inverse probability weight were performed to examine the
total effect of maternal GDM and the controlled direct effect of maternal GDM after accounting
for the mediating role of cesarean section on the risk of asthma in the offspring, respectively. We
used directed acyclic graph to inform and guide us in selecting pertinent confounders and the
analytic approach to estimate the controlled direct effect. We have examined both multiplicative
and additive interactions to assess the joint effect of maternal GDM and smoking during
pregnancy on the risk of asthma in the offspring.
6.4.2. Limitations of Research
Misclassification
Information on health professional-diagnosed asthma, asthma symptoms/attack and medication
were based on self- or parent-report and may have resulted in misclassification of asthma status.

217

In the study addressing objective one, respondents with milder symptoms or longer
symptom-free periods may have underreported asthma status compared with the respondents
with frequent or severe symptoms resulting in an underestimation of the prevalence of asthma or
active asthma in adults. However, a study reviewing literature on asthma assessed by
questionnaires in adults found on average 68% estimated sensitivity (range 48–100%) and 94%
estimated specificity (range 78–100%) of reported physician-diagnosed asthma when validated
against clinical diagnosis of asthma in adults [12].
There is a potential for misclassification of asthma status in the study addressing
objective two. Parent-reported physician-diagnosed asthma had 59% to 89% estimated
sensitivity and 81% to 96% estimated specificity when validated against medical records, health
claims diagnosis or pediatric allergist diagnosis of asthma [10, 13-15]. Furthermore, the recall
period for asthma attack in children was 12 months prior to the interview and could have led to
misreporting of asthma attack because parents of children with mid attacks may forget to report
asthma attack.
There is also the potential for misclassification of asthma status in our study addressing
objective three. As the NLSCY was not an asthma-focused study, misclassifications are expected
to be non-differential with regard to maternal GDM. As a result, the non-differential
misclassification of asthma will bias associations toward the null. There may have also been
errors in the reporting of pregnancy and birthrelated information, including the exposure, GDM.
However, maternal recall of pregnancy-related events occurring even ≥30 years ago is known to
have high reproducibility and accuracy [16, 17]. As a result, we believe that misclassification of
exposure and pregnancy- and birth-related confounders was relatively minor and consequently
was not a major source of bias. We were not able to differentiate between pregestational and
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gestational diabetes mellitus of mothers reporting diabetes during pregnancy. Nevertheless, most
of the diabetes mellitus during pregnancy are likely to be GDM [18].
Residual and unmeasured confounding
In the study addressing objective three, there may have been errors in reporting of sociodemographic confounders leading to misclassification and resulting in residual confounding.
However, we believe that the misclassification would be nondifferential across the exposure
groups as the NLSCY was not an asthma-focused study and information on GDM was collected
along with other pregnancy- and birth-related information from all young children. We could not
adjust for the unmeasured confounder maternal prepregnancy overweight/obesity. However, we
conducted sensitivity analyses to estimate bias corrected association between GDM and asthma
in the offspring across a range of scenarios of the unmeasured confounder.
Sample size and precision of estimates
In the study addressing objective two, our sample size for the identification of asthma
exacerbation trajectories in children was relatively small because we applied certain exclusion
criteria to best address our study objective and to apply the statistical tool. The small sample size
led to considerable uncertainty in estimated trajectory patterns and may also have precluded us
from identifying predictors that distinguished between high decreasing and medium decreasing
trajectory groups. Thus, replication of our results in future studies is warranted.
In the study addressing objective three, despite having a relatively large sample size, our
results on the joint effect of maternal GDM and smoking during pregnancy on the risk of asthma
in the offspring were imprecise for additive and multiplicative interactions likely because of the
low prevalence of exposure, GDM and low incidence of outcome, incident asthma in our study.
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Lack of information
In the study addressing objective two, we were unable to consider some potential predictors of
the trajectory groups such as respiratory tract infection, objective markers of atopy and bronchial
hyper-responsiveness, severity of asthma and asthma medication because of lack of information
in the dataset [19]. Future studies should assess all potential predictors for trajectory group
membership.
6.5.

Future Research Directions

This research addressed some of the gaps in knowledge on three epidemiological aspects of
asthma. However, the findings from this research indicate areas of future research to aid in the
prevention and control of asthma. Firstly, future research using age, period and cohort effect
theoretical and analytical framework is warranted to see whether the age effect on asthma
prevalence, the rising temporal trend along with the variation in asthma prevalence by age
continues beyond our study period in Canadian population to guide public health policy in
resource allocation for asthma management. These studies should also seek to explain the
underlying causes of the effects. Secondly, future studies on identifying trajectories of asthma
exacerbation in children with asthma in other settings and using accurate measures of asthma and
asthma attack are needed to provide further evidence on distinctive asthma exacerbation
trajectories in children and to enable comparison with the findings from our study. Future studies
should assess all potential predictors for trajectory group membership, including respiratory tract
infection, objective markers of atopy and bronchial hyper-responsiveness, severity of asthma and
asthma medication to identify distinct predictors of the trajectory groups to predict individual
child’s exacerbation trajectory pattern. Ultimately, a comprehensive risk assessment model
should be developed incorporating predictors from our study and future studies to aid prediction
220

of distinct asthma exacerbation trajectory groups. Finally, future studies are warranted to identify
effective GDM preventive interventions, particularly in women at risk of developing GDM and if
found effective should evaluate effectiveness in preventing outcomes in offspring, including
asthma. Studies should also seek to identify intervenable mediators in the pathway between
GDM.
6.6.

Conclusions

This dissertation contributes towards providing insights on asthma burden in adults, the course of
asthma in children and the role of a novel exposure maternal GDM in the risk of asthma in the
offspring. The theoretical contributions could potentially help in future studies towards
prevention and control of asthma. We have demonstrated that asthma prevalence in Canadian
adults is higher in young adults and older adults compared to middle-aged adults and increased
over time in all age groups although at different rates in increase and suggests substantial health
burden for Canadian adults. Children with asthma followed three distinct trajectories that require
replication and corroboration in future studies and warrants identification of additional predictors
of trajectories and development of a comprehensive risk assessment model to aid physician’s
prognosticate asthma course. Maternal GDM could be a potential novel candidate for targeting
interventions to prevent asthma in children and requires further evaluation in future studies.
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